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1 INTRODUCTION 
1.1 Background  
Best practice in Alcohol and Other Drug (AOD) care is supported by access 
to clinical expertise and up-to-date, evidence-based resources. Essential 
clinical resources, such as clinical guidelines and tools, should reflect 
changing patterns of AOD use and advances in our understanding of drug 
withdrawal syndromes, assessment and care.  
It is within this context that the Victorian Department of Human Services 
funded a review of the AOD clinical guidelines for withdrawal. The 1995 
Services for Alcohol and Drug Withdrawal (SAW) resource handbook, 
entitled New Concepts in Drug Withdrawal (Frank & Pead, 1995), previously 
set the standard for  AOD withdrawal in Victoria. However, it is now timely to 
update clinical guidelines for the AOD withdrawal sector to ensure 
consistency with the current evidence base and trends in AOD use. The 
Clinical Withdrawal Guidelines (or ‘Guidelines’) presented below are the 
product of this process.  
1.2 Purpose 
Clinical guidelines seek to direct clinical practice by outlining recognised, 
evidence-based treatment interventions. They draw on current literature and 
clinical practice expertise. These Guidelines provide guidance for clinical 
decision-making in the context of individual client requirements, withdrawal 
setting, treatment availability and individual service protocols.  
These Guidelines are consistent with the World Health Organisation’s 
(WHO) United Nations Principles of Drug Dependence Treatment (United 
Nations Office on Drugs and Crime and World Health Organization, 2008). 
They outline current best practice for the management of AOD-dependent 
clients accessing withdrawal care.  
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The Guidelines are suitable for use by clinicians in three settings: 
• Residential and community AOD withdrawal services 
• Inpatient and other acute facilities where patients experience an 
unplanned withdrawal during treatment for a related or unrelated 
medical or psychiatric condition 
• Primary care clinics such as those at which general practitioners (GPs) 
are situated 
Staff should be provided with appropriate workplace training and resources 
to enable the appropriate application of these Guidelines.  
1.3 Content and language 
These Guidelines reflect the current evidence base regarding AOD 
withdrawal syndromes and approaches to withdrawal care. They introduce 
three categories not present in the SAW manual: cannabis, amphetamine-
type substances and nicotine. The impact of polydrug use on withdrawal is 
explored and advances in pharmacotherapy treatment for opioid-dependent 
clients outlined. The appropriate care of clients with a dual diagnosis in 
withdrawal is also examined, reflecting an increased focus on co-occurring 
AOD and mental health conditions. A range of tools for use in withdrawal 
care are provided in the Appendices pertaining to screening, assessment, 
care planning and provision. 
The Guidelines outline the areas of withdrawal care relevant to the following 
AOD categories: 
• Alcohol  
• Amphetamine-type substances  
• Benzodiazepines 
• Cannabis 
• Nicotine 
• Opioids 
Dosing regimens provide a guide to prescribing for AOD withdrawal. Dosing 
regimens are based on mono-dependence of the specified drug. It is noted 
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that, at all times, clinical judgement is an important element of prescribing 
during withdrawal care. 
Note that the term ‘withdrawal treatment’, used in the Frank and Pead 
document, has been replaced by ‘withdrawal care’ in these Guidelines. This 
is consistent with the current paradigm that conceptualises AOD withdrawal 
as one component of a broader continuum of care. 
Finally, bolded statements in this document indicate their content is a 
standard. 
1.4 Allied resources and Web access 
Telephone services such as Drug and Alcohol Clinical Advisory Service 
(DACAS) provide expert clinical advice to doctors, nurses and other health 
and welfare professionals managing clients with AOD issues. Clinicians are 
encouraged to seek support from DACAS as required. DACAS can be 
contacted in Victoria on 1800 812 804. 
A list of Victorian AOD and welfare information services is provided in 
Appendix 1. 
These Clinical Withdrawal Practice Guidelines are available online at 
www.turningpoint.org.au  
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
4 
 
 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
5 
2 DEFINITIONS OF DEPENDENCE 
AND WITHDRAWAL 
There are two key definitions of AOD dependence: 
• The WHO’s The Tenth Revision of the International Classification of 
Diseases and Health Problems (ICD-10; (World Health Organization, 
2004)  
• The American Psychiatric Association’s Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition (DSM IV; (American Psychiatric 
Association, 2000)  
Both definitions are considered appropriate for use in these Guidelines. 
2.1 ICD-10 
The International Classification of Diseases (ICD-10) includes definitions of 
dependence and withdrawal as follows:  
A cluster of physiological, behavioural, and cognitive phenomena in 
which the use of a substance or a class of substances takes on a much 
higher priority for a given individual than other behaviours that once had 
greater value. A central descriptive characteristic of the dependence 
syndrome is the desire (often strong, sometimes overpowering) to take 
the psychoactive drugs (which may or may not have been medically 
prescribed), alcohol, or tobacco. There may be evidence that return to 
substance use after a period of abstinence leads to a more rapid 
reappearance of other features of the syndrome than occurs with 
nondependent individuals (World Health Organization, 2004). 
ICD-10 defines a withdrawal state as: 
Withdrawal state: A group of symptoms of variable clustering and 
severity occurring on absolute or relative withdrawal of a psychoactive 
substance after persistent use of that substance. The onset and course 
of the withdrawal state are time-limited and are related to the type of 
psychoactive substance and dose being used immediately before 
cessation or reduction of use (World Health Organization, 2004). 
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2.2 DSM-IV 
The Diagnostic and Statistical Manual of mental disorders fourth edition 
(DSM-IV) defines dependence as: 
A maladaptive pattern of substance use, leading to clinically significant 
impairment or distress, as manifested by three (or more) of the following, 
occurring at any time in the same 12-month period: 
• Tolerance, as defined by either of the following: 
a. A need for markedly increased amounts of the substance to 
achieve intoxication or desired effect 
b. Markedly diminished effect with continued use of the same 
amount of the substance 
• Withdrawal, as manifested by either of the following: 
a. The characteristic withdrawal syndrome for the substance 
b. The same (or a closely related) substance is taken to relieve or 
avoid withdrawal symptoms 
• The substance is often taken in larger amounts or over a longer 
period than was intended 
• There is a persistent desire or unsuccessful efforts to cut down or 
control substance use 
• A great deal of time is spent in activities necessary to obtain the 
substance (e.g. visiting multiple doctors or driving long distances), 
use the substance (e.g. chain smoking), or recover from its effects 
• Important social, occupational, or recreational activities are given up 
or reduced because of substance use (World Health Organization, 
2004). 
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2.3 Dimensions of drug withdrawal  
AOD withdrawal care has traditionally focused on an individual’s neuro-
adaptation reversal. This is the process by which neurotransmitter 
adaptation to consistently high levels of a drug is reversed and withdrawal 
features result. However, this focus is increasingly being challenged by the 
presentation of clients for whom neuro-adaptation reversal is not an 
appropriate or singular goal of withdrawal care. Rather, these clients seek 
alternative treatment goals addressing physical, psychological and social 
needs. 
These goals of withdrawal care include AOD reduction, stabilisation of use 
and respite. They may be addressed via: 
• Pharmacotherapy reduction or maintenance 
• Interrupting a pattern of heavy and dependent use 
• Stabilising, reducing or abstaining from drug use 
• Preventing withdrawal complications 
• Initiating abstinence 
• Linking into further treatment (Griswold et al., 2007; NSW Department of 
Health, 2008a)  
In these Guidelines, withdrawal care is defined as a course of interventions 
which address the bio-psychosocial elements of withdrawal. These may 
include neuro-adaptation reversal, pharmacotherapy reduction or 
maintenance, management of concurrent illnesses, and psychological, social 
and emotional issues. The provision of non-medical psychosocial support is 
also acknowledged as important. 
Figure 1, below, demonstrates how the bio-psychosocial elements of 
withdrawal require equal consideration in withdrawal care. The degree to 
which each dimension plays a role in an individual’s substance misuse will 
impact significantly on their experience of withdrawal.  
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Figure 1: Dimensions of drug withdrawal  
 
Biological 
Social Psychological 
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3 PRINCIPLES OF AOD 
WITHDRAWAL CARE 
The following principles of withdrawal care reflect current clinical best 
practice in the AOD field. Such principles support the strategies that address 
the three dimensions of AOD withdrawal identified above. 
• The primary objective of withdrawal care is to achieve a client’s goals in 
relation to their AOD misuse, with safety. This is supported by a 
thorough assessment of potential risks at presentation to AOD care. 
• Substance reduction and maintenance goals should not be regarded as 
any less meaningful than a commitment to long-term abstinence. 
• Harm reduction is a central element of AOD withdrawal care. Harm 
reduction occurs via the provision of information and education about 
safer AOD use practices. This may include a reduction in drug 
consumption, safer means of drug administration and improved lifestyle 
(Frank & Pead, 1995). 
• Withdrawal services represent a gateway towards further treatment and 
behaviour change. Treatment during withdrawal should aim to link 
seamlessly with a long-term, therapeutic program (Griswold et al., 2007; 
NSW Department of Health, 2008a; NSW Health Department, 1999; 
Raistrick et al., 2006). 
• Appropriate and recognised screening, assessment and planning 
processes and protocols are essential to withdrawal care. Such tools 
inform the most appropriate withdrawal setting and level of care 
required, and identify risk factors (United Nations Office on Drugs and 
Crime and World Health Organization, 2008). 
• Psychosocial factors play a significant part in an individual’s withdrawal 
experience and can provide a focus for supportive care. Supportive care 
is fundamental to ensuring a holistic approach. 
• Intake and assessment processes should maximise the opportunity for 
clients to access the most appropriate AOD withdrawal care. These 
processes should be considerate of the needs of clients from 
metropolitan, rural and regional areas, women, offenders, those who are 
parenting and clients from Koori and CALD communities (United Nations 
Office on Drugs and Crime and World Health Organization, 2008). 
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• Linkage with family/significant others, where possible, is an important 
aspect of withdrawal care. It can establish strong foundations for 
additional support, particularly in the post-withdrawal period (YSAS, 
2008). 
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4 CONTINUITY OF CARE 
Withdrawal, while effective in achieving neuro-adaptation reversal, has 
greatest potential long-term behaviour change when it is part of a broader 
continuum of care. This continuum incorporates pre-admission planning, 
withdrawal, planning for post-withdrawal, follow-up support and linkages with 
a range of relevant services (Raistrick et al., 2006).  
Strategies that support continuity of care should commence at pre-admission 
with discussion of a client’s goals, strategies for preparing for withdrawal and 
identification of post-withdrawal linkages.  
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5 FEATURES OF AOD WITHDRAWAL 
The features of AOD withdrawal, including its severity and duration, are 
impacted by a range of factors, including: 
• Primary drug of concern 
• Level of AOD dependence  
• Polydrug use and/or dependence 
• The existence of a co-occurring physical illness or mental health 
disorder 
• Psychosocial factors (e.g. environment, relationships, accommodation) 
The half-life of a drug also plays a significant role in the severity of an 
individual’s neuro-adaptation reversal. The half-life of a drug is the length of 
time needed for half the amount of the drug consumed to be broken down by 
the body.  
Table 1 below, outlines common features of the withdrawal syndrome for 
each substance addressed in these Guidelines. These features apply 
specifically to clients not yet medicated to prevent the onset of withdrawal 
symptoms. Note that low-grade symptoms such as dysphoria may persist for 
a number of months beyond the withdrawal phase. 
All clinicians will have a sound understanding of the clinical features of AOD 
withdrawal. 
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Table 1: Features of AOD withdrawal 
Drug  Onset  Duration  Clinical features 
Alcohol 1 
 
Within 24 hours 
and up to 48 
hours 
(depending on 
Blood Alcohol 
Level (BAL); 
hours after last 
drink and level of 
neuro-adaptation) 
3–7 days (up to 
14 days in severe 
withdrawal)  
Anxiety, agitation, sweating, 
tremor, nausea, vomiting, 
abdominal cramps, 
diarrhoea, craving, insomnia, 
elevated blood pressure, 
pulse and temperature, 
headache, seizures, 
confusion, perceptual 
distortions, disorientation, 
hallucinations, seizures, 
delirium tremens, 
arrhythmias and Wernicke’s 
encephalopathy.  
Opioids1 Heroin withdrawal 
occurs within 8–
24 hours of last 
use (may be 
slower in 
methadone/other 
withdrawal)  
Heroin:             
Peaks 2–4 days 
and cease 7–10 
days 
Methadone: 
Symptoms 
emerge 36–48 
hours after last 
dose and low 
grade symptoms 
can remain for 3–
6 weeks  
Anxiety, craving, muscle 
tension, muscle and bone 
ache, muscle cramps, sleep 
disturbance, sweating, hot 
and cold flushes, 
piloerection, yawning, runny 
eyes and nose, abdominal 
cramps, nausea, vomiting, 
diarrhoea, palpitations, 
elevated blood pressure and 
pulse, dilated pupils and 
agitation. 
Benzodiazepines1 1–10 days 
(depending on 
half-life of drug)  
3–6 weeks (or 
longer)  
 
 
 
Anxiety, headache, 
insomnia, muscle aching 
twitching and cramping, 
nausea, vomiting, diarrhoea, 
perceptual changes, feelings 
of unreality, 
depersonalisation, seizures, 
agitation, 
confusion/psychosis 
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Drug  Onset  Duration  Clinical features 
Methamphet-
amines2 
Crash phase: 
within hours of 
last use 
Withdrawal: 1–4 
days after last 
use 
2–4 days                                                                                
                               
Acute phase: 7–
10 days 
Subacute phase: 
a further 2 –4 
weeks 
Cravings, dysphoria,
anhedonia, increased 
appetite, fatigue, agitation, 
anxiety, increased sleep, 
vivid, unpleasant dreams 
and slowing of movement. 
 
Cannabis3  1–2 days of last 
use 
Acute phase: 2–6 
days, subsiding 
after 2–3 weeks 
May persist for 
some months 
Anger, aggression, irritability, 
anxiety, nervousness, 
decreased appetite or weight 
loss, restlessness, sleep 
difficulties, chills, depressed 
mood, shakiness, sweating. 
Adapted from Roberts, Swan and Mugavin (2008) 
1. NSW Health Department (1999) 
2. NSW Health Department (2008) 
3.
 McGregor et al. (2005) 
5.1 Withdrawal complications 
On occasion, withdrawal may precipitate serious and/or life-threatening 
complications. These complications may be associated with: 
• High levels of AOD use 
• Concurrent medical and psychiatric illnesses 
• Polydrug dependence 
Withdrawal complications are associated with a range of substances and 
manifest in a variety of ways, as shown in Table 2, below.  
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Table 2: Complications of withdrawal  
Withdrawal 
complication 
Substance/s with 
which complication 
is associated 
Features of complication 
Seizures 
 
Alcohol  
Benzodiazepines 
Amphetamine-type 
substances 
Convulsions, sensory disturbances, 
loss of consciousness (Merriam-
Webster Inc., 2008) 
 
Hallucinations  
 
Alcohol  
Amphetamines 
 
Transient hallucinations (visual or 
tactile), paranoia, psychological 
disturbances, abnormal affect, auditory 
or visual delusions (McGregor, 2005; 
Shand et al., 2003b) 
Delirium 
 
Alcohol  
Benzodiazepines 
GHB 
Agitation, hyperactivity, tremor, 
confusion and disorientation.  Can 
occur without progressing to Delirium 
Tremens (Ashton, 2005; Shand et al., 
2003b) 
Agitation  Alcohol 
Cannabis 
Methamphetamines 
Anger, aggression, irritability and 
violent outbursts 
Psychosis Amphetamine-type 
substances 
Thought disorder and perceptual 
disturbances 
Wernicke-
Korsakoff’s 
syndrome (WKS) 
Alcohol Cognitive impairments in memory (i.e. 
anterograde amnesia), deficits in 
abstraction and problem solving, 
confusion, ocular and gait disturbances, 
apathy and amnesia (Shand et al., 
2003b) 
Dehydration 
 
Alcohol  
 
Opioids  
Increasing thirst, dry mouth, weakness 
or light-headedness, darkening of the 
urine or decrease in urination 
(MedicineNet, 2008) 
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The safety of clients and staff is integral to effective withdrawal care. This is 
particularly important where withdrawal complications arise. 
Ongoing monitoring and review are essential elements of managing a 
complicated withdrawal. In some circumstances, specialist medical attention 
may be warranted. 
All AOD clinical service staff will be trained in First Aid, including 
Cardiopulmonary Resuscitation (CPR) procedures. Clear accident and 
emergency policies and procedures will be integrated into staff induction and 
orientation processes, with regular updates/reviews for all staff in clinical 
environments. 
5.2 Symptomatic medications 
Table 3, below, provides a general guide to symptomatic medications for 
AOD withdrawal. These medications may be used in accordance with the 
relevant Guidelines and in conjunction with pharmacotherapies and 
supportive care. 
Alcohol and drug-specific symptomatic medication tables with detailed 
dosing regimens are provided within each AOD section of the Guidelines.  
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Table 3: Symptomatic medications 
Symptom Recommended medications 
Diarrhoea  Loperamide 
Kaomagmaa 
Headaches Paracetamol 
Nausea and vomiting Metoclopramide (Maxolon) 
Prochlorperazine (Stemetil) 
Pronounced agitation or insomnia 
 
 
Tricyclic antidepressants such as:  
Doxepin  
Clomipramine  
 Benzodiazepines can be used but there is a risk 
of misuse and exacerbation of depressive 
symptoms:  
Diazepam  
Temazepam tablets 
Pronounced psychomotor retardation Selective serotonin reuptake inhibitors (SSRIs) 
such as Fluoxetine and Paroxetineb may be 
prescribed by a Medical Officer upon referral. 
Stomach cramps Hyoscine (Buscopan)a 
Atrobela 
Source:  
a NSW Department of Health (2008a)  
b Murray (2002)  
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6 SPECIAL NEEDS GROUPS 
6.1 Clients with a dual diagnosis 
The case complexity typical of clients with a dual diagnosis requires a 
strategic and preferably collaborative response by AOD clinicians, primary 
health care providers such as general practitioners and mental health care 
professionals. This should be reflected in all elements of withdrawal care, 
from screening and assessment, choice of setting, to the delivery of care and 
post-withdrawal support.  
Attention to the specific needs of individuals with a dual diagnosis is critical 
to their care. Management strategies should respond to the client’s 
presenting condition, including high prevalence mental health disorders such 
as anxiety and depression and/or low prevalence mental health disorders 
such as schizophrenia and personality disorder. 
Mental health screening is an essential component for AOD withdrawal 
support and should inform assessment and treatment planning. An 
integrated approach of both services is considered best practice and may 
increase the likelihood of a successful course of treatment for the client. 
Early recognition of a dual diagnosis provides an opportunity for creating 
appropriate and long-term client linkages with mental health services.  
Some clients with a dual diagnosis may require an extended period of stay 
within a residential AOD withdrawal setting. Access to stepped care between 
hospital/psychiatric wards and community-based or non-residential AOD 
settings also affords graduated treatment responses based on client 
need/risk. In recognition of their specific needs, withdrawal involving clients 
with a dual diagnosis will be addressed in Chapter 16. 
6.2 Clients who use multiple substances 
Polydrug use refers to the combining of two or more psychoactive drugs and 
is common among AOD clients presenting to withdrawal services. Polydrug 
users should be thoroughly assessed to detect and respond appropriately to 
immediate withdrawal risks. Clinicians should consider referral of 
complicated and high risk clients to residential withdrawal care, as 
appropriate. 
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Assessing dependence for each drug is recommended in order to determine 
the likelihood of withdrawal syndromes occurring for multiple substances. 
The drug with the greater risk is the focus of assessment initially – this drug 
is typically alcohol (NSW Department of Health, 2008a). 
Nicotine dependence is common among illicit drug users. Victoria now 
legislates for restrictions on smoking in buildings and within specified 
proximity to building entrances and exits. AOD services should ensure that 
clients are provided with appropriate information regarding these restrictions 
before admission and clients should be offered nicotine replacement and 
Quit counselling as part of their withdrawal care. 
6.3 Young people 
Young people (12–21 years) have particular needs that may impact on their 
engagement with and experience of withdrawal care. Issues may include 
unresolved trauma, chaotic social situations and a relative lack of cognitive 
and emotional resources. In addition, a lack of information about AOD 
treatment, poor family support, unstable/unsuitable accommodation, 
involvement with the juvenile justice system and feelings of vulnerability may 
limit young people’s access to appropriate support and continuing care 
(United Nations Office on Drugs and Crime and World Health Organization, 
2008).  
Young people are more likely to inhale volatile substances in comparison to 
adults. Volatile substances include adhesives, aerosols, cleaning agents, 
petrol, solvents and gases, and produce depressant effects similar to alcohol 
intoxication. Withdrawal from such substances is typically mild, although 
prolonged and excessive use can produce a severe withdrawal syndrome. 
Specific guidelines for the management of young people withdrawing from 
volatile substances are outlined in the recently updated YSAS Clinical 
guidelines (YSAS, 2008).  
Service providers’ capacity to understand and respond to the range of AOD 
use and needs of young people is critical. Knowledge of, and appropriate 
responses to, such needs have been linked to positive treatment outcomes, 
treatment involvement and retention (Colby et al., 2004).  
Young people presenting to adult withdrawal services should be linked with 
youth-specific services. Ongoing contact with, and adjunct support from, 
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youth-specific workers throughout withdrawal care can promote more 
positive experiences for the young person. Where program capacity allows, 
young people may benefit from limited contact with adult clients. Note, 
however, that premature exposure to information from clients in more 
advanced stages of AOD abuse may have a negative impact on the 
withdrawal experience for young people (United Nations Office on Drugs and 
Crime and World Health Organization, 2008). 
Young people approaching the age of eligibility for adult withdrawal services 
require transitional planning. An examination of service differences, adult 
treatment options and client anxieties is recommended at this time.  
For more detailed AOD withdrawal guidelines for young people, please refer 
to YSAS Clinical Guidelines for Youth AOD Withdrawal (YSAS, 2008). 
6.4 Clients residing in rural and regional areas 
The provision of AOD services to clients residing in rural and regional areas 
can be challenging. It is not always feasible to apply metropolitan strategies 
of intervention to these communities.  
AOD clients residing in rural and regional areas experience significant 
barriers to adequate and appropriate withdrawal care. Barriers include 
geographic isolation, limited public transport, reduced service availability and 
economic constraints. In addition, these clients may experience heightened 
stigma due to the increased visibility of AOD use and treatment-seeking 
within such communities. Access to GPs who prescribe pharmacotherapies 
and pharmacotherapy-dispensing pharmacies may also be limited.  
Flexible treatment strategies are therefore required to accommodate clients 
residing in rural and regional locations. Treatment planning may include 
allowances for telephone triage and assessment, travelling distances and 
discharge planning for post-withdrawal care. 
Berends et al. (2004, p. 17) highlight the increasing capacity of nurse 
practitioners in rural and regional communities:  
The role of the nurse practitioner is to develop an advanced nursing 
framework to enhance health care delivery by combining advanced 
nursing and health knowledge with skills and clinical expertise into their 
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practice. This assists in the promotion of care between health providers 
and in partnership with clients and communities. 
Rural and regional withdrawal care should include consideration of: 
• Service flexibility to enable modification of metropolitan programs to suit 
local conditions 
• Local patterns of drug use and changing patterns that may develop  
• Service linkages 
• Flexible waitlist management 
• Pre-admission planning including preparatory activities 
• Facilitation of linkages to the broader community for post-withdrawal 
support and relapse prevention (Berends, 2004) 
6.5 Aboriginal and Torres Strait Islander 
(ATSI) clients 
Culturally appropriate engagement with ATSI clients by withdrawal services 
should consider the potential involvement of the client’s immediate and 
extended family in the withdrawal process. Awareness of, and sensitivity to, 
the experiences of those affected by the Stolen Generations is necessary 
throughout withdrawal care. 
As such, mainstream AOD withdrawal services should: 
• Offer cultural awareness training to staff 
• Establish and consolidate links with ATSI services  
• Assist ATSI clients to access appropriate ATSI support services, 
according to individual preference 
• Engage Koori Community Alcohol and Drug Workers 
In addition, mainstream withdrawal services may further meet the needs of 
ATSI clients by: 
• Drawing on the expertise of ATSI services to inform appropriate 
withdrawal screening, assessment, planning, engagement, withdrawal 
care and follow-up of ATSI clients 
• Using culturally-specific tools, where available  
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• Formalising relationships with ATSI services through a Memorandum of 
Understanding  
• Considering the use of a narrative approach to conduct assessment with 
ATSI clients 
6.6 Culturally and Linguistically Diverse 
(CALD) clients 
Providers of withdrawal services to CALD clients should consider culturally 
appropriate methods of engagement. Services should: 
• Offer cultural awareness training to staff 
• Establish and consolidate links with CALD services  
• Assist CALD clients to access appropriate CALD support services, 
according to individual preference 
Services are also encouraged to work toward a model of care that: 
• Draws on the expertise of culturally appropriate support services to 
inform appropriate withdrawal screening, assessment, planning, 
engagement, withdrawal care and follow-up of CALD clients 
• Formalises relationships with CALD services through a Memorandum of 
Understanding, particularly in locations where there is a high proportion 
of ethnic minority groups 
• Provides access to an interpreter to support the completion of an 
accurate AOD screen and assessment 
• Provides information about AOD treatment options to CALD clients who 
are unfamiliar with the service system and facilitates access to AOD 
services 
• Works with clients’ family and significant others, where appropriate 
• Considers the most appropriate AOD setting dependent on CALD client 
need and preference  
• Integrates and uses culturally-specific screening and assessment tools, 
where available  
• Considers the heightened need for confidentiality among CALD clients 
who are members of a close community network  
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6.7 Clients with Acquired Brain Impairment 
(ABI) 
Clients with ABI typically present to AOD withdrawal with the following 
conditions:  
• Reduced co-ordination and balance (ataxia) 
• Changes to mood 
• Reduced cognitive capacity (e.g. reduced ability to make decisions, 
memory loss) 
Clients with ABI respond well to routine and do not readily accept change. 
Pre-admission planning is therefore essential in preparing clients with ABI for 
withdrawal care. Multiple visits to the AOD service and introduction to 
withdrawal staff may be of benefit during this pre-admission phase. 
Withdrawal staff should also take care to limit the amount of information 
communicated to clients with ABI at any one time. A number of short 
assessments are preferable to a long assessment interaction. 
Thiamine supplements (Vitamin B1) are recommended for clients with ABI. A 
prolonged period of an inadequate and inappropriate diet may contribute to 
brain impairment (ARBIAS, 2008). 
6.8 People who experience chronic pain  
For some clients presenting to withdrawal care, chronic pain is the condition 
underlying AOD use. Withdrawal care for these clients is just one element of 
a broader response that also addresses pain management. 
Assessment and measurement of pain are critical to appropriate diagnosis, 
care planning and implementation. An assessment should consider the 
physiological, psychological and environmental factors which influence the 
experience of pain (i.e. reflecting the bio-psychosocial model).  
The following elements should be included in pain management assessment 
and care: 
• A thorough general medical assessment including:  
• A specific pain history which documents:  
 Causal pathology, where possible 
 Description 
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 Impact 
 Treatments 
 Medications 
 Context  
• An AOD history 
• A psychiatric history 
• An examination which documents: 
• Features of intoxication 
• Injection sites, where relevant 
• Functional assessment (i.e. movement of relevant joints) 
• Mental state assessment 
• Relevant information from other health care professionals active in a 
clients’ chronic pain management/treatment 
• Discussion of holistic, multidisciplinary management options 
A pain management plan for AOD withdrawal clients should be developed 
and implemented under the supervision of a specialist multidisciplinary team 
in conjunction with an addiction medicine specialist (Roberts, 2008). The 
pain management plan may include: 
• A non-pharmacological approach (e.g. exercise, coping strategies, 
counselling, psychosocial support, alternative therapies/medications 
etc.)  
and/or 
• A pharmacological approach (e.g. paracetamol, NSAIDS, trial of opioids 
in conjunction with other care)(NT Department of Health and Community 
Services, 2008). Where non-opioid analgesics are unsuitable for 
effective pain management, consideration may be given to the use of 
titrated opioids, with particular attention to route of administration. Oral 
rather than injection modes are recommended 
It is critical that planning for the post-withdrawal management of pain is 
addressed during withdrawal care. This may entail: 
• Linking with appropriate medical services for alternative prescribing 
• Linking with other services such as pain management clinics for adjunct 
care 
• Follow-up support 
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6.9 Pregnant women 
The range of adverse effects associated with AOD misuse, dependence and 
withdrawal during pregnancy are well recognised. Opioids and alcohol, in 
particular, present risks for mother and foetus. These risks are further 
discussed in the relevant AOD withdrawal sections. 
It is recommended that all women presenting to withdrawal services who are 
of child-bearing age are offered a urine pregnancy test. The limitations of the 
urine pregnancy test as outlined in the Clinical Treatment Guidelines: 
Prescribing for Drug Withdrawal (Murray et al., 2002) should be discussed 
with the client.  
Screening and assessment of pregnant women should aim to elicit a range 
of information relevant to AOD withdrawal. Importantly, the frequency of past 
and current substance use must be established (NSW Department of Health, 
2008b).  
Tools such as T-ACE1 or TWEAK2 can be used to screen for AOD misuse in 
pregnant women. However, both tools have limited use for detecting low 
levels of alcohol use. The limitations of the Alcohol Use Disorder 
Identification Test (AUDIT) in identifying alcohol use during pregnancy are 
also acknowledged (NSW Department of Health, 2008b).  
In some instances, a client may seek partner involvement in withdrawal care 
planning. This is only appropriate where the clinician believes that the 
partner will be a positive and useful resource in supporting the client’s 
withdrawal. 
Given that AOD use of a significant other increases a woman’s risk of 
continuing or relapsing to drug use (NSW Department of Health, 2008b), 
post-withdrawal planning should address such issues. 
                                                          
1
 T-ACE is a modification of the CAGE screening test and was designed for use in 
obstetric settings to identify at-risk drinkers (Sokol et al., 1989). 
2
 TWEAK is a five-item scale developed originally to screen for risk drinking during 
pregnancy. TWEAK is an acronym based on the five items (tolerance to alcohol; worry 
by spouse about your drinking; have you ever had an eye-opener; amnesia; have you 
ever felt you needed to cut down on your drinking) (Russell et al., 1994). 
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6.10  Families and significant others 
An individual’s AOD misuse often impacts on others. In particular, family 
members and significant others of withdrawal clients may experience 
difficulties during the primary client’s withdrawal care. Such difficulties may 
include the exacerbation of financial stresses, time away from work, and 
child protection intervention. Families and significant others are thus 
important beneficiaries of support from AOD withdrawal providers. The 
rationale for delivering services to families and significant others is 
strengthened by evidence that their inclusion in AOD care is known to have 
a positive impact on client treatment outcomes, particularly for young people 
(YSAS, 2008). 
AOD services should ensure that: 
• Clients are consulted about the potential supportive role of family and 
significant others 
• Client confidentiality is upheld when engaging with family and significant 
others of clients, except where client consent to disclose particular 
information has been obtained  
• Families and significant others are valued for their expertise, with a 
focus on their strengths and resources, and a no-blame approach   
• Indirect and/or direct services are offered to families and significant 
others including: 
• Information and advice 
• Referral to AOD support groups, community-based advocacy and 
information services, and Government services  
• Staff are adequately trained to deliver family work (Patterson & Clapp, 
2004) 
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7 PRESENTATION TO AOD 
WITHDRAWAL  
AOD withdrawal clients present to treatment for a range of reasons. Their 
presentation generally falls into one or more of the following categories: 
• Crisis Presentation: Precipitated by an event or circumstance significant 
enough to impact on an individual’s motivation to participate in care, 
where they otherwise would not have (e.g. child protection, correctional 
intervention) 
• Unplanned Withdrawal: When withdrawal occurs following presentation 
to hospital, psychiatric or medical units for a non-related or co-occurring 
condition, or within a secure correctional setting 
• Elective: An individual is independently motivated to access support 
 
Independent of a client’s motivation for engagement with AOD services, 
withdrawal services should: 
• Fully inform the client of what is involved in withdrawal care  
• Outline the risks and benefits of participating in withdrawal care  
• Outline client and service providers’ rights and responsibilities  
• Seek informed, written client consent prior to withdrawal care 
• Provide ready access to complaints procedures 
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8 AOD WITHDRAWAL SETTINGS 
A comprehensive assessment of the individual needs and withdrawal risks of 
a client should inform the most appropriate withdrawal setting (Frank & 
Pead, 1995). All medical and psychosocial issues that are likely to impact on 
withdrawal completion should be considered. 
In Victoria, a range of specialist withdrawal settings may be available to 
individuals experiencing problematic AOD use. These include:  
• Residential withdrawal  
• Hospital inpatient withdrawal 
• Community residential withdrawal 
• Home-based withdrawal  
• Outpatient withdrawal 
• Rural and regional withdrawal support 
In addition to specialist withdrawal settings, correctional, hospital and 
psychiatric facilities are common sites of unplanned AOD withdrawal 
(Saunders & Yang, 2002b). 
An appropriate withdrawal setting is one that provides a safe and welcoming 
environment, staff expertise and a positive approach. Such a setting can 
play an important part in actualising the withdrawal experience for service 
users. 
Settings with established stepped care processes have enhanced capacity 
to meet client needs. Step-up processes allow clients with high needs to be 
transferred to a more intensive withdrawal setting. Alternately, step-down 
care allows those for whom risk/need is reducing to be stepped down to less 
intensive care (refer to 8.1.3 for more detail). 
An extended period of withdrawal care may be warranted for clients with a 
dual diagnosis or those misusing multiple substances. In such situations, 
service providers require additional time to assess presenting concerns 
and/or deliver appropriate care. Psychosocial issues may also impact on 
length of stay, and a case by case approach to withdrawal care is 
recommended.   
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On occasion, client preference for withdrawal setting does not align with the 
options informed by clinical assessment. In such cases, the client should be 
informed of the risks associated with each treatment option and closely 
monitored during withdrawal.  
8.1 Residential withdrawal  
8.1.1 Hospital inpatient withdrawal 
Hospital inpatient withdrawal settings, when available, provide a high level of 
medical (including pharmacotherapy) care for patients experiencing 
withdrawal, subject to availability of specialist services and staff. 
Hospital inpatient withdrawal may be recommended in the case of 
complicated withdrawal, for example, where there exists: 
• A history of seizures or delirium 
• Significant medical comorbidity 
• Frailty 
• Unstable mental illness 
• Comorbid chronic pain with opioid dependence 
Hospital inpatient withdrawal patients are admitted to hospital for an AOD- 
related or non-related condition. As such, they may be receiving treatment in 
one or more hospital settings. Where this is the case, the support of hospital 
addiction medicine liaison services and other clinical care should be sought 
to ensure the effective management of patients through a coordinated 
withdrawal care response. 
8.1.2 Community residential withdrawal  
Community residential withdrawal services typically provide 24-hour, 
medium level supportive care to AOD clients. Increasingly, these settings are 
also being recognised for their capacity to manage complicated withdrawal. 
Medical and pharmacotherapy support is often provided, although at a lower 
level than in hospital inpatient settings. Duration of stay is generally short-
term. 
Community residential withdrawal services may be able to manage clients 
with a history of complex withdrawal, although close proximity to a public 
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hospital with psychiatric facilities is desirable. This facilitates a timely medical 
or psychiatric response (i.e. step-up to hospital inpatient withdrawal) to high 
level needs that may arise during withdrawal (Frank & Pead, 1995; Victorian 
Department of Human Services, 1997). 
In Victoria, youth-specific residential withdrawal units have also been 
established to provide specialist withdrawal care to young people. The 
average length of stay for youth community residential withdrawal is seven to 
ten days. 
8.1.3 Stepped care 
Stepped care allows the transfer of withdrawal clients between home-based 
or community residential settings to hospital inpatient withdrawal settings or 
psychiatric facilities. There is recognition that a stepped care model of 
service provision has significant benefits such as: 
• Step-up from home-based or community residential withdrawal to 
hospital inpatient withdrawal or step-down from hospital inpatient 
withdrawal to community residential withdrawal in response to changing 
client need/risk  
• Enhanced access to limited hospital inpatient withdrawal services 
• Significant cost benefits, particularly for hospitals with step-down clients 
no longer requiring hospital-level care 
• A framework for collaborative approaches between community-based 
AOD services, inpatient psychiatric units and hospitals (Von Korff & 
Tiemens, 2000) 
Ideally, stepped care arrangements should be formalised and supported 
through the development of a Memorandum of Understanding between 
services.  
8.2 Home-based withdrawal  
Home-based withdrawal may be suitable for adults and young people 
experiencing mild to moderate withdrawal symptoms. Clients with single 
substance dependence, no history of complicated withdrawal and no 
significant medical pathology are most appropriate for this level of care. 
Ideally, the home environment is conducive to a period of withdrawal (i.e. 
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drug free) and family members or friends provide appropriate support (Frank 
& Pead, 1995; Victorian Department of Human Services, 1997).  
Medical care and support is provided via regular home visits by health 
professionals such as GPs. Nursing and medical staff are also available to 
provide on-call advice. Access to 24-hour support is recommended through 
either the presence of a support person or contact with telephone support 
services (Ritter, 2003; Victorian Department of Human Services, 1997).  
Home-based withdrawal carries a higher risk to clients due to unsupervised 
dosing, therefore, lower doses of pharmacotherapies such as diazepam are 
used. GPs are commonly used to manage medications and many clients are 
placed on daily or every second day pick-ups from pharmacies to reduce the 
risk of over-medication. 
8.3 Outpatient withdrawal 
Outpatient withdrawal provides short-term medical care and support to 
people who do not require, or no longer require, residential withdrawal care. 
Suitable for low level, single substance withdrawal for stable clients with low 
predicted withdrawal complexity, this withdrawal type includes outpatient and 
home-based withdrawal.  
Outpatient withdrawal is provided through a hospital outpatient clinic, a 
health care centre or AOD service. Clients attend a series of appointments 
with a GP and interventions focus on establishing ongoing linkages between 
the client and other community-based services to support the withdrawal 
process (Ritter, 2003; Victorian Department of Human Services, 1997).  
8.4 Rural and regional withdrawal support 
Rural withdrawal support may involve a combination of a short hospital stay 
(where necessary and available) followed by a period of home-based 
withdrawal. This treatment setting suits clients whose withdrawal is of mild to 
moderate severity and who cannot access a community residential 
withdrawal unit due to geographical factors.  
Rural and regional withdrawal support services employ specialist withdrawal 
nurses to provide home-based medical advice and care. Their work is 
supported by a local medical practitioner who provides additional care, as 
required. Further support from a family member or friend to care for the client 
between visits from local nursing staff or medical practitioner is a necessary 
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requirement for rural and regional withdrawal (Berends et al., 2004; Victorian 
Department of Human Services, 1997). 
8.5 Minimum qualifications in AOD withdrawal 
services 
The Victorian Department of Human Services’ Minimum Qualification 
Strategy for all Victorian AOD services was fully implemented in July 2006. 
Designed as a mechanism for workforce development, the Minimum 
Qualification Strategy is based on a consistent approach to skill development 
for AOD professionals, using nationally recognised minimum competency 
guidelines.   
All professionals employed in Victorian AOD withdrawal services are 
expected to meet the following minimum core competencies: 
• Core/Induction competencies including: 
• Orientation to the AOD sector 
• Work with clients who are intoxicated 
• Assess the needs of clients who have AOD issues 
• Work with clients who have AOD issues 
• Work specific competencies including: 
• Provide needle and syringe services 
• Provide AOD withdrawal services 
• Provide advanced interventions to meet the needs of clients with 
alcohol and/or other drug issues 
• Certificate IV in alcohol and other drugs work including: 
• Orientation to the AOD work 
• Work with clients who are intoxicated 
• Assess the needs of clients who have AOD issues 
• Work with clients who have AOD issues 
• Use specialist communication skills to build strong relationships 
• Work within a legal and ethical framework 
• Facilitate cooperative behaviour 
• Respond holistically to client issues 
• Work effectively with culturally diverse clients and co-workers                                                             
• Participate in workplace safety procedures 
• Maintain an effective work environment 
• Work with other services 
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9 ASSESSMENT 
On presentation to treatment services, clients undergo AOD screening and 
assessment. The goals of screening and assessment are to: 
• Obtain information about the client 
• Identify potential risks to the client during withdrawal care 
• Establish rapport with the client, hence setting the foundations for 
continuing in the supportive relationship 
• Clarify individual requirements 
• Provide information about withdrawal care and treatment options 
Assessment informs the level of withdrawal care required and the likely 
complexity of withdrawal. This is particularly the case where polydrug 
dependence or co-occurring illnesses may have a significant impact on an 
individual’s experience of withdrawal.  
These Guidelines recommend the use of the Victorian Department of Human 
Services AOD Specialist Assessment Tool (available online at 
http://www.health.vic.gov.au/drugservices/pubs/assess.htm).  
Comprehensive screening and assessment processes are enhanced 
through clear communication. Good clinical practice entails a non-
judgemental, empathic and respectful approach that seeks to engage with 
clients. It aims to provide all clients with a positive, early treatment 
experience, commencing at first contact and continuing throughout 
withdrawal care.  
Clients require adequate time to reflect on the proposed withdrawal option 
and pose questions. They should feel comfortable and supported in 
participating in decision-making processes regarding their AOD withdrawal 
care. The provision of information and education, reassurance and 
counselling may help to reduce client discomfort and anxiety at pre-
admission. 
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Assessment is essential to appropriate treatment planning and 
implementation. The key factors for consideration at assessment include: 
• Communication 
• A clear information exchange between the client and clinician, 
respecting client choice as well as clinical judgement  
• A detailed description of client rights, responsibilities and grievance 
procedures 
• A clear explanation of client confidentiality protocols, including 
concerns regarding harm to themselves and others 
• Establishing the withdrawal care relationship between client and 
clinician 
• Risk factors (bio-psychosocial) 
• A consumption history (daily quantity and frequency of use, person’s 
account of potency) 
• Underlying co-occurring physical and mental health conditions 
• Suicide risk assessment 
• Domestic/family violence  
• Child protection issues 
• Current withdrawal status 
• Identifying polydrug use 
• Identifying psychosocial factors that may present barriers to 
achieving client goals 
• Planning 
• Client goal/s of withdrawal 
• Service setting matching 
• Pre-admission planning to identify opportunities for support and 
intervention, where withdrawal care is not immediately available  
• Establishing an appropriate withdrawal plan  
• Identifying existing service linkages that could offer post-withdrawal 
support 
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Psychosocial issues that should be explored in an assessment of AOD 
clients are detailed in Table 4, below. 
 
Table 4: Psychosocial issues to address during assessment 
Psychosocial issues  Focus 
Perceived barriers to achieving goal of 
withdrawal care 
Relationship issues 
Geographic isolation 
Access to appropriate AOD support and 
information 
Legal and financial issues 
Parenting and child protection issues 
Domestic violence 
Beliefs about withdrawal care Motivation for accessing withdrawal care 
Previous withdrawal experiences 
Fears and expectations  
Identified supports Appropriate accommodation 
Support network (family, friends, workers) 
Source: Key informant interviews  
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9.1 Assessment tools 
Appropriate screening and assessment tools and processes must be 
available to identify and respond to the range of issues with which clients 
present to a treatment setting. These Guidelines recommend the use of the 
Victorian Department of Human Services AOD Specialist Assessment Tool 
(available online at http://www.dhs.vic.gov.au/home). 
While structured and validated screening and assessment tools have been 
developed for specific use in the AOD sector, there exists some support for a 
less structured, narrative approach to collecting client information at 
assessment. For some clients, an assessment process that is embedded in 
conversation and which occurs over time may be more appropriate. 
Assessment tools should guide the conversation and information is recorded 
post-session. 
9.2 Pre-admission planning 
Brief interventions are an effective pre-admission strategy that offers adjunct 
support for clients who continue drug use prior to treatment entry. Harm 
reduction strategies, motivational interviewing, self-care, managing anxiety 
and relaxation techniques may be considered at this time and drawn upon 
pre-, during and post-withdrawal (see Appendix 5 for coping and relaxation 
techniques).  
Pre-admission planning may also explore and implement strategies that 
seek to reduce client drop-out between first service contact and treatment 
commencement. Waiting list support, linkage with support services and 
regular clinician follow-up of clients should be explored as part of pre-
admission planning. 
9.3 Planning for post-withdrawal support  
Linking AOD clients into other services is associated with better treatment 
outcomes. Assessment presents an opportune time to plan for a range of 
these post-withdrawal supports (Griswold et al., 2007; Hilton et al., 2001). 
Regardless of whether an individual intends to remain abstinent, reduce drug 
use or continue drug use, increased awareness of support services is 
important.  
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Appropriate post-withdrawal services may include: 
• AOD support services 
• General practitioners 
• Individual counselling 
• Outpatient programs 
• Outreach support 
• Addiction specialists 
• Self-help and peer support groups 
• Residential rehabilitation 
• Other community-based AOD 
• Post-withdrawal support groups 
• Health and medical services 
• Dieticians/nutritionists 
• Approved pharmacotherapy dispensers 
• Healthy liver clinics 
• Maternal nursing 
• Welfare services 
• Accommodation services 
• Income support services 
• Advocacy services 
• Legal services 
• Child protection agencies 
• Negotiating with employers – provision of medical certificate for period of 
withdrawal care 
• Vocational services 
• Employment, education and training 
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Planning for post-withdrawal support should be revisited throughout 
withdrawal care. Such planning may help to address not only AOD issues, 
but precipitants to treatment presentation, such as child protection or 
criminal justice system involvement or other coercive influence. Such 
planning may also contribute to a reduction in clients’ anxiety about the post-
withdrawal period and play an integral part in relapse prevention (key 
informant interviews). 
Where possible, the inclusion of family and significant others may be 
considered throughout withdrawal care. With client consent, family members 
can be involved in assessment, withdrawal care and planning for post-
withdrawal. Family and significant others may also require support through 
referrals and linkages to community support services (YSAS, 2008). 
9.4 Supportive care 
Supportive care is a key component of drug withdrawal care for all classes of 
drugs. Frequent monitoring, reassurance, providing information and a 
suitable environment can help to reduce withdrawal symptom severity. 
Regular monitoring should occur throughout withdrawal care in order to 
respond to client needs as they arise. The frequency of monitoring will be 
dependent on symptom severity and the withdrawal care setting.  
The following is a guide to providing supportive care in a residential 
withdrawal setting. It is recommended that monitoring of clients occurs on an 
hourly basis. 
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Table 5: Supportive care protocols 
Check withdrawal severity Appropriate withdrawal scale 
Check general health Consciousness 
Blood pressure 
Self-report 
Check environment Calm 
Quiet 
Low lighting 
Privacy 
Safe 
Self report 
Supportive person(s) 
Reassure Allay concerns and fears 
Positive encouragement 
Offer information 
Orientate Time 
Place 
Person 
Offer fluids  
Check physical comfort Pillows 
Blankets 
Hot packs 
9.5 Complementary therapy and natural 
supplements 
Adjunct therapies, such as massage, acupuncture and herbal therapies, are 
available within some treatment settings. These therapies have limited 
evidence supporting their effectiveness, however anecdotal reports suggest 
benefits for some patients.  
Information and options for referral to services that provide these 
interventions can be provided to clients during assessment. 
9.6 Intoxication at assessment 
Finally, and critically, an effective assessment is wholly dependent on the 
capacity of clients to provide relevant information, understand the treatment 
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options available and willingly consent to treatment. Given that client 
intoxication may limit comprehension, assessment information should be 
revisited when acute intoxication has passed. See Appendix 2 for advice on 
how to identify signs of intoxication and potential overdose, and guidance in 
managing intoxication. 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
45 
10  ALCOHOL WITHDRAWAL  
These Guidelines provide a comprehensive approach to withdrawal care. 
The use of prescribing guidelines outlined below focus on alcohol withdrawal 
and will be supported by a comprehensive clinical assessment. 
The prevalence of alcohol misuse is a cause for concern in Australia. 
Approximately 1,401,400 Australians are using alcohol daily (AIHW, 2007). 
More than seven million people or 40% of the population use alcohol on a 
weekly basis and approximately 3.4% of the population could be at high risk 
for alcohol-related problems (AIHW, 2007). 
In delivering alcohol withdrawal services to clients, clinicians should 
consider:  
• Setting 
• Withdrawal syndrome and potential complications  
• Assessment  
• Withdrawal care planning  
• Withdrawal care  
• Planning for post-withdrawal  
• Special needs groups  
Each of these considerations is examined below. 
10.1  Alcohol withdrawal settings 
The most appropriate setting for an individual seeking alcohol withdrawal will 
be informed by a thorough clinical assessment. 
The most appropriate setting for an individual seeking alcohol withdrawal 
should be determined via a thorough clinical assessment. Alcohol withdrawal 
can occur in each of the treatment settings outlined in this document 
(outpatient withdrawal, community residential withdrawal, hospital inpatient 
withdrawal and rural withdrawal support). Many clients are able to undertake 
withdrawal from alcohol in community settings.  
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In some settings, such as hospitals, psychiatric facilities, prisons and police 
watch-houses, individuals may experience an unplanned alcohol withdrawal. 
Staff in such settings will be familiar with, and alert to, the signs of alcohol 
withdrawal in order to respond in a timely and appropriate manner.  
Attention to unplanned alcohol withdrawal is critical to responding in an 
appropriate and timely manner to individuals. Evidence of the onset of 
withdrawal symptoms should be considered potential indicators of alcohol 
withdrawal.   
The best withdrawal care facilitates step-up and step-down care, according 
to client need.  
Regardless of withdrawal setting, the best withdrawal care facilitates step-up 
and step-down care, as appropriate. This allows clients whose needs 
warrant greater withdrawal care to be transferred to a more intensive 
withdrawal setting. Alternatively, stepped care allows those for whose need 
is reducing to be stepped down to less intensive care.  
Pharmacotherapy support in alcohol withdrawal is subject to a range of 
setting-specific considerations. These are outlined below in Table 6. 
 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
47 
Table 6: Pharmacotherapy considerations for alcohol 
withdrawal settings 
Alcohol 
withdrawal 
setting 
Pharmacotherapy considerations  
Outpatient 
withdrawal 
Appropriate for clients able to undertake alcohol withdrawal in the 
community 
Unsuitable for clients where there is a history of DTs, previous complicated 
withdrawal or a high level of alcohol dependence 
Dosing of benzodiazepines such as diazepam should be reduced over the 
period of withdrawal and care should be taken not to over-sedate the client 
Ideally, clients should be monitored by a health professional (e.g. outreach 
nurse) for the first four days of withdrawal and then every two days until the 
completion of withdrawal 
Detailed information should be provided to both the client and any support 
people who may be present throughout the withdrawal process. Symptoms, 
onset and duration of withdrawal and side effects of benzodiazepines 
should be explained. Risk factors associated with outpatient withdrawal 
settings should be clearly outlined and contingency planning put in place 
Community 
residential 
withdrawal 
Appropriate where a moderate–severe alcohol withdrawal syndrome is 
anticipated, as determined at the time of assessment 
These settings are increasingly recognised as having the capacity to 
manage complicated withdrawal  
Hospital 
inpatient 
withdrawal 
Appropriate where clients are likely to experience a severe or complicated 
alcohol withdrawal syndrome  
Alcohol withdrawal is commonly associated with presentation to hospital 
accident and emergency or psychiatric settings for co-occurring health 
issues. The cessation of alcohol consumption at this time may trigger the 
onset of withdrawal  
Staff in these settings should undertake screening and assessment for 
alcohol withdrawal, and any patient reporting alcohol consumption in excess 
of the NHMRC recommendations for safe levels of drinking should be 
considered at risk 
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10.2 Alcohol withdrawal syndrome 
The alcohol withdrawal syndrome occurs on a continuum from mild to 
severe, with the onset of alcohol withdrawal usually occurring 6–24 hours 
after the last drink. Use of benzodiazepines or other sedatives may delay the 
onset of withdrawal symptoms. In some severely dependent drinkers, simply 
reducing the level of consumption may precipitate withdrawal, even if they 
have consumed alcohol recently.  
While unsupported alcohol withdrawal is generally completed within three 
days, polydrug use and other factors may significantly prolong symptoms. 
Acute symptoms of mild to moderate alcohol withdrawal commonly include:  
• Agitation 
• Anxiety 
• Fever 
• Insomnia 
• Nausea 
• Nightmares 
• Restlessness 
• Sweats 
• Tachycardia 
• Tremor 
• Vomiting (Ntais et al., 2005) 
More serious features associated with alcohol withdrawal include: 
• Delirium Tremens (DTs) 
• Symptoms of DTs usually occur between two and five days after 
cessation of drinking 
• Symptoms include disorientation, anxiety and agitation, tremors, 
paranoia, hallucinations and fluctuating blood pressure 
• This most serious complication of alcohol withdrawal is potentially 
life-threatening and requires immediate medical attention (Shand et 
al., 2003a) 
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• Cardiac arrest and death - can occur in very severe alcohol withdrawal 
syndrome 
• Hallucinations - auditory, visual, tactile 
• Increased agitation 
• Seizures - usually occur within the first 48 hours of cessation of drinking 
(Ntais et al., 2005) 
• Wernicke’s encephalopathy 
• Wernicke’s encephalopathy is caused by inadequate intake or 
absorption of thiamine (Vitamin B1) associated with prolonged 
alcohol consumption 
• Symptoms may include abnormal eye movement, staggering, 
agitation, confusion and drowsiness 
• This condition requires thiamine dosing as outlined in Section 10.5.5 
The major features, time-course, onset, duration and severity of alcohol 
withdrawal are shown in Figure 2 below. 
Figure 2: Symptoms and duration of alcohol withdrawal 
Source: NSW Health (2008, p.22) 
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10.3 Alcohol withdrawal assessment 
Clinicians should be familiar with the general principles of assessment 
(refer section 9).  
During withdrawal assessment, clinical staff will be alert to signs of client 
intoxication.  
A thorough assessment of alcohol-dependent clients is critical in determining 
the most appropriate withdrawal care. Assessment is, however, largely 
dependent on the capacity of clients to provide relevant information. Recent 
alcohol use may limit clients’ capacity to share and absorb accurate 
assessment information.  
Intoxicated clients presenting to assessment may have slurred speech, 
reduced motor control and lack of emotional inhibition. Intoxication may limit 
their capacity to share and absorb accurate assessment information.  
For intoxicated clients, all services should: 
• As soon as possible, identify the most recent drug type, quantity and 
time consumed (to inform medical intervention in the event of an 
overdose) 
• Implement regular clinical observations of the client at frequent intervals 
at first then decreasing over time as evidence of intoxication subsides 
• Revisit the assessment when acute intoxication has passed 
10.3.1 Medical conditions and alcohol withdrawal 
assessment 
Withdrawal service staff will consider the potential for alcohol withdrawal to 
complicate clients’ existing medical conditions and provide specialist medical 
care and monitoring, as required. 
Some medical conditions may be complicated by alcohol withdrawal and are 
at times difficult to manage in alcohol withdrawal settings. For example, the 
management of malnutrition, liver and gastric conditions and platelet 
dysfunction may be affected by the withdrawal process. There is also an 
increased risk of post-operative morbidity and longer inpatient hospital stay 
for alcohol-dependent surgical patients. Emotional, economic and social 
impacts may also result from alcohol withdrawal (Foy et al., 1997).  
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10.3.2 Alcohol screening and assessment tools 
Note: Withdrawal scales may lack the sensitivity to detect progression to 
serious illness in complicated withdrawal. Withdrawal monitoring should 
always include regular clinical observation. 
The CIWA-Ar (Appendix 6) is a tool used to scale symptom severity for 
simple alcohol withdrawal, and complicating factors such as co-occurring 
disorders and polydrug use may impact on the appropriateness of its use. 
The ten-item scale can be used to evaluate the presence and severity of 
withdrawal symptoms, with higher scores indicating increased risk for severe 
withdrawal.  
Scoring on the CIWA-Ar correlates directly with the severity of withdrawal, 
that is,  the higher the score, the more severe the withdrawal symptoms. It is 
recommended that staff using the CIWA-Ar receive appropriate training, as 
incorrect scoring will result in increased benzodiazepine dosing. Using 
benzodiazepine doses triggered by the CIWA-Ar reduces the risk of 
progression to serious complications of withdrawal such as seizures (Mayo-
Smith, 1997).  
Symptom-triggered pharmacotherapy can be titrated against the total CIWA-
Ar score (Puz & Stokes, 2005). Instructive information for use of the CIWA-
Ar is included in Appendix 6. 
A consumption calendar (Appendix 3) can also be completed by the client to 
inform treatment planning. It provides information regarding the client’s 
alcohol consumption for the week preceding the assessment. The 
consumption calendar records: 
• Substances consumed in the past week 
• Quantities of substances consumed in the past week 
• Method of ingestion of substances consumed during the last week 
• Most recent use and quantities of substances to alert staff to possible 
overdose 
• Patterns of substance misuse 
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10.4  Alcohol withdrawal care planning 
Information obtained during assessment will inform the withdrawal care plan. 
Information obtained during assessment informs the client’s withdrawal care 
plan, which documents: 
• The likely severity of withdrawal based on the consumption calendar and 
CIWA-Ar 
• Previous history of complicated withdrawal 
• The client’s motivation for withdrawal care, where this is a planned 
withdrawal presentation  
• The client’s goals during withdrawal care 
• Potential barriers that may impact on achieving the client’s withdrawal 
goals 
• Available support to enhance the likelihood of success 
• A post-withdrawal plan, including relapse prevention and linkages to 
external support networks to address the client’s psychosocial needs 
• Inclusion of family/significant others, where appropriate 
10.5  Alcohol withdrawal care 
10.5.1 Psychosocial support in alcohol withdrawal  
Psychosocial interventions complement the medical management of alcohol 
withdrawal symptoms and will be available at all alcohol withdrawal services.  
The overarching principles of supportive care are fundamental to the 
provision of a holistic model of withdrawal care. Psychosocial interventions 
should explore: 
• Client goals, including any change in these goals over time 
• Perceived barriers to achieving an individuals’ goal/s of withdrawal care 
• An individual’s beliefs about withdrawal care 
• Appropriate interventions and support services 
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10.5.2 Benzodiazepines 
Where required, benzodiazepines remain the preferred pharmacotherapy for 
managing alcohol withdrawal symptoms. 
The majority of alcohol-dependent clients complete withdrawal without 
pharmacotherapy support. However, where required, benzodiazepines 
manage a range of withdrawal symptoms and have been shown to prevent 
alcohol withdrawal seizures. There is also some evidence to show that 
benzodiazepines may prevent progression to delirium (Mayo-Smith, 1997).  
Long-acting benzodiazepines, and diazepam in particular, are recommended 
for use in the management of alcohol withdrawal in a number of recent 
Australian Clinical Guidelines (D’Onofrio et al., 1999; Mattick & Jarvis, 1993; 
Mayo-Smith, M., 1997; Mayo-Smith, M. F. et al., 2004; NSW Health 
Department, 1999; Salloum et al., 1995; Shand et al., 2003a). 
Treatment with benzodiazepines in alcohol withdrawal is normally 
considered once a client’s Blood Alcohol Level (BAL) is lower than 0.1. 
Services may have access to breathalysers for continued monitoring of a 
person’s BAL. Dosing commencement should also be informed by setting, 
level of monitoring and support available, particularly in rural and regional 
withdrawal settings.  
Table 7 outlines three benzodiazepine medication regimes for use in alcohol 
withdrawal. 
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Table 7: Medication regimes for the use of benzodiazepines in 
alcohol withdrawal (as at March 2009) 
Type of dosing 
regime 
Client group Dosing regime 
Fixed schedule 
 
Appropriate for clients at risk 
of complicated withdrawal 
who are not in a hospital or 
other supervised 
environment (e.g. 
community-based 
withdrawal) 
Specified doses at fixed 
intervals, tapered over a set 
number of days 
 
Symptom-triggered 
dosing 
 
Appropriate for alcohol 
withdrawal clients in a 
medically supervised setting 
Doses administered according 
to individually-experienced 
symptoms of alcohol 
withdrawal 
Loading dose 
 
Appropriate for alcohol 
withdrawal clients at high risk 
of complicated withdrawal 
who are in an inpatient 
environment 
Large doses until alcohol 
withdrawal subsides or light 
sedation is reached 
Source: (NSW Department of Health, 2008a; Saunders et al., 2002a; Shand et al., 
2003a) 
 
Inpatient/residential withdrawal settings can administer diazepam dosing 
based on the results of the CIWA-Ar conducted every one to four hours. 
Dosing regimens may vary from setting to setting, depending on level of 
support available, the duration of admission and clinician preference.  
A standard benzodiazepine dosing schedule example is provided in Table 8, 
below. 
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Table 8: Examples of benzodiazepine dosing regimens (as at 
March 2009) 
Level of dependence/setting of 
withdrawal 
Example of diazepam dosing 
Mild dependence in outpatient withdrawal 
setting 
Day 1: 5–15 mg qid 
Day 2: 5–10 mg qid 
Day 3: 5–10 mg tds 
Day 4: 10 mg bd 
Day 5: 5 mg bd 
Moderate severity dependence in inpatient 
setting 
5–20 mg 2–4 hourly as needed if CIWA Ar 
score>10 for 3–4 days 
High level of dependency and/or risk of 
complex withdrawal in inpatient setting 
Loading doses of 10–20 mg every 2–4 
hours until light sedation achieved 
followed by CIWA Ar triggered or fixed 
dose therapy for 3–4 days 
Source: Key informant interviews  
Dehydration is common among alcohol withdrawal clients. Continued fluid 
consumption and clinical monitoring is advised. In severe cases, intravenous 
fluid replacement may be required.   
Continued monitoring and medical review of medications is recommended 
throughout the course of withdrawal. 
10.5.3 Anti-craving therapies 
Medications used to treat alcohol use disorders include the anti-craving 
therapies acamprosate (Campral®) and naltrexone (Revia®), and the 
aversive agent disulfiram (Antabuse®). These agents may be commenced in 
both inpatient and outpatient settings to prevent relapse in alcohol 
dependence.  
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There is no consistent evidence to support the effectiveness of one agent 
over another. Choice of anti-craving medication should be dependent upon 
drug interactions, patient experience, likely adherence to dosing and 
potential adverse effects.  
Some research suggests that naltrexone may be suitable in the treatment of 
patients seeking to reduce heavy alcohol intake and that acamprosate may 
be suitable for patients seeking abstinence (Rösner et al, 2008).  
There is varying evidence that indicates combination therapy with 
acamprosate and naltrexone is more effective than monotherapy with either 
agent (Kiefer et al., 2003). 
Alcohol pharmacotherapies are best used as part of a comprehensive 
management plan with appropriate psychosocial supports, and both agents 
may be commenced early in withdrawal treatment. Therapy should normally 
be maintained in the event of relapse to alcohol use, and patients should not 
normally be advised to discontinue anti-craving therapy in this instance. 
Relapse should prompt review of the individual’s withdrawal care plan. 
The main anti-craving medications are detailed below. 
 
The following is a summary of the principles behind these therapies. 
Prescribers should refer to the detailed Australian product information 
found in MIMS or similar reference prior to prescribing these therapies. 
Naltrexone  
Naltrexone is an opioid receptor antagonist medication which exerts its effect 
through interruption of alcohol reward pathways. Randomised placebo 
controlled trials show that naltrexone increases duration of abstinence and 
reduces amount of alcohol consumed in relapse (Carmen, 2004; Kranzler, 
2003).  
Dosing and commencement of therapy 
Naltrexone therapy may be commenced from day three of alcohol withdrawal 
and dosing will be determined by a medical professional. Duration of 
naltrexone therapy depends on the response to treatment and individual 
patient goals. 
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Adverse effects and contraindications 
Naltrexone is generally well tolerated and adverse effects are usually 
associated with dosing levels, which may need to be adjusted. Side effects 
generally resolve within a few days of commencement of treatment and may 
include: 
• Dizziness 
• Fatigue 
• Headache 
• Nausea 
Naltrexone is contraindicated in acute hepatitis or liver failure and its safety 
in pregnancy has not been established. Patients on opioid therapy should 
not be treated with naltrexone (see Interactions below). Liver function 
monitoring is usually recommended in long-term treatment.  
Interactions 
As a potent opioid mu receptor antagonist, naltrexone should not be given to 
patients on opioid therapy as it is likely to precipitate withdrawal. If an 
individual on long-term opioids is considered for this intervention, opioids 
should be ceased for at least seven days before commencing naltrexone.  
Clients who are taking anti-depressant or anti-anxiety medications are 
generally able to commence naltrexone, as it possesses no mood-altering or 
addictive properties. 
Acamprosate 
Acamprosate acts on the brain’s glutamatergic pathways through NMDA 
receptor systems that are involved in alcohol dependence and withdrawal. 
Randomised placebo controlled trials show benefit of acamprosate in 
prolonging duration of abstinence and increasing alcohol-free days (Mann, 
2004; Carmen, 2004; Kranzler, 2003). In most cases acamprosate need not 
be ceased if patients relapse into alcohol use. 
Dosing and commencement of therapy 
Therapy may be commenced early in alcohol withdrawal management, and 
there is some evidence of the benefit of acamprosate in reducing neuronal 
damage in alcohol withdrawal. As acamprosate does not reduce acute 
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alcohol withdrawal severity it should not be used as a treatment for 
withdrawal per se.  
Acamprosate is available in 333 mg tablets and dosing regimens should be 
determined by a medical professional. The duration of therapy is dependent 
on individual response to acamprosate and treatment goals.  
Adverse effects and contraindications 
Acamprosate is generally well tolerated. Most adverse effects are mild and 
transient and rarely necessitate cessation of treatment. The most common 
adverse effect is diarrhoea. 
Interactions 
While acamprosate does not have any significant interactions, it is a calcium-
based compound and a theoretical interaction may occur with drugs such as 
tetracyclines. There is no interaction between acamprosate and alcohol. 
Note that the safety of acamprosate use during pregnancy has not been 
established. 
Disulfiram 
Disulfiram (Antabuse ®) has previously been used in the management of 
alcohol withdrawal. However, the severity of associated adverse effects, cost 
of treatment and the extensive planning required for disulfiram therapy has 
resulted in it rarely being used in the treatment of alcoholism in Australia. 
The use of disulfiram is outside the scope of these Guidelines and should be 
discussed with Specialist Addiction Medicine services. 
10.5.4 Symptomatic care for alcohol withdrawal  
A range of symptomatic medications is appropriate for use in alcohol 
withdrawal. 
Alcohol withdrawal is primarily managed with benzodiazepines. Additional 
medication may be used for management of symptoms as described in 
Table 9, below. 
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Table 9: Symptomatic medications for use in alcohol withdrawal 
(as at March 2009) 
Symptoms Symptomatic medication 
Nausea and vomiting  
 
Antiemetics  
Metoclopramide (Maxolon®) 10 mg every 4–6 hoursa  
Prochlorperazine (Stemetil®) 5 mg every 4–6 hours orally 
or intramuscularly. Reduce the dose rate to 8-hourly as 
symptoms abatea  
Diarrhoea 
 
Antidiarrhoeal 
Loperamide (Imodium®)or Kaomagma®a   
Atropine and diphenoxylate (Lomitil®)b 
Abdominal cramps Hyoscine butylbromide (Buscopan®) 
Headaches Paracetamol  
Note: Paracetamol is often preferable to aspirin or 
ibuprofen, especially if there is a suspicion of peptic 
ulceration b 
To minimise gastrointestinal symptoms encourage fluids and a simple diet b 
Prophylactic treatment for seizures (for example with phenytoin, carbamazepine or sodium 
valproate) is not proven to have any clinical benefit. 
Medications which do not have any demonstrated benefits over benzodiazepines and cannot 
be recommended as first line treatments for alcohol withdrawal include:  
• Anticonvulsants 
• Antidepressants 
• Major tranquilisers 
a)  NSW Department of Health (2008a) 
b)  Murray et al. (2002)  
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10.5.5 Use of thiamine in alcohol withdrawal 
Suspected or diagnosed Wernicke’s encephalothopy is a serious condition 
that should be treated with intravenous thiamine in an acute hospital setting. 
Additionally, prophylactic thiamine should be given routinely to alcohol 
withdrawal clients.  
Wernicke’s is an acute encephalopathy of thiamine deficiency and may be 
seen in alcohol-dependent individuals presenting for withdrawal care. This 
condition, although uncommon, may progress to a chronic form of cognitive 
damage known as Korsakoff’s syndrome. Signs of Wernicke’s 
encephalopathy include confusion and ataxia. 
All clients with suspected Wernicke’s encephalopathy should be referred to a 
hospital emergency department. An example of thiamine dosing regimens 
and routes of administration for alcohol-dependent clients and clients with 
suspected Wernicke’s encephalopathy are outlined in Table 10, below. 
 
Table 10: Example of thiamine dosing for alcohol-dependent 
clients and clients with suspected Wernicke’s encephalopathy 
(as at March 2009) 
Alcohol withdrawal 
presentation 
Thiamine dose 
All patients 100–300 mg intravenously or intramuscularly for 3–5 days 
300 mg orally daily thereafter  
Suspected Wernicke’s 
encephalopathy 
At least 300 mg intramuscularly or intravenously for 3–5 days 
100–300 mg orally thereafter 
Source: Key informant interviews 
 
 
10.5.6 Complementary therapies in alcohol withdrawal 
Complementary therapies such as massage, acupuncture and herbal 
remedies are available within some withdrawal settings. There is anecdotal 
evidence that these therapies assist in alcohol withdrawal and clients should 
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be made aware of the availability of these services during treatment 
planning. Complementary therapies include but are not limited to: 
• Dietary supplements: 
• B Group Vitamins, especially high dose B1, B3 and B6 
• Vitamin C 
• Zinc 
• Stress reduction, relaxation and sleep assistance: 
• DL-Phenylalanine 
• Valerian 
• Kava 
• Rescue Remedy 
• Zizyphus & Polygala pills (Chinese Herbal Medicine) 
• Nausea and vomiting: 
• Ginger or Homeopathic Remedy (Vomiplex) 
• Peppermint 
• Formula for Joint Pain 
• Calcium 
• Fish oils 
• Magnesium 
• Liver function 
• Silymarin (YSAS, 2008) 
10.6  Planning for post-withdrawal  
Post-withdrawal support is an essential component of the treatment 
continuum for alcohol-dependent clients.  
Planning for post-withdrawal may include consideration of additional 
pharmacotherapies (acamprosate or naltrexone) for alcohol withdrawal 
symptom management and relapse prevention. Planning for post-withdrawal 
will: 
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• Commence at the assessment phase of withdrawal care 
• Support the client’s goals which may pertain to accommodation, child 
protection, domestic violence and legal support 
• Support client access to post-withdrawal services that provide ongoing 
support and advocacy  
• Involve family/significant others in post-withdrawal care, as appropriate, 
to help implement the client’s post-withdrawal plan 
10.7  Special needs groups 
10.7.1 Infants of alcohol-dependent women  
A foetus that is exposed to regular, excessive maternal alcohol consumption 
will be closely monitored for withdrawal symptoms during their first days of 
life.  
Close monitoring will entail: 
• Medical and nursing staff monitoring for signs of Foetal Alcohol 
Syndrome (FAS) and subsequent alcohol withdrawal 24–48 hours after 
birth  
• Specialist medical attention and medication to manage alcohol 
withdrawal symptoms (NSW Department of Health, 2008b) 
Babies with FAS will be followed up for at least the first six months by a 
health professional where the neonate’s mother has: 
• Engaged in risky levels of drinking (as defined by the Australian 
Alcohol Guidelines), or  
• Given birth previously to a baby with FAS (NSW Department of 
Health, 2008b) 
Note: Diagnosis of FAS at birth is difficult. In suspected cases, the infant 
should be re-assessed at about six months of age (NSW Department of 
Health, 2008b). 
10.7.2 Clients with a dual diagnosis  
Clients for whom a psychiatric condition emerges during alcohol withdrawal 
will receive care that addresses their specific needs. 
Specifically, they will be: 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
63 
• Linked with appropriate mental health services 
• Encouraged to continue to seek mental health support beyond 
withdrawal care 
• Monitored for symptoms, such as agitations during withdrawal, and 
managed appropriately 
10.7.3 Families/significant others  
Consideration will be given to the needs of family/significant others in contact 
with an alcohol-dependent person during outpatient withdrawal or reduction.  
Where appropriate, information will be provided to family/significant others 
regarding the alcohol withdrawal process and support services such as 
Directline and/or Lifeline.  
10.7.4 Young people 
Young people presenting to AOD services will be linked with youth-specific 
services, where available. 
As outlined above (see section 6.3), young people may present with varying 
psychosocial factors contributing to their drug use which impact upon their 
long-term plan for recovery. It is important to be mindful of the potential 
differences in treatment approach and care when commencing withdrawal 
care. Ongoing contact with, and adjunct support from, youth-specific workers 
throughout withdrawal care can promote more positive experiences for the 
young person.  
For further detailed information related to the withdrawal care of young 
alcohol users, please refer to the YSAS Clinical Practice Guidelines (YSAS, 
2008). 
10.8      Recommended reading 
Mayo-Smith, M. (1997). Pharmacological management of alcohol 
withdrawal:  A meta-analysis and evidence-based practice guidelines. JAMA, 
278(2), 144–151. 
Mayo-Smith, M. F., Beecher, L. H., Fischer, T., Gorelick, D. A., Guillaume, J. 
L., Hill, A. et al. (2004). Management of Alcohol Withdrawal Delirium: An 
Evidence-Based Practice Guideline. Archives of Internal Medicine, 164, 
1405–1412 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
64 
NSW Department of Health. (2008a). NSW Drug and Alcohol Withdrawal 
Clinical Practice Guidelines. NSW: NSW Department of Health. 
NSW Department of Health. (2008b). Nursing and Midwifery Clinical 
Guidelines: Identifying and responding to drug and alcohol issues. NSW: 
NSW Department of Health. 
Ntais, C., Pakos, E., Kyzas, P. & Ioannidis, J. P. A. (2005). Benzodiazepines 
for alcohol withdrawal. The Cochrane Database of Systematic Reviews, 2. 
Shand, F., Gates, J., Fawcett, J. & Mattick, R. (2003). Guidelines for the 
treatment of alcohol problems: Sydney; Commonwealth of Australia. 
YSAS. (2008). YSAS Clinical Practice Guidelines - Management of alcohol 
and other drug withdrawal. YSAS, Melbourne. 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
65 
11  OPIOID WITHDRAWAL  
These Guidelines provide a comprehensive approach to withdrawal care. 
The use of prescribing guidelines outlined below will be supported by a 
comprehensive clinical assessment. 
Opioids are a broad class of opiate analogue compounds that have opium or 
morphine-like activity (e.g. methadone). The derivative term, opiates, applies 
only to drugs derived directly from opium (e.g. morphine, codeine, and 
heroin).  
Opioid withdrawal involves neuro-adaptation reversal and withdrawal 
symptom management. Given that many opioid users fail to complete 
withdrawal and relapse rates are high, opioid withdrawal should be seen as 
one step in ongoing therapy, rather than a stand-alone intervention. Planning 
for post-withdrawal support is an essential component of providing a 
continuum of care to clients and can assist them to continue to work towards 
their treatment goals beyond the withdrawal itself (Amato et al., 2005; 
McCambridge et al., 2007). 
Significant developments in pharmacotherapy treatment for opioid users 
have occurred in recent years. While methadone has been the gold standard 
for maintenance pharmacotherapy treatment of opioid addiction, 
buprenorphine has some features (such as safety due to ‘ceiling of effects’ 
and ease of dosing) that make it a preferable option to methadone in some 
settings for some clients.  
In delivering opioid withdrawal services to clients, clinicians should consider:  
• Setting 
• Withdrawal syndrome and potential complications  
• Assessment  
• Withdrawal care planning  
• Withdrawal care  
• Planning for post-withdrawal  
• Special needs groups  
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Each of these considerations is examined below. 
11.1  Opioid withdrawal settings  
The most appropriate setting for an individual seeking opioid withdrawal will 
be informed by a thorough clinical assessment. 
The most appropriate setting for an individual seeking opioid withdrawal 
should be determined via a thorough clinical assessment. In general, opioid 
withdrawal clients can be managed in outpatient withdrawal settings, 
although residential treatment settings such as hospital-based withdrawal or 
community residential withdrawal are more suitable for patients with: 
• A history of repeated, unsuccessful attempts at withdrawal in a non-
residential setting 
• Significant comorbid physical illnesses or mental health issues 
• A concurrent dependence on alcohol or benzodiazepines 
• Limited social and community support available to complete their 
withdrawal safely 
• Inadequate access to a registered prescriber, such as in rural settings 
In some settings, such as hospitals, psychiatric facilities, prisons and police 
watch-houses, individuals may experience an unplanned opioid withdrawal. 
Staff in settings, will be familiar with, and alert to, the signs of opioid 
withdrawal in order to respond in a timely and appropriate manner.  
Attention to unplanned opioid withdrawal is critical to responding in an 
appropriate and timely manner to individuals. Evidence of injecting sites, the 
onset of withdrawal symptoms and frequent or unusual requests for opiate-
based pain management should be considered potential indicators of opioid 
withdrawal.   
The best withdrawal care facilitates step-up and step-down care, according 
to client need.  
Stepped care allows clients whose needs warrant greater withdrawal care to 
be transferred to a more intensive withdrawal setting and those for whom 
need is reducing to be stepped down to less intensive care. 
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11.2  Opioid withdrawal syndrome 
Unlike alcohol or benzodiazepine withdrawal, opioid withdrawal is not life   
threatening to users with few medical complications (Lintzeris et al., 2006; 
NCETA, 2004). However, opioid withdrawal does heighten the risk of 
overdose on relapse, due to a reduced level of post-withdrawal tolerance. 
The onset and time course of opioid withdrawal is associated with the half-
life of the drug used. The withdrawal symptoms of short-acting, agonist 
opioids, such as heroin and morphine, typically emerge more rapidly than 
long-acting agonist opioids, such as methadone. 
11.2.1 Heroin and morphine withdrawal symptoms  
Symptoms of withdrawal in short-acting agonist opioids such as heroin and 
injection morphine commence 6–24 hours after last use, peak at 24–48 
hours and resolve within five to ten days. The symptoms of heroin 
withdrawal include:  
• Abdominal cramps 
• Anxiety, irritability and dysphoria 
• Back aches 
• Cramps 
• Diarrhoea 
• Disturbed sleep  
• Elevated blood pressure 
• Increased sweating   
• Joint pain 
• Lacrimation 
• Muscle spasm leading to headaches 
• Nausea and vomiting  
• Rhinorrhoea 
• Twitching 
• Urinary frequency 
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11.2.2 Methadone and buprenorphine withdrawal 
Management of methadone or buprenorphine withdrawal is less common in 
clinical withdrawal settings than the management of heroin, morphine or 
oxycodone withdrawal. Typically, methadone and buprenorphine clients are 
encouraged to remain on these pharmacotherapies unless their use is illicit. 
11.2.3 Methadone withdrawal symptoms 
Methadone is a long-acting opioid. Symptoms of methadone withdrawal 
mimic those experienced during heroin withdrawal (see 11.2.1, above), but 
emerge 36–48 hours after the last dose. The longer half-life of methadone 
may result in some low-grade symptoms of withdrawal lingering for three to 
six weeks after last use (NSW Department of Health, 2008a).  
Figure 3: Symptoms and duration of heroin and methadone 
withdrawal  
Source: NSW Health (2008, p.37) 
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11.2.4 Buprenorphine withdrawal symptoms 
Buprenorphine is an opioid partial agonist used in treatment of opioid 
dependence.  
The symptoms of buprenorphine withdrawal are consistent with those 
reported for heroin withdrawal (see 11.2.1 above), although milder in 
severity. They typically emerge within three to five days of last dose, and can 
continue for up to several weeks (Lintzeris et al., 2006).  
11.3   Opioid withdrawal assessment 
Clinicians should be familiar with the general principles of assessment 
(refer section 9).  
During withdrawal assessment, clinical staff will be alert to signs of client 
impairment.  
A thorough assessment of opioid-dependent clients is critical in determining 
the most appropriate withdrawal care. Assessment is, however, largely 
dependent on the capacity of clients to provide relevant information. Recent 
opioid use may limit clients’ capacity to share and absorb accurate 
assessment information.  
Signs of impairment include pinpoint pupils, sedation, low blood pressure, 
slowed pulse, respiratory depression and slurred speech. Where the client is 
impaired, all services should: 
• As soon as possible, identify the most recent drug type, dose and time 
consumed (to inform medical intervention in the event of an overdose) 
• Implement regular clinical observations of the client at frequent intervals 
at first then decreasing over time as evidence of intoxication subsides 
• Revisit the assessment when acute intoxication has passed 
Assessment should determine opioid dependence based on DSM-IV or ICD-
10 definitions, and explore:  
• Physical health 
• Mental health 
• Polydrug use/dependence 
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• Chronic pain conditions 
• Previous withdrawal history 
11.3.1 Physical health 
Assessment will include a thorough medical examination to identify the 
presence of concurrent illness. 
Common among opioid-dependent users are liver conditions and injecting-
related harms such as abscesses and blood borne virus infections. Nutrition 
may be poor and dietary management should be addressed during 
withdrawal care. 
11.3.2 Mental health 
An anxiety and depression screen, such as PsyCheck or the K10, will 
be undertaken during assessment to inform the withdrawal care plan. 
The prevalence of depression is high among opioid-dependent users. The 
use of appropriate mental health screening tools such as PsyCheck or K10 
(Appendix 4) during assessment is critical to early identification and 
response to mental health issues. 
In the event that screening alerts clinicians to a potential mental health issue, 
further risk assessment should be undertaken to ascertain potential 
suicidality or the need for referral/transfer of the client to a mental health 
service. 
Section 16 provides a comprehensive overview of appropriate interventions 
for clients with a dual diagnosis in AOD withdrawal. 
11.3.3 Polydrug use/dependence 
Identification of polydrug use/dependence will be undertaken at 
assessment. 
Given the prevalence of polydrug use among individuals dependent on 
opioids, it is important to assess for concomitant use of all drugs. In 
particular, assessment for concurrent use of benzodiazepines is warranted 
amongst this group.  
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11.3.4 Chronic pain 
Assessment will explore the presence of chronic pain conditions 
among clients.  
Common among opioid-dependent clients is dependence to prescribed 
opioids and/or over-the-counter medications. Assessment of chronic pain 
conditions will inform pain management options and flag the need for 
specialist medical advice and linkages. Guidelines for approaching 
withdrawal care for clients with an underlying chronic pain issue are included 
in section 6.8, above. 
11.3.5 Previous withdrawal experience 
Assessment will explore previous withdrawal experiences and identify 
helpful medication and coping strategies. 
Previous withdrawal symptoms provide important information related to the 
likely severity of the current withdrawal experience.  
11.4  Withdrawal care planning 
Information obtained during assessment will inform the withdrawal 
care plan. 
The withdrawal care plan documents: 
• Likely severity of withdrawal based on previous history of complicated 
withdrawal 
• Risks associated with substance use, such as overdose history 
• The client’s motivation for withdrawal care, where this is a planned 
withdrawal presentation  
• The client’s goals during withdrawal care i.e. withdrawal, maintenance, 
reduction or substitution 
• Potential barriers that may impact on achieving the client’s withdrawal 
goals 
• Available support to enhance the likelihood of success 
• A post-withdrawal plan, including relapse prevention and linkages to 
external support networks to address the client’s psychosocial needs 
• Inclusion of family/significant others where appropriate 
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11.5   Opioid withdrawal care 
Opioid withdrawal care options will include neuro-adaptation reversal, 
reduction and substitution therapies. 
In recent years, withdrawal care options for opioid-dependent clients have 
been expanded from neuro-adaptation reversal to include reduction and 
substitution therapies. Maintenance on appropriate pharmacotherapies such 
as buprenorphine or methadone is the most widely supported option for 
treatment. 
Clients with a history of repeated withdrawal should be encouraged to 
undertake substitution treatment, with a treatment goal of stabilisation. This 
is lower risk than unsupported abstinence-based treatment which has a high 
risk of overdose associated with relapse. 
Opioid withdrawal can be managed through gradually reducing 
buprenorphine or methadone dosing. Polydrug use of substances with 
sedative properties carries risks when used during buprenorphine and 
methadone treatment. Respiratory difficulties, coma and sometimes death 
can occur with concurrent use of opioids, alcohol and benzodiazapines. 
Symptomatic medications may be used to manage withdrawal as outlined in 
Table 12, below. Alternatively, clients can be provided with general principles 
and guidelines for coping and relaxation (refer Appendix 5).  
All withdrawal care is predicated on ongoing and objective monitoring in the 
initial stages of a client’s presentation to withdrawal care. Monitoring should 
then occur at regular intervals, the frequency of which is dependent on the 
severity of the withdrawal syndrome. 
11.5.1 Opioid withdrawal scale 
Withdrawal scales are recommended for use in determining the severity of 
symptoms of withdrawal. The Short Opiate Withdrawal Scale (SOWS) is 
recommended for use in these Guidelines (Appendix 7).  
Note: Withdrawal scales should not be solely relied upon to monitor 
complicated withdrawal as they may lack the sensitivity to detect progression 
to serious illness. Withdrawal monitoring should always include close clinical 
observation and judgement. 
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11.5.2 Buprenorphine   
Buprenorphine is largely considered the most effective 
pharmacotherapy in the management of opioid withdrawal. 
Buprenorphine effectively reduces the acute symptoms encountered during 
neuro-adaptation reversal. As such, buprenorphine-assisted withdrawal 
requires less adjunctive symptomatic medication. 
Buprenorphine is registered as a Schedule 8 medication. Each Australian 
jurisdiction is responsible for a system of authorising medical practitioners to 
prescribe buprenorphine to a particular patient for the management of opioid 
dependence within a framework of medical, social and psychological 
treatment. Buprenorphine dosing is supervised and administered by 
registered buprenorphine prescribers and dispensaries (Lintzeris et al., 
2001). In addition, buprenorphine can be prescribed by hospital-based 
doctors.  
The use of additional substances, such as opioids, alcohol and 
benzodiazepines, in combination with buprenorphine can cause respiratory 
depression, coma and death. Where there is evidence or concern that a 
person may be using multiple substances, close monitoring of the client is 
required. 
Buprenorphine dosing 
Buprenorphine dosing is initiated after a client shows signs of opioid 
withdrawal. This is usually after one half-life of the opioid has expired, that is, 
at least 6 hours for heroin and 24–48 hours for methadone. Dosing should 
be flexible enough to address the severity of withdrawal symptoms. Opioid 
withdrawal scales such as the SOWS (refer Appendix 7) can be 
administered to determine the severity of withdrawal symptoms. 
Table 11 below, outlines the dosing regimen recommended for residential 
withdrawal settings by the Australian National Guidelines for the Use of 
Buprenorphine (Lintzeris et al., 2006). 
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Table 11: Buprenorphine dosing regimen for residential 
withdrawal settings 
Day Buprenorphine S/L tablet regime  Total daily 
dose 
Day 1 4 mg at onset of withdrawal and additional 2 to 4 mg 
evening dose prn 
4 to 8 mg 
Day 2 4 mg mane, with additional 2 to 4 mg evening dose prn 4 to 8 mg 
Day 3 4 mg mane, with additional 2 mg evening dose prn 4 to 6 mg 
Day 4  2 mg mane prn; 2 mg evening prn 0 to 4 mg 
Day 5 2 mg prn 0 to 2 mg 
Day 6 no dose  
Day 7 no dose  
Total proposed dose 12 to 28 mg   
Source: Lintzeris et al (2006) 
 
Over the first few days of buprenorphine dosing, daily review of patients 
should assess the need for dosing adjustments. This period should also 
include provision and monitoring of symptomatic medications, information 
and reassurance. Thorough information and support for clients should be 
available due to the high risk of overdose associated with lapse/relapse to 
opioid use after a period of abstinence. 
11.5.3 Methadone to buprenorphine transfer 
Supervision of methadone to buprenorphine transfers by a medical 
professional such as an addiction medicine specialist or general 
practitioner is recommended.  
Methadone to buprenorphine transfer can be a complex process due to the 
transition from a potent full agonist opioid (methadone) to a partial agonist 
opioid (buprenorphine). Premature transfer can precipitate a relatively rapid 
and potentially severe withdrawal from methadone. 
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Before administering buprenorphine in this context, an addiction medicine 
specialist may be recommended to be consulted. A methadone-
buprenorphine transfer client should also: 
• Show significant methadone withdrawal symptoms 
• Be on a methadone dose of less than 30 mg 
11.5.4 Naltrexone 
Naltrexone: ultra-rapid and rapid detoxification 
The use of naltrexone for ultra-rapid and rapid detoxification is not 
recommended. 
Ultra-rapid and rapid detoxification aim to reduce the duration of withdrawal 
and manage the severe symptoms of withdrawal. Such methods use high 
doses of opioid antagonists such as naltrexone at the onset of withdrawal. 
Ultra-rapid detoxification occurs within a 24-hour period under a general 
anaesthetic and rapid detoxification occurs over hours to days with some 
level of sedation.  
Ultra-rapid and rapid detoxification using naltrexone is costly due to the high 
level of medical supervision required. It is also associated with serious risks, 
including death. As such, the use of naltrexone for ultra-rapid and rapid 
detoxification is not recommended. 
Naltrexone: relapse prevention  
Naltrexone is appropriate for use as a relapse prevention measure, 
subject to the supervision of an addiction medicine specialist. 
Naltrexone may be used in relapse prevention to assist previously opioid-
dependent people to remain opioid-free. It achieves this by reducing 
cravings and blocking the euphoria experienced with opioid use. Unlike 
buprenorphine and methadone, naltrexone has no narcotic properties and 
therefore cannot be misused to obtain or elicit a euphoric effect. 
Naltrexone is administered in Australia for relapse prevention in two ways: 
• Daily, oral dosing that can only commence post-withdrawal  
• Slow-release implants following an initial period of tablet form naltrexone 
(implants are only available from prescribing doctors via the Therapeutic 
Goods of Australia’s Special Access Scheme) 
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The use of naltrexone for relapse prevention should incorporate consultation 
and monitoring by a medical professional.  
11.5.5 Symptomatic medications 
A range of symptomatic medications is appropriate for use in opioid 
withdrawal. 
The use of buprenorphine in the treatment of opioid withdrawal generally 
limits the need for symptomatic medication. Where required, Clonidine is the 
most commonly used symptomatic medication for opioid withdrawal. An anti-
hypertensive agent that may be given in place of opioids, Clonidine can 
markedly reduce many of the symptoms of withdrawal (Akhondzadeh et al., 
2001). It is usually administered in conjunction with other medications for 
symptomatic relief of nausea, diarrhoea, muscle cramps, headache and 
severe sleep disturbance. 
The most significant side effect of Clonidine is a reduction in blood pressure. 
It is not appropriate to administer Clonidine to an individual who is 
hypotensive, has a heart rate of below 50 BPM or shows signs of poor 
circulation. Individuals who experience vomiting, sweating or diarrhoea 
should also be monitored for dehydration. Maintaining fluid levels is an 
important part of withdrawal care. 
Other commonly used symptomatic medications for opioid withdrawal are 
outlined below, in Table 12. 
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Table 12: Symptomatic medications for use in opioid withdrawal 
(as at March 2009) 
Symptom of opioid 
withdrawal  
Symptomatic medication  
Nausea  and vomiting  
 
 
 
 
Severe nausea/vomiting 
Antiemetics such as:  
• Metoclopramide (Maxolon®) 10 mg three times a 
day as required for up to three to four daysa, b or  
• Prochlorperazine (Stemetil®) 5 mg three times a day 
for 4–7 days, best 30 minutes before food or as 
requireda,  
• Ondansetron 4–8 mg, every 12 hours as required. 
 Note: Also encourage fluids and a simple dietb 
Diarrhoea Antidiarrhoeal such as:  
• Atropine and diphenoxylate (Lomotil®)  One to two 
tablets three times a day for up to three to four daysb 
• Loperamide (Imodium®) One to two tablets twice a 
day as required for up to 5 daysb 
• Kaomagma or loperamide (Imodium®) 2 mg as 
requireda 
Skeletal muscle cramps Quinine 300–600 mg at night as requiredb 
Note: Quinine is potential toxic in overdose (causing 
blindness or severe liver disease)b therefore supply may 
need to be monitored  
Abdominal cramps 
 
 
Severe gastrointestinal 
symptoms (for use in a hospital 
setting only) 
Antispasmodics (but they are of limited effectiveness) b 
such as:  
• Hyoscine butylbromide (Buscopan® 10–20 mg four 
times a day for up to three to four daysb or every 12 
hours as requireda 
• Octreotide 0.05–0.1 mg, every 8–12 hours as 
required by subcutaneous injection a 
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Symptom of opioid 
withdrawal  
Symptomatic medication  
Muscles and joint pains Non-steroidal anti-inflammatory agents (NSAIDs) such as: 
• Ibuprofen (Brufen® or Nurofen®) 200–400 mg four 
times a day for up to a week (to be taken with food 
as required) (Use only if no history of peptic ulcer or 
gastritis)a,b or 
• Paracetamol 1000 mg, every 4 hours as required 
(maximum 4000 mg in 24 hours)a 
Anxiety and insomnia (along 
with other symptoms 
associated with excessive 
sympathetic nervous system 
activity such as sweating, 
diarrhoea, vomiting and 
abdominal cramps) 
Clonidinea,b  
• Administer 75 µg test dose and monitor for 
hypotension after half an hour. Measure the patient’s 
blood pressure lying and standing. If hypotensive, 
clonidine is not recommended 
• If no hypotension occurs, and dizziness or other side 
effects of clonidine are not a problem, give a second 
75 µg dose and continue treatment as shown in the 
table of symptomatic treatmentsa 
Note: the side effects of drowsiness and hypotension, 
however, limit its usefulness in an outpatient setting 
particular if higher doses are usedb 
Note: Do not use clonidine if: 
• Patient is hypotensive (i.e. blood pressure is less 
than systolic 90 mmHg or diastolic 50 mmHg) 
• Heart rate is less than 50 per minute 
• There is clinical evidence of impaired circulationa 
Anxiety and/or sleep 
disturbances 
Diazepam  5–10 mg per dose (maximum 40 mg per day), 
tapering towards the end of the withdrawal coursea, b  
Note: use a reducing regime (e.g. diazepam up to 5 mg 
four times a day for 3/7; then twice a day for 2/7 then at 
night for 1/7)b 
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Symptom of opioid 
withdrawal  
Symptomatic medication  
Sleep problems Temazepam 10 to 30 mg (at nightb Cease the dose after 
3–5 nights)a 
Note with benzodiazepines:   
• Reduce doses over three to seven days, no longer 
than 10 days medication with either drugb 
• Higher doses may be prescribed in an inpatient 
setting with experienced nursing staffb 
• The risk exists of adding to a potentially fatal 
sedative cocktail if clients continue to use heroinb 
Restless legs Diazepam (as above) or baclofen 10–25 mg every 8 
hoursa 
Note: benzodiazepines can be useful but are not usually required or recommended beyond 
five days.  
Paracetamol-codeine preparations can alleviate symptoms, but prolong the duration of 
withdrawal discomfort. If prescribed, use up to two tablets four times a day for 2/7 then two 
tablets three times a day for 2/7 then ceaseb. Due to the risk of liver toxicity with paracetamol 
combination products, these medication should be supplied under supervision, ideally with 
frequent interval dispensing or other supervision of medication. 
a)  NSW Department of Health (2008a) 
b)  Murray et al. (2002)  
Natural supplements 
A range of natural supplements are appropriate for use in opioid 
withdrawal. 
In addition to medications, natural supplements are used in adult and youth 
AOD withdrawal settings to manage withdrawal symptoms. These include 
but are not limited to: 
• Dietary supplements: 
• B Group Vitamins, especially high dose B1, B3 and B6 
• Vitamin C 
• Zinc 
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• Stress reduction, relaxation and sleep assistance: 
• DL-Phenylalanine 
• Valerian 
• Kava 
• Rescue Remedy 
• Zizyphus & Polygala pills (Chinese Herbal Medicine) 
• Nausea and vomiting: 
• Ginger or Homeopathic Remedy (Vomiplex) 
• Peppermint 
• Formula for Joint Pain 
• Calcium 
• Fish oils 
• Magnesium 
• Liver function 
• Silymarin (YSAS, 2008) 
 
11.5.6 Psychosocial support in opioid withdrawal  
Psychosocial interventions complement the medical management of 
opioid withdrawal symptoms and will be available at all opioid 
withdrawal services.   
The overarching principles of supportive care are fundamental to the 
provision of a holistic model of withdrawal care. Psychosocial interventions 
should explore: 
• Client goals, including any change in these goals over time 
• Perceived barriers to achieving an individual’s goal of withdrawal care 
• An individual’s beliefs about withdrawal care 
• Appropriate interventions and support services 
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11.5.7 Planning for post-withdrawal  
Post-withdrawal support is an essential component of the treatment 
continuum for opioid-dependent clients.  
Planning for post-withdrawal should: 
• Commence at the assessment phase of withdrawal care 
• Support the client’s goals, which may pertain to accommodation, child 
protection, domestic violence and legal support 
• Support client access to post-withdrawal services that provide ongoing 
support and advocacy  
• Involve family/significant others in post-withdrawal care, as appropriate, 
to help implement the client’s post-withdrawal plan 
11.6   Special needs groups  
11.6.1 Pregnant women 
Opioid withdrawal is not recommended during pregnancy as it poses 
potential risks to mother and baby.  
Pregnant women wishing to undertake an opioid withdrawal will be: 
• Informed of the risks and benefits of withdrawal, including the risks to 
the foetus (increased risk of infant mortality and low birth weight for 
gestational age) and the high risk of relapse 
• Encouraged to consider methadone maintenance treatment instead of 
withdrawal  
Where pregnant women decline methadone maintenance treatment, the 
risks of supervised withdrawal may be reduced by undertaking withdrawal: 
• In the second trimester only (weeks 14 to 32) with foetal monitoring, in a 
monitored setting, such as an inpatient obstetric unit 
• Via tapered doses of methadone to produce a gradual withdrawal. 
During this period, the benefits of methadone maintenance should be 
continually discussed (NSW Department of Health, 2008b) 
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The following is also recommended: 
• Pregnant women should be encouraged to undertake methadone 
maintenance treatment, given that post-partum retention in such 
treatment is more likely (with a view to implementing a longer-term 
treatment plan) 
• Babies of opioid-dependent women will possibly experience a neonatal 
withdrawal syndrome and specialist paediatric care is required for these 
babies 
The 2008 Nursing and Midwifery Clinical Guidelines (NSW Department of 
Health, 2008b) and The National Clinical Guidelines for the Management of 
Drug Use During Pregnancy, Birth and the Early Development Years of the 
Newborn (NSW Department of Health, 2006) are recommended resources 
for managing opioid-dependent women who are pregnant. 
Withdrawal service protocols will outline the management of 
withdrawal during pregnancy, particularly during the late stages and 
labour.  
Withdrawal protocols for pregnant women should address:  
• Inpatient admission  
• Assessment of: 
• AOD use history 
• Physical signs and symptoms of withdrawal 
• A thorough recent drug use history (due to risk of overestimating or 
underestimating opioid tolerance) which will also inform decisions about 
opioid replacement therapy (if indicated) 
• Current opioid treatment by the client. If so, the prescriber, clinic or 
dosing point should be contacted to establish: 
• The client’s current dose 
• Whether she has been dosed that day  
• Whether the client has received takeaway doses (NSW Department 
of Health, 2007) 
With informed consent, opioid-dependent pregnant women (who are not in 
opioid treatment) should be inducted into methadone maintenance treatment 
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under close monitoring, according to the Victorian policy for inpatient 
induction. The general protocol and principles for commencing 
patients/clients onto methadone maintenance should be adhered to for 
pregnant women (NSW Department of Health, 2008b). 
Note: Buprenorphine is currently not approved for use in pregnancy.  
 
Methadone regime for pregnant women 
Withdrawal from methadone should be discouraged during pregnancy (NSW 
Department of Health, 2008a). The Nursing and Midwifery Clinical 
Guidelines (2008) outline the following considerations pertinent to 
methadone dosing during pregnancy:  
• Methadone doses should be titrated to a level that not only blocks 
withdrawal symptoms, but suppresses heroin use  
• Methadone doses should not be kept low in an attempt to reduce 
neonatal abstinence syndrome 
• Methadone dose increases may be required due to increased 
metabolism and increased blood volume during pregnancy (NSW 
Department of Health, 2008a) 
Figure 4, below outlines the dosing regimen for pregnant women stabalising 
on methadone. 
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Day 1 
• Dosage titrated according to woman’s symptoms with rapid 
increases 
• Initial dose (inpatient) at 20 mg, reviewed every 4 hours 
• Assess for signs of withdrawal at each 4-hourly review (using 
OOWS) 
• Where objective signs of withdrawal are detected, administer an 
additional 10 mg (where no signs of withdrawal are identified, no 
additional dose is given until the next scheduled review) 
• In the first 24 hours the maximum dose should not exceed 50 mg. 
(Thirty (30) mg should be sufficient for most women, however, in 
exceptional cases higher doses of up to 40 mg or even 50 mg will 
be necessary and required on day 1) 
Day 2 
• Where a dose of over 30 mg is used on day 1, extreme caution 
should be exercised when assessing the patient’s requirements on 
subsequent days in order to prevent accumulation and possible 
toxicity from methadone on subsequent days 
• Dosage titrated according to woman’s symptoms with rapid 
increases (as per day 1) (woman will almost certainly require less 
methadone) 
• Start with a 20 mg dose in the morning, and review symptoms every 
4 hours.  Administer additional aliquots of 10 mg as required up to a 
maximum of 50 mg (as per day 1) 
• Note:  If at any time the woman becomes sedated (small pupils, 
drowsiness), increase frequency of observation and ensure that no 
methadone is administered until sedation is reversed.  
Day 3 
• A reasonable idea of the required total daily dose will have been 
established. If prescribing the dose as a split dose, give 2/3 in 
morning and 1/3 in afternoon. 
 
Figure 4: Inpatient methadone dosing regimen for pregnant 
women (as at March 2009) 
Source: NSW Department of Health (2008b) 
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11.6.2 Clients with a dual diagnosis  
Clients for whom a psychiatric condition emerges during opioid 
withdrawal will receive care that addresses their specific needs. 
Specifically, they will be: 
• Linked with appropriate mental health services 
• Encouraged to continue to seek mental health support beyond 
withdrawal care 
• Monitored for symptoms during withdrawal and managed appropriately 
11.6.3 Families/significant others  
Consideration will be given to the needs of family/significant others in 
contact with an opioid-dependent person during outpatient withdrawal 
or reduction.  
Where appropriate, information will be provided to family/significant others 
regarding the withdrawal process and support services such as DirectLine 
and/or Lifeline.  
11.6.4 Young people 
Young people presenting to AOD services will be linked with youth-
specific services, where available. 
As outlined above (section 6.3), young people may present with varying 
psychosocial factors contributing to their drug use which impact upon their 
long-term plan for recovery. It is important to be mindful of the potential 
differences in treatment approach and care when commencing withdrawal 
care. Ongoing contact with, and adjunct support from, youth-specific workers 
throughout withdrawal care can promote more positive experiences for the 
young person.  
For further detailed information related to the withdrawal care of young 
opioid users, please refer to the YSAS Clinical Practice Guidelines (YSAS, 
2008). 
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12 BENZODIAZEPINES 
These Guidelines provide a comprehensive approach to withdrawal care. 
The use of prescribing guidelines outlined below will be supported by a 
comprehensive clinical assessment. 
Benzodiazepines are a class of psychoactive drugs commonly used in the 
treatment of anxiety disorders and insomnia. Benzodiazepines are also 
administered as supportive pharmacotherapies in alcohol and other drug 
withdrawal.  
Dependence on benzodiazepines can occur within weeks or months (Denis 
et al., 2006). Individuals dependent on high doses of benzodiazepines may 
’doctor shop’ or obtain the medication illegally in order to support their use.  
Benzodiazepine withdrawal clients generally fall into two categories:  
• Those who use benzodiazepines exclusively for therapeutic purposes 
• Those who use benzodiazepines erratically, in high doses, and with 
other drugs 
In delivering benzodiazepine withdrawal services to clients, clinicians should 
consider:  
• Setting 
• Withdrawal syndrome and potential complications  
• Assessment  
• Withdrawal care planning  
• Withdrawal care  
• Planning for post-withdrawal  
• Special needs groups  
Each of these considerations is examined below. 
12.1   Benzodiazepine withdrawal settings 
The most appropriate setting for an individual seeking benzodiazepine 
withdrawal will be informed by a thorough clinical assessment. 
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The most appropriate setting for an individual seeking benzodiazepine 
withdrawal should be determined via a thorough clinical assessment. For 
individuals with a high daily dose of benzodiazepines, who are elderly or use 
benzodiazepines in conjunction with alcohol, an inpatient setting is most 
appropriate. Consideration should also be given to the likelihood of a longer 
period of withdrawal care for these clients. 
In some settings, such as hospitals, psychiatric facilities, prisons and 
police watch-houses, individuals may experience an unplanned 
benzodiazepine withdrawal. Staff in such settings will be familiar with, 
and alert to, the signs of benzodiazepine withdrawal in order to 
respond in a timely and appropriate manner.  
Evidence of the onset of withdrawal symptoms and frequent or unusual 
requests for pain management should be considered potential indicators of 
benzodiazepine withdrawal.   
The best withdrawal care facilitates step-up and step-down care, 
according to client need.  
Access to stepped care allows clients whose needs warrant greater 
withdrawal care to be transferred to a more intensive withdrawal setting. 
Alternately, stepped care allows those for whom need is reducing to be 
stepped down to less intensive care. 
12.2  Benzodiazepine withdrawal syndrome 
The withdrawal syndrome for mono-dependent benzodiazepine users can vary 
from relatively mild to extremely uncomfortable or painful, however it is rarely life 
threatening. The potential risks of polydrug dependence and drug substitution 
should be considered in withdrawal assessment and the withdrawal 
management plan. Polydrug users should be managed by specialist AOD 
services due to the risk of seizures upon sudden cessation of use.  
Withdrawal typically occurs within two days of ceasing short-acting 
benzodiazepines (e.g. oxazepam), and between two and ten days after 
ceasing long-acting benzodiazepines (e.g. diazepam). However, the onset of 
benzodiazepine withdrawal may be as late as three weeks after cessation of 
drugs with a long half-life (Saunders & Yang, 2002b). Withdrawal from 
benzodiazepines with a short half-life tends to be more severe than from 
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benzodiazepines with a long half-life. Withdrawal is often protracted and may 
extend over a number of weeks or months.  
Benzodiazepine withdrawal symptoms include: 
• Anxiety 
• Depression 
• Diarrhoea, constipation, bloating  
• Insomnia  
• Irritability 
• Muscle aches  
• Poor concentration and memory  
• Restlessness  
• Less commonly, perceptual disturbances and panic attacks 
• Occasionally, seizures and symptoms of psychosis (NSW Department of 
Health, 2008a) 
As shown in Figure 5, below, the symptoms and duration of a 
benzodiazepine withdrawal vary. The amount and frequency of dose 
reduction is the most important factor affecting severity of the withdrawal 
syndrome. Additional contributing factors include: 
• Polydrug dependence 
• A history of seizures 
• A history of underlying anxiety, depression or trauma 
• High daily benzodiazepine doses 
• Unclear daily doses (due to doctor shopping/illegal purchase)  
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Figure 5: Symptoms and duration of benzodiazepine withdrawal 
Source: NSW Health (2008, p.30) 
12.3 Benzodiazepine withdrawal assessment 
Clinicians should be familiar with the general principles of assessment 
(refer section 9).  
During withdrawal assessment, clinical staff will be alert to signs of client 
impairment.  
A thorough assessment of benzodiazepine-dependent clients is critical in 
determining the most appropriate withdrawal care. Assessment is, however, 
largely dependent on the capacity of clients to provide relevant information. 
Recent benzodiazepine use may limit clients’ capacity to share and absorb 
accurate assessment information.  
For impaired clients, all services should: 
• As soon as possible, identify the most recent drug type, dose and time 
consumed (to inform medical intervention in the event of an overdose) 
• Implement regular clinical observations of the client at frequent intervals 
at first then decreasing over time as evidence of impairment subsides 
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• Revisit the assessment when acute impairment has passed 
The most consistent feature of benzodiazepine withdrawal is that its course 
can vary among individuals. Therefore, flexible, responsive and 
individualised assessment and treatment planning is critical.  
Benzodiazepine withdrawal clients commonly experience a concurrent 
physical and/or psychosocial problem, such as anxiety or a sleeping 
disorder. This concern is typically a driver of benzodiazepine misuse and 
must be addressed during withdrawal care.  
Assessment should seek to identify the user category into which a 
benzodiazepine client falls. Among therapeutically-dependent clients, the 
potential re-emergence of the physical and/or psychosocial problem for 
which they were self-medicating will require a planned response such as a 
non-prescription medication alternative.  
Polydrug users who consume large quantities of benzodiazepines in a short 
period of time also require particular attention. Experienced clinicians should 
be consulted in relation to the potential risks of benzodiazepine stabilisation 
versus discontinuation. Stabilisation carries a risk of overdose due to 
decreased levels of substance tolerance, while discontinuing dosing risks 
seizure associated with sudden cessation of use. Given these potential risks, 
dosing changes should be informed by established regimes in combination 
with clinical expertise. 
12.4  Withdrawal care planning 
Information obtained during assessment will inform the withdrawal 
care plan. 
The withdrawal care plan documents: 
• Likely severity of withdrawal based on previous history of complicated 
withdrawal 
• Risks associated with substance use, such as overdose history 
• The client’s motivation for withdrawal care, where this is a planned 
withdrawal presentation  
• The client’s goals during withdrawal care i.e. withdrawal, maintenance, 
reduction or substitution 
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• Potential barriers that may impact on achieving the client’s withdrawal 
goals 
• Available support to enhance the likelihood of success 
• A post-withdrawal plan, including relapse prevention and linkages to 
external support networks to address the client’s psychosocial needs 
• Inclusion of family/significant others where appropriate 
Given that benzodiazepine withdrawal can occur over an extended period of 
time, psychosocial support and continuing care are key elements of a 
withdrawal management plan. Remaining flexible throughout the course of 
treatment is also essential due to the varied nature of the withdrawal 
syndrome amongst benzodiazepine clients. The development of an 
individualised withdrawal care plan that can be revised over the course of 
treatment is of most benefit to clients. 
12.5   Withdrawal care 
Benzodiazepine-dependent clients may experience mild, moderate or severe 
withdrawal. Clinical withdrawal symptoms upon treatment presentation 
generally inform dosing and reduction regimes. In cases of protracted 
withdrawal, substitution pharmacotherapy should be maintained at a fixed 
dose until the person feels able to continue reduction. 
All benzodiazepine withdrawal care is predicated on the provision of ongoing 
and objective monitoring in the initial stages of a client’s presentation to 
withdrawal care. Monitoring should occur at regular intervals, the frequency 
of which is dependent on the severity of the withdrawal syndrome. 
It is noted that mono-dependent benzodiazepine clients are the focus of 
existing literature on benzodiazepine withdrawal regimes. Ideally 
benzodiazepines should be avoided or used very cautiously in polydrug 
users and those on methadone or buprenorphine. 
Table 13, below, outlines the recommended dosing regimen for therapeutic 
benzodiazepine clients. 
Table 14, which follows, provides a conversion table for 
benzodiazepine/diazepam transfer. 
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Table 13: Outpatient dosing regimen for therapeutic 
benzodiazepine users (as at March 2009) 
Client 
type/setting 
Withdrawal 
goal 
Recommended regime 
Therapeutic users 
(regular dose of a 
long-acting 
benzodiazepine) in 
outpatient withdrawal  
Reduction or 
stabilisation 
Tapered withdrawal 
• Convert the patient to diazepam and 
reduce by 10% every 1–2 weeks 
• When dose is at around 5 mg, 
reduce by 1 mg 
• Provide ongoing review, support and 
reassurance 
• Manage therapeutic issues 
underlying the benzodiazepine 
dependence 
• Supervised pick-up of doses should 
be based on a management plan in 
conjunction with a community 
prescribing doctor 
Source: Key informant interviews; CEAG 
Table 14: Conversion table for benzodiazepine/diazepam 
transfer (as at March 2009) 
Benzodiazepine (brand 
name) 
Approximate equivalent to 5 mg 
diazepam 
Alprazolam (Xanax, Kalma) 0.5 mg 
Oxazepam (Serepax, Murelax) 30  mg 
Clonazepam (Rivotril) 0.5 mg 
Nitrazepam (Mogadon, Aldorm) 5   mg 
Flunitrazepam (Hypnodorm) 1   mg 
Lorazepam (Ativan) 0.5 mg 
Source: Adapted from Ashton (2005) 
Clients who consume larger quantities of benzodiazepines within a short 
period of time generally do not require a slow tapering benzodiazepine 
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regimen. Low doses of benzodiazepines for a few days may be sufficient to 
manage anxiety. Adjunct therapy and natural supplements may also assist. 
12.5.1 Symptomatic medications 
A range of symptomatic medications is appropriate for use in 
benzodiazepine withdrawal.  
Table 15 outlines symptomatic medications suitable for use in managing 
benzodiazepine withdrawal. 
Table 15: Symptomatic medications for use in benzodiazepine 
withdrawal (as at March 2009)  
Symptoms Symptomatic medication 
Sedation Tricyclic antidepressants (TACs)b may be used but may 
lower the seizure threshold 
Histories of multiple seizures Anticonvulsantsb 
Physical symptoms such as 
tremors 
Beta-blockersb  
a)  NSW Department of Health (2008a) 
b)  Murray et al. (2002)  
 
General principles and guidelines for coping with, and relaxing during, 
benzodiazepine withdrawal may also assist some clients withdrawing from 
benzodiazepines (Appendix 5). 
12.5.2 Benzodiazepine withdrawal scales 
Withdrawal from benzodiazepines may be monitored using the 
Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) (Appendix 8) 
(Tyrer et al., 1990). The BWSQ is a 20-item self-report, validated 
questionnaire (Couvee & Zitman, 2002). 
The Clinical Institute Withdrawal Assessment Scale-Benzodiazepines 
(CIWA-B) (Appendix 9) is a 22-item instrument designed to assess and 
monitor the type and severity of symptoms of benzodiazepine withdrawal 
(Busto et al., 1989). Although the CIWA-B is commonly used within AOD 
treatment settings (Saunders & Yang, 2002b), its psychometric properties 
have not been extensively evaluated.  
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Note: Withdrawal scales should not be solely relied upon to monitor 
complicated withdrawal as they may lack the sensitivity to detect progression 
to serious illness. Withdrawal monitoring should always include close clinical 
observation and judgement. 
12.5.3 Cognitive behavioural therapy 
Cognitive Behavioural Therapy (CBT) is an effective adjunct to a tapered 
medication regimen in some benzodiazepine patients (Morin et al., 2004). It 
is also an appropriate way of linking clients into ongoing, post-withdrawal 
care. 
12.5.4 Psychosocial support 
Psychosocial interventions complement the medical management of 
benzodiazepine withdrawal symptoms and will be available at all 
withdrawal services.   
The overarching principles of supportive care are fundamental to the 
provision of a holistic model of withdrawal care. Psychosocial interventions 
should explore: 
• Client goals, including any change in these goals over time 
• Perceived barriers to achieving an individual’s goals of withdrawal care 
• An individual’s beliefs about withdrawal care 
• Appropriate interventions and support services 
• Longer term support strategies for clients whose benzodiazepine 
withdrawal  results in the re-emergence of symptoms for which they 
were originally prescribed benzodiazepine medication  
12.5.5 Planning for post-withdrawal 
Post-withdrawal support is an essential component of the treatment 
continuum for benzodiazepine-dependent clients.  
Planning for post-withdrawal should: 
• Commence at the assessment phase of withdrawal care 
• Support the client’s goals, which may pertain to accommodation, child 
protection, domestic violence and legal support 
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• Support client access to post-withdrawal services that provide ongoing 
support and advocacy  
• Involve family/significant others in post-withdrawal care, as appropriate, 
to help implement the client’s post-withdrawal plan 
12.6  Special needs groups 
12.6.1 Clients with chronic physical illness and the 
elderly  
The elderly and those with chronic comorbid physical illness are likely to 
experience benzodiazepine withdrawal toxicity. This is typically due to poor 
metabolism and physical frailty. The impact of multiple drug regimes should 
be closely monitored by withdrawal clinicians.  
12.6.2 Pregnant women 
Pregnant women should undertake a gradual, supervised reduction of 
benzodiazepines, rather than abrupt withdrawal (NSW Department of Health, 
2008b). 
12.6.3 Clients with a dual diagnosis  
Clients for whom a psychiatric condition emerges during 
benzodiazepine withdrawal will receive care that addresses their 
specific needs. 
Specifically, they will be: 
• Linked with appropriate mental health services 
• Encouraged to continue to seek mental health support beyond 
withdrawal care 
• Monitored for symptoms such as agitations during withdrawal and 
managed appropriately. 
12.6.4 Families/significant others  
Consideration will be given to the needs of family/significant others in 
contact with a benzodiazepine-dependent person during outpatient 
withdrawal or reduction.  
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Where appropriate, information will be provided to family/significant others 
regarding the withdrawal process and support services such as Directline 
and/or Lifeline.  
12.6.5 Young people 
Young people presenting to AOD services will be linked with youth-
specific services, where available. 
As outlined above (section 6.3), young people may present with varying 
psychosocial factors contributing to their drug use which impact upon their 
long-term plan for recovery. It is important to be mindful of the potential 
differences in treatment approach and care when commencing withdrawal 
care. Ongoing contact with, and adjunct support from, youth-specific workers 
throughout withdrawal care can promote more positive experiences for the 
young person.  
For further detailed information related to the withdrawal care of young 
benzodiazepine users, please refer to the YSAS Clinical Practice Guidelines 
(YSAS, 2008). 
12.7   Recommended reading 
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NSW Department of Health. (2008b). Nursing and Midwifery Clinical 
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13 AMPHETAMINE-TYPE 
SUBSTANCES (ATS)  
These Guidelines provide a comprehensive approach to withdrawal 
care. The use of prescribing guidelines outlined below will be 
supported by a comprehensive clinical assessment. 
Amphetamine-type substances (ATS) include amphetamines, cocaine and 
ecstasy. Methamphetamine, a potent ATS, is the most widely available type 
of ATS available in Australia (Jenner & McKetin, 2004), and injectors and 
smokers of crystalline methamphetamine are at great risk of developing 
methamphetamine dependence (Degenhardt et al., 2008; McKetin et al., 
2008).  
Animal and human studies have shown that long-term exposure to heavy 
methamphetamine use leads to both short-term neurotransmitter depletion 
(particularly dopamine) and changes in brain structure and function. This can 
cause chronic dopamine underactivity, resulting in memory and cognitive 
impairment, poor concentration, lack of impulse control, and emotional 
dysregulation (Davidson et al., 2001). 
The existence and clinical significance of ATS withdrawal is firmly 
established (Lee et al., 2007). While scales exist to monitor ATS withdrawal 
(see 13.5.2, below), the role of medication in ATS withdrawal has not yet 
been determined.  
While ATS withdrawal is not life threatening, the complex presentation of 
many ATS users seeking treatment warrants thorough clinical assessment. 
Assessment should explore physical and mental health, concurrent drug use 
and dependence.  
ATS users are drawn from varying demographics. The underlying 
precipitants to commencement of use also vary, and may include 
professional reasons (e.g. the need to stay awake for long periods of time), 
management of underlying mood disorders, cultural issues and use as an 
aid to weight loss. 
There is currently no validated dosing regimen for ATS withdrawal (NCETA, 
2006; NSW Department of Health, 2008a). In practice however, 
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benzodiazepines (e.g. diazepam) and anti-psychotics are used to assist with 
agitation and sleep disturbance associated with ATS withdrawal. There is 
indicative support that the use of benzodiazepines enhances treatment 
completion (Cruickshank & Dyer, 2006). Given the potential for 
benzodiazepine abuse and diversion among this group, careful monitoring of 
benzodiazepine dosing is recommended.   
Continuing care is critical to successful ATS treatment. In particular, 
collaborative work with external support services to address the presenting 
psychosocial factors associated with ATS misuse is advised.  
In delivering ATS withdrawal services to clients, clinicians should consider:  
• Setting 
• Withdrawal syndrome and potential complications  
• Assessment (CIWA-Ar and Consumption Calendar) 
• Withdrawal care planning  
• Withdrawal care  
• Planning for post-withdrawal  
• Special needs groups  
Each of these considerations is examined below. 
13.1   ATS withdrawal settings 
The most appropriate setting for an individual seeking ATS withdrawal 
will be informed by a thorough clinical assessment. 
The most appropriate setting for an individual seeking ATS withdrawal 
should be determined via a thorough clinical assessment. ATS users 
typically undertake withdrawal in the community, and, for the most part, it is 
considered safe to do so (Jenner & Saunders, 2004).  
Supervised residential withdrawal settings are appropriate for clients with: 
• Multiple drug dependence 
• Severe amphetamine dependence 
• Serious medical or psychiatric complications 
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• An unfavourable home environment 
• A history of multiple, unsuccessful attempts to withdraw from ATS 
(Jenner & Saunders, 2004; NSW Department of Health, 2008a) 
In some settings, such as hospitals, psychiatric facilities, prisons and police 
watch-houses, individuals may experience an unplanned ATS withdrawal. 
Staff in such settings should be familiar with, and alert to, the signs of ATS 
withdrawal in order to respond in a timely and appropriate manner to 
unplanned withdrawal. Evidence of the onset of withdrawal symptoms should 
be considered potential indicators of ATS withdrawal.   
The best withdrawal care facilitates step-up and step-down care, 
according to client need.  
Stepped care allows clients whose needs warrant greater withdrawal care to 
be transferred to a more intensive withdrawal setting. Alternately, stepped 
care allows those for whom need is reducing to be stepped down to less 
intensive care. 
13.2   ATS withdrawal syndrome 
Many users of ATS will experience what is sometimes called a ‘crash’ 
following their use. During this time, the user is likely to sleep and eat 
excessively and experience some irritability of mood. This is akin to an 
alcohol ‘hangover’ and does not in itself constitute a clinically significant 
withdrawal syndrome, although withdrawal can follow in some dependent 
users.  
Unlike the features of alcohol or opioid withdrawal, which tend to be the 
opposite of intoxication, some symptoms of ATS withdrawal can mimic 
intoxication, with symptoms of agitation, hyper-arousal and sleep 
disturbance (Jenner & Saunders, 2004).  
13.2.1 ATS withdrawal syndrome 
ATS include amphetamine and methamphetamine, but also extend to other 
substances such as MDMA, ephedrine, pseudoephedrine and 
methcathinone. Symptoms of withdrawal tend to emerge at day one of 
abstinence, peak during days one to three and decrease in a linear fashion 
over seven to ten days. Some symptoms persist for several weeks, 
particularly sleep disturbance and increased appetite. Some individuals 
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might experience more prolonged symptoms which are probably attributable 
to neurotoxicity (McGregor et al., 2005; Newton et al., 2004).  
Reports of the natural history of ATS withdrawal are variable. Onset, 
symptom severity and duration of withdrawal are likely to be influenced by 
the severity of dependence, duration and frequency of use, medical or 
psychiatric complications and psychosocial factors (Jenner & Saunders, 
2004).  
Amphetamine withdrawal is characterised by:  
• Craving for sleep 
• Irritability 
• Depressed mood 
• Lack of energy 
• Slowing of movement 
• Loss of interest or pleasure (Jenner & Saunders, 2004) 
Symptoms of methamphetamine withdrawal include: 
• Inactivity 
• Fatigue 
• Depressed mood 
• Anxiety 
• Motor retardation 
• Agitation 
• Vivid dreams  
• Craving 
• Poor concentration 
• Irritability and tension 
Figure 6 shows the symptoms and duration of a methamphetamine 
withdrawal syndrome. 
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Figure 6: Symptoms and duration of methamphetamine 
withdrawal 
Source: Connolly (2006) 
13.3   ATS withdrawal assessment 
Clinicians should be familiar with the general principles of assessment 
(refer section 9).  
During withdrawal assessment, clinical staff will be alert to signs of 
client impairment.  
A thorough assessment of ATS users is critical in determining the most 
appropriate withdrawal care. Assessment is, however, largely dependent on 
the capacity of clients to provide relevant information. Recent ATS use may 
limit clients’ capacity to share and absorb accurate assessment information.  
Signs of ATS intoxication include:  
• Increased confidence and energy  
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• Decrease fatigue and appetite 
• Increased heart rate and breathing 
• Sweating 
• Anxiety 
• Panic attacks 
• Paranoia 
• Psychosis 
• Headaches 
• Agitation 
• Depression 
For impaired clients, all services should: 
• As soon as possible, identify the most recent drug type, dose and time 
consumed  
• Implement regular clinical observations of the client at frequent intervals 
at first then decreasing over time as evidence of impairment subsides 
• Revisit the assessment when acute impairment has passed 
Assessment of ATS withdrawal clients should explore: 
• ATS dependence as determined by DSM-IV and ICD-10 (see section 2: 
Definitions of dependence and withdrawal) 
• Quantity, potency, frequency of ATS use, and route of administration 
• Polydrug use/dependence, particularly concurrent alcohol, cannabis and 
nicotine use (common in the psychostimulant-dependent population) 
• Physical health issues associated with injecting stimulant use, as 
required 
• Physical health issues, including medical complications associated with 
ATS use, such as respiration, neurological and cardiovascular 
conditions.  
• Mental health issues, including symptoms of depression and/or 
psychosis  
• Pregnancy 
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• The severity of any previous withdrawal symptom (Cruickshank et al., 
2008; Dyer & Cruickshank, 2005; McKetin et al., 2005; McKetin et al., 
2008) 
Assessment of these domains will inform the likely severity of the current 
withdrawal syndrome and contribute to appropriate withdrawal care planning.  
13.4 ATS withdrawal care planning 
Information obtained during assessment will inform the withdrawal 
care plan. 
The withdrawal care plan documents: 
• Likely severity of withdrawal based on previous history of complicated 
withdrawal 
• Risks associated with substance use, such as overdose history 
• The client’s motivation for withdrawal care, where this is a planned 
withdrawal presentation  
• The client’s goals during withdrawal care, i.e. withdrawal, maintenance, 
reduction or substitution 
• Potential barriers that may impact on achieving the client’s withdrawal 
goals 
• Available support to enhance the likelihood of success 
• A post-withdrawal plan, including relapse prevention and linkages to 
external support networks to address the client’s psychosocial needs 
• Inclusion of family/significant others where appropriate 
13.5 ATS withdrawal care 
Clients will be withdrawn from other drugs prior to commencing ATS 
withdrawal. 
Withdrawal care for ATS clients typically entails use of: 
• Benzodiazepines to manage anxiety and agitation, however, this may 
not be appropriate in the event that a client is on a methadone or 
buprenorphine maintenance program 
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• Additional symptomatic pharmacotherapies such as antidepressant and 
antipsychotic medications  
• Supportive care such as counselling or specialist mental health 
interventions (Jenner & Saunders, 2004) 
Amphetamine-type substance withdrawal requires regular monitoring of 
mental health symptoms. Symptoms still present a week after withdrawal 
commencement may require further investigation by a mental health 
professional (Jenner & Saunders, 2004). Clients with psychosis secondary to 
ATS dependence are typically managed in mental health hospitals and 
require antipsychotic medication to relieve associated symptoms. 
All withdrawal care is predicated on ongoing and objective monitoring in the 
initial stages of a client’s presentation to withdrawal care. Monitoring should 
then occur at regular intervals, the frequency of which is dependent on the 
severity of the withdrawal syndrome. 
13.5.1 Symptomatic medications 
A range of symptomatic medications may be appropriate for use in 
ATS withdrawal. 
While a range of symptomatic medications may be useful in managing 
withdrawal symptoms, the role of symptomatic medication in amphetamine 
withdrawal remains unclear, and no specific medication schedule is 
recommended (NSW Department of Health, 2008a). The toxicity of some 
medications in overdose, in particular tricyclic antidepressants, should be 
considered, and supply should be monitored for this reason. Daily 
dispensing may be appropriate in some cases.  
Symptomatic medications available for ATS withdrawal are outlined in Table 
16 below.  
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Table 16: Symptomatic medications for use in ATS withdrawal 
(as at March 2009) 
Symptoms Symptomatic medication 
Pronounced agitation or 
insomnia  
 
 
Tricyclic antidepressants (TCAs) may be useful for their 
sedative effects:  
• Doxepin (50 mg to 75 mg at night, titrating upwards if 
required and tolerate to 150 mg maximum dose)b 
• Clomipramineb 
Benzodiazepines can be used, however, there may be a 
risk of misuse and exacerbation of depressive symptoms:  
• Diazepam 5–20 mg twice a day for restlessness (split 
doses are best)b 
• Temazepam 10–40 mg at night for insomniab  
Pronounced psychomotor 
retardation or lowered affect 
(these drugs may counter the 
reduced dopaminergic, 
noradrenergic and/or 
serotonergic activity 
associated with stimulant 
withdrawal)a 
Selective serotonin reuptake inhibitors (SSRIs) such as:  
• Fluoxetine (20 mg mane, titrating upwards if required 
and tolerated to 80 mg as the maximum dose) 
• Paroxetineb 
• Desipramine, bromocriptine, amantadinea 
 
Psychotic features are present 
(psychosis, thought disorder, 
such as paranoid ideation, or 
perceptual disturbances) 
Antipsychotic medication such as:   
• Haloperidol 
• Atypical agents (such as olanzapine or risperidone)  
• Chlorpromazine 
Note: If these symptoms are marked, assessment with an 
experience mental health clinician (or psychiatrist) may be 
required. In some cases involuntarily certification may be 
required for the safety of the patient and othersb 
Consult a psychiatrist if symptoms are severe or do not 
quickly resolve (within days). Medication should be 
continued for at least 1–2 weeks after symptoms resolve 
with careful monitoring for return of symptoms as the 
medication is withdrawna 
Note: Do not use more than one antidepressant at the same time, and an appropriate ‘wash 
out’ time should be observed if changing from one antidepressant to another b  
In each of these situations, start on a low dose and titrate the dose upwards  
a)  NSW Department of Health (2008a) 
b)  Murray et al. (2002)  
General principles and guidelines for coping with, and relaxing during, ATS 
withdrawal may also assist some clients (Appendix 5). 
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13.5.2 ATS withdrawal scale  
The Amphetamine Withdrawal Questionnaire (AWQ) (Appendix 10) is a 10-
item self-report instrument based on DSM-IV criteria for amphetamine 
withdrawal (Srisurapanont et al., 1999). While not a validated instrument, it is 
a useful guide for monitoring an ATS withdrawal syndrome. 
Note: Withdrawal scales should not be solely relied upon to monitor 
complicated withdrawal as they may lack the sensitivity to detect progression 
to serious illness. Withdrawal monitoring should always include close clinical 
observation and judgement. 
13.5.3 Psychosocial support in ATS withdrawal  
Psychosocial interventions complement the medical management of 
ATS withdrawal symptoms and will be available at all withdrawal 
services.   
The overarching principles of supportive care are fundamental to the 
provision of a holistic model of withdrawal care. Psychosocial interventions 
should explore: 
• Client goals, including any change in these goals over time 
• Perceived barriers to achieving an individual’s goals of withdrawal care 
• An individual’s beliefs about withdrawal care 
• Appropriate interventions and support services 
13.6  Planning for post-withdrawal  
Post-withdrawal support is an essential component of the treatment 
continuum for ATS-dependent clients.  
Planning for post-withdrawal should: 
• Commence at the assessment phase of withdrawal care 
• Support the client’s goals which may pertain to accommodation, child 
protection, domestic violence and legal support 
• Support client access to post-withdrawal services that provide ongoing 
support and advocacy  
• Involve family/significant others in post-withdrawal care, as appropriate, 
to help implement the client’s post-withdrawal plan 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
109 
13.7  Special needs groups 
13.7.1 Pregnant women 
The health risks associated with ATS use during pregnancy are limited. The 
National Guidelines recommend the following approach:  
• Advise the client of the potential health risks to herself and to her baby 
(higher rates of obstetric complications such as spontaneous abortion, 
miscarriage and placental abruption) 
• Provide, or refer the client to, relevant support services (preferably within 
a multidisciplinary framework) 
• Encourage the client to reduce or cease ATS use 
• Discuss the risks associated with ATS use and mental illness, and 
monitor mental health where necessary (NSW Department of Health, 
2008b) 
 
13.7.2 Clients with a dual diagnosis  
Clients for whom a psychiatric condition emerges during ATS 
withdrawal will receive care that addresses their specific needs. 
Specifically, they will be: 
• Linked with appropriate mental health services 
• Encouraged to continue to seek mental health support beyond 
withdrawal care 
• Monitored for withdrawal symptoms and managed appropriately 
 
13.7.3 Families/significant others  
Consideration will be given to the needs of family/significant others in 
contact with an ATS-dependent person during outpatient withdrawal or 
reduction.  
Where appropriate, information will be provided to family/significant others 
regarding the withdrawal process and support services such as Directline 
and/or Lifeline.  
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13.7.4 Young people 
Young people presenting to AOD services will be linked with youth-
specific services, where available. 
As outlined above (section 6.3), young people may present with varying 
psychosocial factors contributing to their drug use which impact upon their 
long-term plan for recovery. It is important to be mindful of the potential 
differences in treatment approach and care when commencing withdrawal 
care. Ongoing contact with, and adjunct support from, youth-specific workers 
throughout withdrawal care can promote more positive experiences for the 
young person.  
For further detailed information related to the withdrawal care of young ATS 
users, please refer to the YSAS Clinical Practice Guidelines (YSAS, 2008). 
13.8  Recommended reading 
Jenner, L. & Saunders, J. B. (2004). Psychostimulant withdrawal and 
detoxification. In A. Baker, N. K. Lee & L. Jenner (Eds.), Models of 
intervention and care for psychostimulant users - 2nd Edition. (pp. 102–119): 
Commonwealth of Australia. 
Lee, N., Johns, L., Jenkinson, R., Johnston, J., Connolly, K., Hall, K., & 
Cash, R. (2007). Clinical Treatment Guidelines for alcohol and drug 
clinicians. No. 14: Methamphetamines dependence and treatment. Fitzroy, 
Victoria: Turning Point Alcohol and Drug Centre Inc. 
NSW Department of Health. (2008a). NSW Drug and Alcohol Withdrawal 
Clinical Practice Guidelines. NSW: NSW Department of Health. 
NSW Department of Health. (2008b). Nursing and Midwifery Clinical 
Guidelines: Identifying and responding to drug and alcohol issues. NSW: 
NSW Department of Health. 
YSAS. (2008). YSAS Clinical Practice Guidelines - Management of alcohol 
and other drug withdrawal. Melbourne: YSAS. 
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14 CANNABIS 
These Guidelines Provide a comprehensive approach to withdrawal 
care. The use of prescribing guidelines outlined below will be 
supported by a comprehensive clinical assessment. 
Cannabis is the most widely used illicit drug worldwide (AIHW, 2007). It is 
estimated that around ten per cent of people who ever use cannabis will 
become dependent at some time in their lives (Copeland et al., 2006). 
Cannabis can be smoked (generally mixed with tobacco) in a pipe, a joint, or 
a water-pipe (bong). Cannabis can also be ingested with food.  
In delivering cannabis withdrawal services to clients, clinicians should 
consider:  
• Setting 
• Withdrawal syndrome and potential complications  
• Assessment  
• Withdrawal care planning  
• Withdrawal care  
• Planning for post-withdrawal  
• Special needs groups  
Each of these considerations is examined below. 
14.1 Cannabis withdrawal syndrome 
The existence of a cannabis withdrawal syndrome is now well established. 
The nature of the withdrawal syndrome is not life threatening and is suited to 
community-based withdrawal settings. 
Cannabis dependence is often seen in clients with polydrug dependence 
(alcohol, opioid, benzodiazepine and/or tobacco dependence). The cannabis 
withdrawal syndrome is generally longer than the syndrome for these other 
substances.  
Adverse effects of cannabis intoxication can include anxiety and depression, 
paranoia, increased appetite and sedation. In users who have a psychiatric 
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predisposition, acute drug-induced psychosis can occur from the ingestion of 
toxic levels of cannabis and during cannabis withdrawal. Agitation is 
associated with cannabis withdrawal and management of this condition 
should be carefully considered in withdrawal care planning.  
While benzodiazepines are commonly used for symptomatic relief during 
cannabis withdrawal, there is currently no data to support this approach 
(NSW Department of Health, 2008a; Palmer, 2001).  
14.2   Cannabis withdrawal settings  
The most appropriate setting for an individual seeking cannabis 
withdrawal will be informed by a thorough clinical assessment. 
The nature of the cannabis withdrawal syndrome is not life threatening and, 
in most cases, withdrawal can occur in the community. On occasion, 
cannabis withdrawal warrants an inpatient setting. The most appropriate 
setting should be determined via a thorough clinical assessment. 
The best withdrawal care facilitates step-up and step-down care, 
according to client need.  
Stepped care allows clients whose needs warrant greater withdrawal care to 
be transferred to a more intensive withdrawal setting. Alternately, stepped 
care allows those for whom risk/need is reducing to be stepped down to less 
intensive care. 
14.3   Cannabis withdrawal syndrome 
The extent to which withdrawal symptoms occur in light or non-daily 
cannabis users remains unclear (Budney & Hughes, 2006). However, the 
presence of a cannabis withdrawal syndrome in heavy or daily cannabis 
users who cease use has been established. The most common symptoms 
for these clients are: 
• Anger, aggression, irritability 
• Anxiety/nervousness 
• Agitation 
• Decreased appetite or weight loss 
• Nausea and vomiting 
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• Restlessness 
• Sleep difficulties including strange dreams 
Less common symptoms include: 
• Chills 
• Depressed mood 
• Stomach pain/physical discomfort 
• Shakiness 
• Sweating 
Most symptoms emerge on day one to two of abstinence and peak between 
days two and six. Most symptoms abate within two to three weeks (Budney 
& Hughes, 2006; Kouri & Pope, 2000). Figure 7 below, shows the symptoms 
and duration of cannabis withdrawal. 
 
 
Figure 7: Symptoms and duration of cannabis withdrawal  
Source: NSW Health (2008, p.44) 
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14.4   Cannabis withdrawal assessment 
Clinicians should be familiar with the general principles of assessment 
(refer section 9).  
During withdrawal assessment, clinical staff will be alert to signs of 
client impairment.  
A thorough assessment of cannabis-dependent clients is critical in 
determining the most appropriate withdrawal care. Assessment is, however, 
largely dependent on the capacity of clients to provide relevant information. 
Recent cannabis use may limit clients’ capacity to share and absorb 
accurate assessment information.  
For impaired clients, all services should: 
• As soon as possible, identify the most recent drug type, dose and time 
consumed (to inform medical intervention in the event of an overdose) 
• Implement regular clinical observations of the client at frequent intervals 
at first then decreasing over time as evidence of impairment subsides 
• Revisit the assessment when acute impairment has passed 
A cannabis assessment should explore AOD use, including: 
• Cannabis dependence as determined by DSM-IV and ICD-10 (see 
section 2: Definitions of dependence and withdrawal) 
• Quantity, potency, frequency of cannabis use, and route of 
administration 
• Polydrug use/dependence  
• Physical health issues  
• Mental health issues, including symptoms of depression and/or 
psychosis  
• Pregnancy 
• The severity of any previous withdrawal symptoms (Cruickshank & Dyer, 
2006; Cruickshank et al., 2008; Dyer & Cruickshank, 2005; McKetin et 
al., 2005; McKetin et al., 2008) 
Assessment of these domains will inform the likely severity of the current 
withdrawal syndrome and contribute to appropriate withdrawal care planning.  
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14.5  Cannabis withdrawal care planning 
Information obtained during assessment will inform the withdrawal 
care plan. 
The withdrawal care plan documents: 
• Likely severity of withdrawal based on previous history of complicated 
withdrawal 
• Risks associated with substance use, such as overdose history 
• The client’s motivation for withdrawal care, where this is a planned 
withdrawal presentation  
• The client’s goals during withdrawal care i.e. withdrawal, maintenance, 
reduction or substitution 
• Potential barriers that may impact on achieving the client’s withdrawal 
goals 
• Available support to enhance the likelihood of success 
• A post-withdrawal plan, including relapse prevention and linkages to 
external support networks to address the client’s psychosocial needs 
• Inclusion of family/significant others where appropriate 
• Care plan for agitation management  
The use of self-help booklets can be helpful, such as: Mulling it over, 
available at: 
http://www.adf.org.au/store/article.asp?ContentID=product_33212 
14.6  Cannabis withdrawal care 
Although no medications have proven to be successful in cannabis 
withdrawal, benzodiazepines such as diazepam are commonly used to treat 
some symptoms of cannabis withdrawal, such as anxiety and insomnia 
(NSW Department of Health, 2008a; Palmer, 2001). Benzodiazepine dosing 
during cannabis withdrawal is based on ongoing assessment and 
monitoring. The efficacy of benzodiazepines in human cannabis withdrawal 
has not been empirically determined.  
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In outpatient settings, tapered or reducing benzodiazepine dosing may be 
used in conjunction with psychosocial interventions. There are numerous 
strategies to consider for outpatient cannabis reduction, including: 
• Gradually limiting the quantity used per day 
• Gradually reducing the frequency of use per day in conjunction with a 
smaller quantity 
• Setting weekly reduction goals 
Severity of cannabis withdrawal symptoms is dependent on a number of key 
factors such as: 
• Method of ingestion  
• Potency 
• Quantity used per day  
• Comorbid mental health conditions 
• Polydrug dependence, including tobacco  
• Current engagement in an outpatient or inpatient treatment setting 
All withdrawal care is predicated on ongoing and objective monitoring in the 
initial stages of a client’s presentation to withdrawal care. Monitoring should 
then occur at regular intervals, the frequency of which is dependent on the 
severity of the withdrawal syndrome. 
14.6.1 Symptomatic medications 
A range of symptomatic medications is appropriate for use in cannabis 
withdrawal. 
Symptomatic medications are also useful in managing cannabis withdrawal 
symptoms, as outlined in Table 17 below. 
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Table 17: Symptomatic medications for use in cannabis 
withdrawal (as at March 2009) 
Symptoms Symptomatic medication 
Stomach cramps Hyoscine (Buscopan®)a 
Belladonna Herb (Atrobel®)a 
Nausea Promethazine (Phenergan®)a  
Metoclopramide (Maxolon®)a 
Physical pain and/or 
headaches 
Paracetamola 
Non-steroidal anti-inflammatory drugs (NSAIDS)a such as 
ibuprofen (Brufen® or Nurofen®) 
Sleep problems/ sleep 
disturbances 
Short-acting benzodiazepines may be helpful for sleep  problems 
(in small, controlled doses in the initial few days)b  
Temazepam 10 mg tablets: one or two at night as required for up 
to seven days 
Zolpidem (Stilnox®) or zopiclone (Imovane®) or sedating 
antihistamines such aspromethazine (e.g. Phenergan®) may also 
be of some value  
Anxiety/restlessness/irrit
ability 
 
If anxiety symptoms predominate, a longer acting benzodiazepine 
may be of more value e.g.  
Diazepam 5 mg tablets: up to 20 mg daily (in divided doses) 
initially, reducing the doses over three to seven days (maximum 
of 10 days duration)b 
Outpatient regimens might be: 
• 7 days of diazepam 5 mg four times daily,  
• Zopiclone 7.5 mg at night 
• NSAIDs/hyoscine butylbromide (Buscopan®) as needed;  
or 
• 7 days of zolpidem 7.5 mg at nighta 
Sedation  Tricyclic antidepressants (TCAs) 
Doxepin 50–75 mg at night for up to seven daysb 
Note:  
Do not mix benzodiazepines - use one or the other 
Dosages and prescribing schedules for symptomatic relief will most effectively be decided 
upon only after thoroughly exploring the individual patient’s symptom profile and 
circumstances 
a)  NSW Department of Health (2008a) 
b)  Murray et al. (2002) 
General principles and guidelines for coping with, and relaxing during, 
cannabis withdrawal may also assist some clients (Appendix 5). 
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14.6.2 Cannabis withdrawal scales 
At present, there are no validated cannabis withdrawal scales. However, the 
Cannabis Withdrawal Assessment Scale (CWAS)(Appendix 11) is currently 
used in some Australian AOD settings and is a useful tool for assessment 
purposes. The CWAS is a nine-item scale that assesses the domains of 
restlessness/agitation, fear, racing thoughts, drowsiness, mood changes, 
hunger, feelings of unreality and amount of sleep, on a scale of zero to 
seven (de Crespigny et al., 2003). 
Note: Withdrawal scales should not be solely relied upon to monitor 
complicated withdrawal as they may lack the sensitivity to detect progression 
to serious illness. Withdrawal monitoring should always include close clinical 
observation and judgement. 
14.6.3 Psychosocial support in cannabis withdrawal  
Psychosocial interventions complement the medical management of 
cannabis withdrawal symptoms and will be available at all cannabis 
withdrawal services.   
The overarching principles of supportive care are fundamental to the 
provision of a holistic model of withdrawal care. Psychosocial interventions 
should explore: 
• Client goals, including any change in these goals over time 
• Perceived barriers to achieving an individual’s goals of withdrawal care 
• An individual’s beliefs about withdrawal care 
• Appropriate interventions and support services 
14.7  Planning for post-withdrawal  
Post-withdrawal support is an essential component of the treatment 
continuum for cannabis-dependent clients.  
Planning for post-withdrawal should: 
• Commence at the assessment phase of withdrawal care 
• Support the client’s goals, which may pertain to accommodation, child 
protection, domestic violence and legal support 
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• Support client access to post-withdrawal services that provide ongoing 
support and advocacy  
• Involve family/significant others in post-withdrawal care, as appropriate, 
to help implement the client’s post-withdrawal plan 
14.8  Special needs groups  
14.8.1 Pregnant women 
There is limited evidence of adverse effects of cannabis consumption on a 
pregnant woman or foetus. Where polydrug use exists, specialist paediatric 
consultation should be sought. Cannabis reduction or abstinence should be 
encouraged among pregnant women and the use of supportive medications 
should be minimal. 
14.8.2 Tobacco 
Cannabis is commonly mixed with tobacco for smoking and there is some 
evidence that withdrawal from both nicotine and cannabis at the same time 
leads to more severe withdrawal symptoms than would be experienced 
during withdrawal from either substance alone (Vandrey et al., 2008). The 
role of nicotine replacement therapy (NRT) in residential withdrawal settings 
should be strongly considered for all clinically dependent on nicotine. 
14.8.3 Clients with a dual diagnosis 
Clients for whom a psychiatric condition emerges during cannabis 
withdrawal will receive care that addresses their specific needs. 
Specifically, they will be: 
• Linked with appropriate mental health services 
• Encouraged to continue to seek mental health support beyond 
withdrawal care 
• Monitored for symptoms such as agitation during withdrawal and 
managed appropriately. 
14.8.4 Families/significant others 
Consideration will be given to the needs of family/significant others in 
contact with a cannabis-dependent person during outpatient 
withdrawal or reduction.  
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Where appropriate, information will be provided to family/significant others 
regarding the withdrawal process and support services such as Directline 
and/or Lifeline.  
14.8.5 Young people 
Young people presenting to AOD services will be linked with youth-
specific services, where available. 
As outlined above (section 6.3), young people may present with varying 
psychosocial factors contributing to their drug use which impact upon their 
long-term plan for recovery. It is important to be mindful of the potential 
differences in treatment approach and care when commencing withdrawal 
care. For example, young people have reported an increase in disputes with 
parents and peers during cannabis withdrawal and a reduction in capacity to 
undertake school work (Dawes et al., 2006). Ongoing contact with, and 
adjunct support from, youth-specific workers throughout withdrawal care can 
promote more positive experiences for the young person.  
For further detailed information related to the withdrawal care of young 
cannabis users, please refer to the YSAS Clinical Practice Guidelines 
(YSAS, 2008). 
14.9   Recommended reading 
Budney, A. J., & Hughes, J. R. (2006). The cannabis withdrawal syndrome. 
Current Opinion in Psychiatry, 19(3), 233–238. 
NSW Department of Health. (2008a). NSW Drug and Alcohol Withdrawal 
Clinical Practice Guidelines. NSW: NSW Department of Health. 
Palmer, B. (2001). Alcohol and Drug Withdrawal: A Practical Approach. A 
manual for doctors to assist in the treatment of patients withdrawing from 
alcohol and other drugs. Mt Lawley: Next Step Specialist Drug & Alcohol 
Services. 
YSAS. (2008). YSAS Clinical Practice Guidelines - Management of alcohol 
and other drug withdrawal. Melbourne; YSAS. 
‘Mulling it over’: A self-help booklet for cannabis users. Available at 
http://www.adf.org.au/store/article.asp?ContentID=product_33212 
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15 NICOTINE 
These Guidelines provide a comprehensive approach to withdrawal 
care. The use of prescribing guidelines outlined below will be 
supported by a comprehensive clinical assessment. 
In Australia, the prevalence of tobacco use is high among the AOD treatment 
population, with reports that 80–90% of clients are dependent on nicotine 
(Lee et al., 2005). This represents a rate at least four times higher than the 
general population (AIHW, 2008). 
The adverse health effects and pharmacokinetic properties of nicotine are 
well established. The most common health problems associated with 
nicotine include acute effects on the central nervous system, gastrointestinal 
and musculoskeletal systems and longer-term effects on the cardiovascular 
system and respiratory system (NSW Department of Health, 2008a). 
In delivering nicotine withdrawal services to clients, clinicians should 
consider:  
• Setting 
• Withdrawal syndrome and potential complications  
• Assessment  
• Withdrawal care planning  
• Withdrawal care  
• Planning for post-withdrawal  
• Special needs groups  
Each of these considerations is examined below. 
15.1 Nicotine withdrawal settings 
In general, nicotine dependence may be addressed in conjunction with 
treatment for another drug in both residential and outpatient withdrawal 
settings. Withdrawal from other drugs creates an opportunity for clients to 
address their nicotine dependence simultaneously.  
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15.2  Nicotine withdrawal syndrome 
According to the DSM-IV, the diagnostic criteria for nicotine dependence 
include at least four of the following symptoms occurring within 24 hours 
after cessation or reduction of nicotine intake: 
• Depressed mood 
• Insomnia 
• Irritability, frustration or anger 
• Anxiety 
• Difficulty concentrating 
• Restlessness 
• Increased appetite or weight gain 
While craving is considered an important element of nicotine withdrawal, it is 
not considered a diagnostic criterion for nicotine dependence (Ruiz et al., 
2007).  
The number and severity of nicotine withdrawal symptoms varies between 
individuals, with most clients experiencing only mild symptoms. Withdrawal 
symptoms generally present within several hours of the last cigarette and 
peak in the first 24–72 hours. Most withdrawal symptoms will decline and 
resolve within two to four weeks, although some symptoms may fluctuate for 
longer (Benowitz, 1988). 
15.3   Nicotine withdrawal assessment 
Clinicians should be familiar with the general principles of assessment 
(refer section 9).  
During withdrawal assessment, clinical staff will be alert to signs of 
client intoxication or impairment.  
A thorough assessment of nicotine-dependent clients is critical in 
determining the most appropriate withdrawal care. Assessment is, however, 
largely dependent on the capacity of clients to provide relevant information. 
Recent AOD use may limit clients’ capacity to share and absorb accurate 
assessment information.  
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For intoxicated or impaired clients, all services should: 
• As soon as possible, identify the most recent AOD type, dose and time 
consumed (to inform medical intervention in the event of an overdose) 
• Implement regular clinical observations of the client at frequent intervals 
at first then decreasing over time as evidence of intoxication or 
impairment subsides 
• Revisit the assessment when acute intoxication or impairment has 
passed 
Assessment of nicotine use and dependence is becoming increasingly 
important as part of the overall drug history for clients attending withdrawal 
services. This is particularly so for clients attending residential AOD services, 
which are now required to comply with legislation restricting smoking in 
these settings.  
The two-item, modified Fagerström nicotine dependence scale (Appendix 
12) is the recommended tool for determining nicotine dependence 
(Heatherton et al., 1991).  
15.4   Nicotine withdrawal care planning 
Information obtained during assessment will inform the withdrawal 
care plan. 
The withdrawal care plan documents: 
• Likely severity of withdrawal based on previous history of complicated 
withdrawal, based on the Fagerström nicotine dependence scale 
• Risks associated with substance use, such as overdose history 
• The client’s motivation for withdrawal care, where this is a planned 
withdrawal presentation  
• The client’s goals during withdrawal care i.e. withdrawal, maintenance, 
reduction or substitution 
• Potential barriers that may impact on achieving the client’s withdrawal 
goals 
• Available support to enhance the likelihood of success 
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• A post-withdrawal plan, including relapse prevention and linkages to 
external support networks to address the client’s psychosocial needs 
• Inclusion of family/significant others where appropriate 
15.5   Nicotine withdrawal care 
Nicotine is known to interact with and affect the action and metabolism of 
some medication and drugs. Changes in metabolism, particularly related to 
the use of clozapine and olanzapine, may occur upon cessation of smoking 
or Nicotine Replacement Therapy (NRT)(Benowitz, 1988; Next Step 
Inpatient Withdrawal Unit, 2008).  
Clients withdrawing from nicotine should be informed of the body’s ability to 
more readily metabolise and absorb caffeine (i.e. coffee, chocolate, tea and 
soft drinks). An increase in caffeine levels may lead to increased 
restlessness and sleep disturbances. Clinicians should also monitor clients 
for signs of depression and anxiety. This is particularly relevant to clients 
with previous mental health concerns (NSW Department of Health, 2007; 
Zwar et al., 2007).  
First-line pharmacotherapy options for nicotine withdrawal include nicotine 
replacement therapy (NRT), varenicline and bupropion sustained-release. 
Nortriptyline can be used as a second-line option (Zwar et al., 2007). Each of 
these pharmacotherapies is outlined below. 
15.5.1 Nicotine replacement therapy (NRT) 
Where required, NRT can minimise the physiological withdrawal symptoms 
of nicotine withdrawal and increase the likelihood of a successful intervention 
(NSW Department of Health, 2008a).  
There are four main types of NRT, including: 
• Patches 
• Gum  
• Inhaler 
• Lozenges 
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Nicotine replacement therapy should not be commenced without a clinical 
assessment, including exploration of the following:   
• Patient preference 
• Pattern of any previous withdrawal symptoms 
• Need for a combination of NRT agents rather than a single agent, 
especially if withdrawal not controlled   
• Consideration of the local toxic effects associated with NRT: 
• Sore mouth, mouth ulcers (nicotine gum) 
• Local itching, erythema, burning (nicotine patches) 
• Nasal irritation, sneezing, watery eyes (nicotine spray)(NCETA, 
2004; Zwar et al., 2007)  
NRTs are not recommended for clients who: 
• Are pregnant or likely to become pregnant  
• Are currently breastfeeding 
• Have significant active cardiac or vascular disease 
• Report nicotine sensitivities or allergies (Zwar et al., 2007) 
Clinicians managing clients on NRT should: 
• Regularly review the client’s withdrawal to tailor the NRT dose  
• Emphasise the need for complete abstinence from nicotine 
• Address cravings, triggers and stress through psychosocial interventions 
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NRT dosing guidelines are outlined in Table 18 below.  
Table 18: Nicotine replacement therapies: dose, duration, side 
effects and contraindications (as at March 2009) 
Type Dose and duration 
 
Side 
effects 
Contra-
indications 
 Low 
dependence 
(0–9 
cigarettes 
per day) 
Low to 
moderate 
dependence 
(10–20 
cigarettes per 
day) 
Moderate to 
high 
dependence  
(21+ cigarettes 
per day) 
  
Patches None Nicobate® 14 
mg (if 
dependence 
requirement 
not met 
increase patch 
to 21 mg/24 
hrs 
OR  
Nicorette® 10 
mg 
Nicobate® 21 
mg 
 
Nicorette® 15 
mg 
Transient 
skin irritation 
Itching 
Dreams 
Sleep 
disturbance 
Indigestion 
Diarrhoea 
Relative:  
Ischaemic 
heart disease 
 
Absolute:  
Recent MI 
Serious 
arrhythmias 
Unstable 
angina 
Pregnancy 
Gum None 2 mg, 8–12 
per day 
4 mg, 8–12 
per day 
Jaw 
discomfort 
Nausea 
Indigestion 
Hiccups 
Excess 
saliva 
Sore throat 
Inhaler None Nicorette® 6–
12 cartridges 
per day 
Not 
recommended 
Mouth/throat 
irritation 
Cough 
Nausea 
Indigestion 
Source: Adapted from Alcohol and Other Drugs: A Handbook for Health Professionals 
(NCETA, 2004) 
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15.5.2 Bupropion 
Bupropion is a partial nicotine agonist and is another first-line 
pharmacotherapy for nicotine withdrawal. It can be offered as an alternative 
to NRT. Bupropion blocks the re-uptake of dopamine and norepinephrine, 
with no clinically significant effects on serotoin (Ruiz et al., 2007). 
Bupropion is not recommended for clients with a history of:  
• Previous seizures 
• Bipolar disorders 
• Eating disorders (bulimia, anorexia)(NCETA, 2004) 
It is recommended that the bupropion regime commences seven days prior 
to the negotiated quit date and is taken for seven weeks (NCETA, 2004). 
Table 19 outlines the appropriate dosing schedule for bupropion. 
Table 19: Dosing schedule of bupropion (Zyban (R)) (as at 
March 2009) 
Type Dose and duration 
 
Side 
effects 
Contraindications 
 0–9 
cigarettes 
per day 
10–20 
cigarettes 
per day 
21+ 
cigarettes 
per day 
  
Bupropion 150 mg for 3 days, then 150 mg b.d. 
for 7 weeks 
Headaches 
Dry mouth 
Impaired 
sleep 
Seizures 
Nausea 
Constipation 
Anxiety 
Dizziness 
Seizure disorders or 
risk of seizure 
Bulimia 
Anorexia nervosa 
Bipolar disorder 
Source: NCETA (2004, p.67) 
Insomnia, headache, dry mouth, nausea, dizziness and anxiety are the most 
commonly reported adverse effects associated with bupropion (Zwar et al., 
2007).  
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15.5.3 Varenicline (Champix®) 
Varinicline is a new first-line pharmacotherapy available on the Australian 
PBS as a short-term adjunct therapy for nicotine dependence. It is 
recommended that clients set a nicotine quit date of one to two weeks after 
commencing varenicline. Table 20 outlines the dosing schedule for 
varenicline. 
Table 20: Varenicline dosing schedule (as at March 2009) 
The recommended dose of varenicline is mg twice daily following a 1 
week titration as follows: 
Day 1–3 0.5 mg once daily 
Day 4–7 0.5 mg twice daily 
Day 8 I mg twice daily 
Source: Zwar (2007, p.12)  
For clients with severe renal impairment, dosing should begin at 0.5 mg once 
daily for the first three days, increased to 1 mg once daily. No dose 
adjustment is needed for patients with hepatic impairment (Zwar et al., 
2007).  
Adverse effects of varenicline include abnormal dreams and nausea. 
Nausea can be reduced if taken with food and water. As the efficacy and 
safety of varenicline in clients with a dual diagnosis is not well established, 
its use with such clients should be avoided (Zwar et al., 2007). 
15.5.4 Supplementary NRTs  
Nicotine lozenges may be used as supplementary NRT and administered as 
follows:  
• Nicotine Lozenge Max dose: up to 15 lozenges per day, spaced at least 
one-hourly 
• 2 mg lozenge if time to first cigarette after waking is greater than 30 
minutes  
• 4 mg lozenge if time to first cigarette after waking is less than 30 
minutes (Next Step Inpatient Withdrawal Unit, 2008) 
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Two second-line pharmacotherapies, clonidine and nortriptyline have been 
identified as efficacious and may be considered by clinicians if first-line 
pharmacotherapies are not effective. Note that both of these 
pharmacotherapies have potentially serious adverse side effects if ceased 
abruptly (NCETA, 2004).   
15.5.5 Psychosocial support in nicotine withdrawal  
Psychosocial interventions complement the medical management of 
nicotine withdrawal symptoms and will be available at all withdrawal 
services.   
The overarching principles of supportive care are fundamental to the 
provision of a holistic model of withdrawal care. Psychosocial interventions 
should explore: 
• Client goals, including any change in these goals over time 
• Perceived barriers to achieving an individual’s goals of withdrawal care 
• An individual’s beliefs about withdrawal care 
• Appropriate interventions and support services 
15.5.6 Complementary therapies in nicotine withdrawal 
Adjunct therapies such as massage, acupuncture and herbal remedies are 
available within some withdrawal settings. Where available, these options 
should be explored with clients. 
Note that scientific evidence on the efficaciousness of acupuncture, hypnosis 
and relaxation therapy for assisting with nicotine withdrawal and cessation is 
limited (NCETA, 2004). 
15.6   Planning for post-withdrawal  
Post-withdrawal support is an essential component of the treatment 
continuum for nicotine-dependent clients.  
Planning for post-withdrawal should: 
• Commence at the assessment phase of withdrawal care 
• Support the client’s goals, which may pertain to accommodation, child 
protection, domestic violence and legal support 
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• Support client access to post-withdrawal services that provide ongoing 
support and advocacy  
• Involve family/significant others in post-withdrawal care, as appropriate, 
to help implement the client’s post-withdrawal plan 
15.7  Special needs groups 
15.7.1 Clients with a dual diagnosis  
Clients for whom a psychiatric condition emerges during nicotine 
withdrawal care will receive care that addresses their specific needs. 
Specifically, they will be: 
• Linked with appropriate mental health services 
• Encouraged to continue to seek mental health support beyond 
withdrawal care 
• Monitored for withdrawal symptoms during withdrawal and managed 
appropriately 
15.7.2 Families/significant others  
Consideration will be given to the needs of family/significant others in 
contact with a nicotine-dependent person during outpatient withdrawal 
or reduction.  
Where appropriate, information will be provided to family/significant others 
regarding the withdrawal process and support services such as Directline 
and/or Lifeline.  
15.7.3 Young people 
Young people presenting to AOD services will be linked with youth-
specific services, where available. 
As outlined above (section 6.3), young people may present with varying 
psychosocial factors contributing to their drug use which impact upon their 
long-term plan for recovery. It is important to be mindful of the potential 
differences in treatment approach and care when commencing withdrawal 
care. Ongoing contact with, and adjunct support from, youth-specific workers 
throughout withdrawal care can promote more positive experiences for the 
young person.  
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For further detailed information related to the withdrawal care of young 
nicotine users, please refer to the YSAS Clinical Practice Guidelines (YSAS, 
2008). 
15.8   Recommended reading 
Benowitz, N. L. (1988). Pharmacologic aspects of cigarette smoking and 
nicotine addiction. New England Journal of Medicine, 319, 1318–1330. 
Lee, N., Coonan, D., Dunlop, A., Stephens, R., & Ritter, A. (2005). Clinical 
Treatment Guidelines for Alcohol and Drug Clinicians. No 12: Smoking 
cessation - working with clients to quit. Fitzroy, Victoria: Turning Point 
Alcohol and Drug Centre Inc. 
NCETA. (2004). Alcohol and Other Drugs: A Handbook for Health 
Professionals. Canberra: Australian Government Department of Health and 
Ageing. 
Ruiz, P., Strain, E., & Langrod, J. (2007). The Substance Abuse Handbook: 
A Comprehensive Textbook. Philadelphia, Pennsylvania, Lippincott Williams 
& Wilkins 
YSAS. (2008). YSAS Clinical Practice Guidelines - Management of alcohol 
and other drug withdrawal. Melbourne; YSAS. 
Zwar, N., Richmond, R., Borland, R., Peters, M., Stillman, S., Litt, J., et al. 
(2007). Smoking cessation pharmacotherapy: an update for health 
professionals. Royal Australian College of General Practitioners. 
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16 AOD WITHDRAWAL FOR CLIENTS 
WITH A DUAL DIAGNOSIS 
16.1 Introduction 
There is increased recognition and responsiveness in the Victorian AOD 
sector to the needs of clients with co-occurring AOD and mental health 
problems.  The case complexity involved requires a collaborative response 
that draws on the skill base of the AOD and mental health professions. This 
is true for all elements of withdrawal care, from withdrawal placement, 
screening and assessment and treatment matching to treatment and post-
withdrawal support. 
The impact of dual diagnosis on the individual, carers, family and significant 
others as well as the AOD and mental health service systems should be 
recognised.  These Guidelines act as a supporting framework for the AOD 
sector in its approach to the enhancement of service capability and, 
ultimately, service users and their supportive networks. 
16.2 Understanding what is meant by the term 
‘dual diagnosis’ 
The term ‘dual diagnosis’ is commonly used to describe “one or more 
diagnosed mental health problems occurring at the same time as 
problematic drug and alcohol use” (DHS, 2007, p. 4).  This inter-relationship 
between AOD use and mental health conditions may include the following 
(DHS, 2007, p 4): 
• A mental health problem or disorder leading to or associated with 
problematic alcohol and other drug use; 
• A substance use disorder leading to or associated with a mental 
health problem or disorder; and  
• Alcohol and/or other drug use worsening or altering the course of a 
person’s mental illness. 
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Definitions for mental health conditions are provided in:  
• The Tenth Revision of the International Classification of Diseases 
and Health Problems (ICD-10;(World Health Organization, 2004)  
• Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
(DSM-IV; (American Psychiatric Association, 2000).  
Both sources are considered appropriate for use with these Guidelines, and 
can be accessed online: 
• DSM-IV 
http://www.psychiatryonline.com/resourceTOC.aspx?resourceID=1  
• ICD-10 http://www.who.int/classifications/apps/icd/icd10online/ 
Table 21 provides a brief overview of the mental health disorders that may 
be experienced by clients with AOD problems.   
In an analysis of the 1997 National Study of Mental Health and Well Being, 
Burns and Teesson ( 2002) identified that 37% of respondents with an 
alcohol use disorder had at least one other mental health disorder.  Of these, 
18% had an affective disorder (predominantly depression (17%)), 15% had 
an anxiety disorder (predominantly generalized anxiety disorder (7%)) and 
17% had another drug use disorder (predominantly cannabis (14%)).  
High prevalence disorders include anxiety spectrum disorders, mood 
disorders and personality disorders.  These high prevalence dual diagnoses 
can often be missed by health practitioners and later re-emerge with severe 
consequences, presenting a greater impact to the individual and on health 
services (Croton, 2005).   
Mental health conditions with increased visibility tend to be lower prevalence 
but higher impact psychotic disorders, such as schizophrenia (Esterberg et 
al., 2009).   Individuals with psychosis have been observed as having a 
higher prevalence of substance use than the general population (Smith et 
al., in press), 
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Table 21: Mental health conditions that may be observed in the 
AOD setting 
 General characteristics Specific 
disorders 
High 
prevalence 
disorders 
Anxiety 
spectrum 
disorders 
Abnormal or inappropriate 
anxiety, including:  
• Increased heart rate  
• Tensed muscles  
• Quickened breathing  
in the absence of reason for this 
to occur (i.e. medical or physical 
cause) 
Panic disorder 
Phobic anxiety 
disorders (including 
agoraphobia, social 
phobias and specific 
phobias) 
Generalised anxiety 
disorder 
Post traumatic stress 
disorder (PTSD) 
Obsessive compulsive 
disorder 
Mood 
disorders 
A disturbance in mood, including 
inappropriate or exaggerated 
mood 
Dysthymia 
Major depression 
Ante/post natal 
depression 
Mania 
Bipolar disorder 
Personality 
disorders 
Disorder of thoughts, emotions, 
interpersonal functioning and 
impulse control that impacts the 
way a person interacts with the 
world 
Anti-social personality 
disorder 
Borderline personality 
disorder 
Low 
prevalence 
disorders 
Psychotic 
disorders 
Psychosis, delusions and/or 
hallucinations 
Schizophrenia 
Schizoaffective 
disorder 
Delusional disorder 
Acute and transient 
psychotic disorders 
Schizotypal disorder 
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16.3 Principles and practice in withdrawal care 
for dual diagnosis 
In addition to the principles documented in section 3, Principles of 
Withdrawal Care, the following are reflective of best practice in the AOD and 
mental health sectors for withdrawal care for dual diagnosis clients: 
• A dual diagnosis should be considered the normal expectation, not 
the exception in AOD clients (Minkoff, 2001; Croton, 2007) 
• Screening should occur for both mental health disorders and 
substance use disorders in all instances, and through both mental 
health and AOD services (i.e., the ‘no wrong door’ philosophy) 
(Croton, 2007; Staiger, 2008) 
• An integrated and collaborative approach must be applied to 
screening, assessment and care (Minkoff, 2001; Croton, 2007; 
Proudfoot et al, 2003; Sacks and Ries, 2005) 
• Interventions need to be matched to diagnosis, phase of recovery 
and stage of treatment (Minkoff, 2001) 
• There is no single correct dual diagnosis intervention or program. 
The correct intervention must be individualised, according to 
diagnosis, stage of treatment or stage of change, phase of 
recovery, need for continuity, extent of disability, availability of 
external contingencies (e.g. legal), and level of care assessment 
(Minkoff, 2001) 
16.4  Screening and assessment 
Clinicians will be familiar with the general principles of assessment 
(refer section 9).  
All clients presenting to AOD services will undergo mental health 
screening as a part of initial screening procedures. 
The factors needing consideration during assessment that have been 
identified in section 9 also apply when screening and assessing clients with 
a suspected dual diagnosis.  Effective communication, the consideration of 
bio-psychosocial risk factors and individualised care planning are central to 
the process.   
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At all times, and particularly when clients present with complex conditions, 
screening and assessment should be a part of a broader continuum of care 
to increase the likelihood of successful outcomes wherever possible.  
Continuous monitoring of clients’ needs and risks throughout withdrawal care 
is essential. 
16.4.1 Components of screening 
Mental health screening is a mandatory component for people accessing 
AOD withdrawal support. Screening aims to identify the presence of key 
psychiatric symptoms as a flag for the need to complete a more targeted 
assessment.  
An assessment should subsequently look further at presenting 
symptomatology and gather information needed to make a diagnosis through 
either an internal or external assessor, and to develop an Individual 
Treatment Plan (ITP).  
An integrated approach of AOD, primary care providers and/or mental health 
services is considered best practice, as it increases the likelihood of a 
successful episode of care.  Early recognition of a dual diagnosis provides 
opportunity for the establishment of appropriate long-term linkages to such 
service providers for clients. 
Screening for both mental health and substance use disorders should occur 
when the client is first seen by a clinician or practitioner in an AOD service or 
a mental health service.  This initial screening will determine if further 
treatment is required and when it is required (Sacks and Ries, 2005; Lee et 
al, 2007).  In addition, it will also establish the most appropriate setting in 
which withdrawal should take place. 
Factors for consideration include: 
• Risk of self-harm and suicide 
• Risk to others  
• Current level of intoxication 
• Severity of substance use disorder 
• History of repeated, unsuccessful withdrawal 
• Severity of mental health disorder 
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• Previous diagnoses and treatment 
• Any complicating factors such as additional co-occurring health 
conditions 
• Current medications  
• Clients current level of motivation and willingness to engage in 
support 
• Current level of support available to a client (Croton, 2007) 
 
16.4.2 Screening and assessment tools  
The use of screening tools within AOD withdrawal care provides guidance 
during assessment. Clinical judgement is critical and secondary consultation 
should be sought where uncertainties exist about the client’s presentation 
and the results of screening tools.  
There are numerous validated screening tools for dual diagnosis that are 
available for use in AOD withdrawal services. In Australia, the Screening for 
and Assessment of Co-occurring Substance Use and Mental Health 
Disorders by Alcohol and Other Drug and Mental Health Services (Croton, 
2007) provides an overview of the available tools for screening and 
assessment of patients/clients at intake.  The following options, outlined in 
Table 22, are recommended for consideration: 
• Kessler 10(K10) 
• PsyCheck  
• Modified Mini Screen  
• Mental Health Screening Form (MHSF 3) 
Links to these tools are available in Appendix 4. 
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Table 22: Screening and assessment tools 
Tool Description 
Kessler 10 (K10) Ten item scale designed to detect high 
prevalence mental health disorders 
PsyCheck Screening tool designed for non-mental health 
experts that includes: 
• Self-Reporting Questionnaire (WHO 
mental health screen)  
• Suicide risk assessment  
• Brief mental health history  
• Mental health probes 
Mental Health Screening Form (MHSF 3) 17 item tool that examines lifetime psychiatric 
history 
Modified Mini Screen  
 
Assessment tool designed to detect mood 
disorders, anxiety disorders and psychotic 
disorders 
As mental health symptoms may or may not be related to AOD use and 
intoxication, it is important that screening for each condition is repeated 
following withdrawal.  This will ensure that the care plan developed initially is 
still relevant (Minkoff, 2005). 
16.4.3 Components of assessment  
Assessment forms the basis for development of an ITP. Results inform the 
most appropriate withdrawal setting, service involvement, medication and 
pharmacotherapy options as well as initiating both pre-admission and post-
withdrawal planning. In addition to issues covered in the screening process, 
assessments will seek more information on the following: 
• History of suicidality, suicide attempt or self-harm 
• Recent substance use history 
• Longitudinal substance use history 
• Previous experience of withdrawal 
• Bio-psychosocial history 
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• History of mental health issues 
• History of contact with mental health services 
• History of medications 
• Interactions between substance use and mental health issues (i.e. 
what a client experiences when substance use increases or 
ceases. 
A suicide risk assessment should be included in services’ standard 
assessment processes. Identification of imminent risk warrants an immediate 
response in accordance with organisational protocols. The PsyCheck 
screening tool (Appendix 4) includes a suicide risk assessment and can be 
referred to as an example.  
In any screening or assessment process, clinicians should be aware of recall 
bias (which may be due to memory impairment resulting from substance use 
or mental health disorders) when obtaining the following information: 
• Chronology of symptoms, i.e. substance use or the mental health 
symptom 
• Substance use history 
• Family history of addiction 
• Family history of mental health disorders 
• Nature of the symptoms, e.g. presence of visual hallucinations or 
other psychotic symptoms 
• Experience in the event of abstinence or controlled use (more than 
one month) 
Clients have a range of needs that drive their withdrawal care, from high to 
low risk.  Table 23 provides an overview of the treatment pathways that may 
result from risk assessments.  Clinicians with less experience should ensure 
they have access to senior/more experienced staff for a secondary 
consultation where there is any doubt as to a client’s current level of risk. 
Results of the risk assessment may necessitate internal or external referral 
to a dual diagnosis specialist, with the client’s consent. 
Staff in settings such as hospitals, psychiatric facilities, prisons and police 
watch-houses will be familiar with, and alert to, the signs of mental health 
distress in order to respond in a timely and appropriate manner.  
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Table 23: Risk assessment and care planning 
Treatment 
pathway   
Assessment Referral  Setting Service 
linkages 
High risk  
 
Continuous 
review 
As required Inpatient or 
high care 
CAT team 
Psychiatric 
units 
Medium risk Admission, exit 
and follow-up 
GP Home-based 
Community 
residential 
Area mental 
health services 
Low risk Admission, exit 
and follow-up 
GP Home-based  
Outpatient 
community  
Area mental 
health services 
Symptomatology  
Clinicians will focus on symptom acuity and respond to risk factors 
accordingly. 
Distinguishing between intoxication, symptoms of withdrawal and mental 
health symptoms can be extremely challenging.  On presentation, clinicians 
should not necessarily be concerned by the origin of the symptoms.  Instead, 
their focus should be on treating symptom acuity and responding to risk 
factors accordingly.  
If a client has engaged in very recent substance misuse prior to service 
presentation, it is more likely that their symptoms are substance-related. 
However, as time between the symptoms and point of admission lengthens, 
the likelihood of symptoms being caused by mental illness increases. This 
can be complicated by longer periods of withdrawal for some patients (e.g. 
where alcohol withdrawal is complicated by polydrug use).  
In the absence of substance use, it is easier to obtain a clearer view of 
causal pathology. Attempts should be made to ascertain the clients’ 
understanding of the relationship between mental health symptoms and 
substance use. Clients may be able to indicate whether symptoms are 
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related to substance use or mental health conditions. This is especially the 
case if they enter withdrawal care with a known diagnosis or via direct 
referral from a mental health service. 
A thorough assessment of psychiatric history and AOD use, along with any 
experience of previous episodes of withdrawal, should be conducted. 
Variance in clinician skill and experience may impact on the quality of these 
assessments, and a secondary consultation should be considered in the 
event of uncertainty of results.  
Table 24 provides an overview of symptoms present in withdrawal, and 
identifies symptoms that may also be present in a mental health disorder. 
Table 24: Symptoms of AOD withdrawal that are also present in 
mental health disorders 
Substance Withdrawal symptoms Symptoms also present in 
mental health disorders 
Alcohol Mild to moderate severity 
Tremor, restlessness, insomnia, 
nightmares, sweats, tachycardia, 
fever, nausea and vomiting 
Restlessness, insomnia, 
nightmares, nausea and vomiting 
Severe  
Hallucinations, increased agitation, 
tremulousness 
Hallucinations, increased agitation, 
tremulousness 
Most severe  
Delirium tremens (DTs), cardiac 
arrest, death 
N/A 
Benzodiazepine Common 
Anxiety, insomnia, restlessness, 
irritability, poor concentration and 
memory, depression and muscle 
aches 
Anxiety, insomnia, restlessness, 
irritability, poor concentration and 
memory, depression and muscle 
aches 
Less common 
Perceptual disturbances and panic 
attacks 
Perceptual disturbances and panic 
attacks 
Rare 
Seizures and symptoms of 
psychosis 
Symptoms of psychosis 
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Substance Withdrawal symptoms Symptoms also present in 
mental health disorders 
Amphetamine-
type 
substances 
Amphetamine 
Craving sleep, irritability, 
depressed mood, lack of energy, 
slowing of movement, loss of 
interest or pleasure  
Craving sleep, irritability, 
depressed mood, lack of energy, 
loss of interest or pleasure 
Methamphetamine – less severe 
Anxiety, motor retardation, 
agitation, vivid dreams, craving, 
poor concentration, irritability and 
tension, mild to moderate 
depression 
Anxiety, motor retardation, 
agitation, vivid dreams, craving, 
poor concentration, irritability and 
tension, mild to moderate 
depression 
Methamphetamine – severe 
Inactivity, fatigue, anhedonia and 
dysphoria 
Inactivity, fatigue, anhedonia and 
dysphoria 
 
Opiates 
(severity alters 
with different 
substances) 
Increased sweating, lacrimation, 
rhinorrhea, urinary frequency, 
diarrhoea, abdominal cramps, 
nausea, vomiting, muscle spasm 
leading to headaches, backaches 
and cramps, twitching, arthralgia, 
piloerection, papillary dilatation, 
elevated blood pressure, 
tachycardia, anxiety, irritability, 
dysphoria, disturbed sleep, 
increased cravings for opioids 
Anxiety, irritability, dysphoria, 
disturbed sleep  
Nicotine Depressed mood, insomnia, 
irritability, anxiety, difficulty 
concentrating, restlessness, 
decreased heart rate, and 
increased appetite 
Depressed mood, insomnia, 
irritability, anxiety, difficulty 
concentrating, restlessness 
Cannabis Most common 
Anger, aggression, irritability, 
anxiety, nervousness, decreased 
appetite or weight loss, 
restlessness, sleep difficulties (inc 
strange dreams) 
Anger, aggression, irritability, 
anxiety, nervousness, decreased 
appetite or weight loss, 
restlessness, sleep difficulties (inc 
strange dreams) 
Less common 
Chills, depressed mood, stomach 
pain/physical discomfort, 
shakiness, sweating 
Depressed mood 
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16.5 Withdrawal settings for clients with a dual 
diagnosis 
Clients with a dual diagnosis frequently have complex needs, and they may 
require longer episodes of care than patients with a substance use or mental 
health disorder.  
Treatment presentation may be for a range of reasons3 (Section 7, 
Presentation to AOD withdrawal). The motivation for presenting to 
withdrawal care will influence the location at which withdrawal occurs.  The 
current ‘no wrong door’ philosophy aims to ensure that people have access 
to the AOD and mental health services that they require, irrespective of their 
entry point to health services (DHS, 2008).  
Clients with a dual diagnosis may be placed on an involuntary order by 
public mental health services as a result of their mental illness (Mental 
Health Act 1986, s 8), if all of the following conditions are met: 
• The person appears to be mentally ill 
• The person's mental illness requires immediate treatment and that 
treatment can be obtained by the person being subject to an 
involuntary treatment order 
• Because of the person's mental illness, involuntary treatment of the 
person is necessary for his or her health or safety (whether to 
prevent a deterioration in the person's physical or mental condition 
or otherwise) or for the protection of members of the public 
• The person has refused or is unable to consent to the necessary 
treatment for the mental illness 
• The person cannot receive adequate treatment for the mental 
illness in a manner less restrictive of his or her freedom of decision 
and action 
                                                          
3
 Crisis Presentation: Precipitated by an event or circumstance significant enough to 
impact on an individual’s motivation to participate in care, where they otherwise would 
not have (e.g. child protection, correctional intervention);  
Unplanned Withdrawal: When withdrawal occurs following presentation to hospital, 
psychiatric or medical units for a non-related or co-occurring condition, or within a 
secure correctional setting;  
Elective: An individual is independently motivated to access support 
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In these circumstances, clients can be treated as an inpatient or on a 
community treatment order, depending on the outcomes of a risk 
assessment.  
It should be noted that a person is not considered to be mentally ill based 
solely on the fact that they use alcohol or other drugs. 
The most appropriate setting for an individual with a dual diagnosis 
seeking withdrawal will be informed by a thorough clinical assessment, 
including a risk assessment. 
16.5.1 Settings 
The following information provides an overview of the withdrawal treatment 
settings available to clients with a dual diagnosis. The most appropriate 
setting will be determined by the outcomes of screening and assessment in 
conjunction with clinical judgement. Clients with a dual diagnosis should 
ultimately undergo the same pathway of referral as other clients; however 
decisions about the best care options should involve clinicians from both 
services to determine whether a mental health or AOD setting is more 
appropriate. 
As noted previously, dual diagnosis clients are not a homogenous group due 
to the complicated mix of AOD and mental health diagnoses.  It is important 
that the most acute presentation (substance use or mental health disorder) is 
treated first.  In the event of significant distress resulting from either disorder, 
screening and assessment may be deferred until severe symptoms abate. 
The best withdrawal care facilitates step-up and step-down care, 
according to client need.  
Clients’ progress should be continuously monitored in any treatment setting; 
observing their mental health and substance use disorder symptoms and 
ensuring that the current setting continues to be the most appropriate 
according to their changing needs.   
Hospital or psychiatric inpatient 
It is important to understand the individual needs of the client/patient, and 
their care requirements, including levels of anxiety, depression and other 
psychiatric symptoms. Patients with severe mental health disorders or 
severe substance use disorders are more likely to be matched to an 
inpatient or residential program, given their risk profiles and specific needs. 
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Psychiatric inpatient withdrawal care often occurs as a result of a client 
presenting with serious mental health symptomatology, such as suicidality or 
psychosis, through a hospital ED, CAT team, or if the client is known to a 
psychiatric unit. Admission and the decision to undergo a period of 
detoxification is made on the basis of risk and acuteness of the client’s 
mental health issue, including measures (or judgement) of impairment and 
function.  
If the severity of psychopathology and associated risk factors is prominent, 
AOD withdrawal is generally more appropriate in a mental health facility.  
The staff, setting and structure of the ward are designed to support a high 
level of responsiveness to an exacerbation of psychosis or the presentation 
of suicidal ideation or highly aggressive behaviour. Time out facilities that are 
available in mental health settings and staff training in the management of 
severe behavioural disturbances facilitate adequate support for clients with 
low-prevalence mental health problems/disorders.  
Community residential withdrawal 
Community residential withdrawal (CRW) settings are appropriate for some 
clients with low to medium severity mental health and substance use 
symptom acuity.  CRW is generally suitable provided there has been 
sufficient preparatory planning with the client and other service providers 
who are engaged prior to admission.   
To facilitate effective integrated withdrawal care, CRW units should have 
access to internal or consultant psychiatry services. Ideally, area mental 
health case managers and primary health care services such as GPs will 
also work in partnership with CRW units throughout withdrawal care.  
Consideration must be given to clients who may have commenced 
medication for mental health disorders, such as anti-depressants, before 
admission. It is important to ensure that appropriate follow-up strategies 
have been initiated for continuation of medication management during and 
post-withdrawal. 
Linkage to a community GP can be useful in the management of high 
prevalence disorders, as well as those with untreated psychotic symptoms. 
CRW settings may also facilitate early intervention for individuals who have 
been experiencing psychotic symptoms for a number of years but are not yet 
diagnosed. In these cases, establishing a link with a community GP for an 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
147 
assessment post-withdrawal will provide an opportunity for referral to a 
psychiatrist, should this be required.  
A residential setting is generally best suited to the needs of people with 
lower prevalence mental health disorders. A home-based environment may 
not be appropriate for these individuals due to the level of structure and 
support that is required to undergo withdrawal. In the event that the client is 
residing in community mental health supported accommodation, it may be 
best to make an alternative arrangement for the duration of the withdrawal 
phase.  Clinical judgement is required to determine the degree and nature of 
support and care that is needed.  It may be possible to work in collaboration 
with the Psychiatric Disability Rehabilitation and Support Services (PDRSS) 
or AOD case manager to address this. 
Home-based withdrawal/Outpatient community withdrawal 
Some clients may benefit from remaining in their own environment. The 
critical issue to consider is the level of risk posed for the client as an 
outpatient.  In these instances, risks include the client’s capacity to manage 
their medication and the stability of their mental state and personal 
vulnerability.  
Adequate preparatory planning is necessary prior to commencement of 
withdrawal, involving the client as well as both AOD and mental health 
service staff. Ideally, there will be liaison between the mental health treating 
team and withdrawal team throughout the withdrawal phase. Extra services 
may be needed as well; such as home visits or clinic reviews. Clients should 
be provided with information on how to access mental health support 
services readily throughout the withdrawal phase. 
Referral to home-based withdrawal or outpatient community withdrawal is 
contingent on a number of factors, including: 
• History of repeated, unsuccessful attempts at withdrawal in this 
setting 
• History of a significant psychiatric disorder 
• The complexity and severity of the client’s co-occurring condition 
• Limited social support for the client  
• The suitability of the home environment for withdrawal 
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• Client preference 
Clinicians will provide clients with information on how to access 
mental health support services throughout withdrawal. 
Length of stay 
As mentioned, dual diagnosis clients are not a homogenous group. An 
extended period of stay within residential AOD withdrawal settings or mental 
health facilities (if appropriate) may be necessary for some clients. Access to 
stepped care between hospital/psychiatric wards, community-based or non-
residential AOD settings also affords graduated treatment responses based 
on client need/risk. 
The length of stay for a client in withdrawal care may impact on the 
effectiveness of their treatment. Clients with a dual diagnosis may require 
time for mental health symptoms to stabilise, and withdrawal is often 
protracted because of the impact of mental health medications.   
A client’s anxiety is generally not apparent in a residential withdrawal setting 
until they have ceased withdrawal medications (around day 5).  An extended 
period within the treatment setting provides an opportunity for further 
assessment and the exploration of interventions that are matched to 
presenting symptoms. Withdrawal may not be completed within a standard 
period of care and flexibility is required.   
Post-withdrawal planning is an integral part of withdrawal care. Dual 
diagnosis clients often experience poorer social functioning, hence linkages 
with mental health and primary health care providers need to be established 
prior to discharge, to reduce the risk of relapse.  
Discharge planning should also attempt to address psychosocial issues such 
as the client having access to appropriate and stable accommodation and 
contact with significant others for additional support. It is acknowledged that 
services may have limited capacity to address such issues in their entirety 
prior to discharge; however the provision of contact details for targeted 
services is an appropriate alternative. 
Clinicians will ensure clients have access to appropriate and stable 
accommodation prior to discharge. 
Clinicians will ensure that clients have access to sufficient support 
prior to discharge. 
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16.5.2 Service capability and linkages 
Current best practice for clients with a dual diagnosis requires treatment 
capability of both disorders across the AOD and mental health sectors. The 
inclusion of cross-sectoral development and training as part of organisational 
strategic planning will enhance service capacity to meet the needs of this 
client group.  
Organisational policy articulating the ‘no wrong door’ philosophy should be 
actualised through the development of partnerships with primary care and 
mental health providers. These Primary Care Partnerships, through 
formalised memoranda of understanding, enable linkages and referral 
processes across agencies; ensuring that comprehensive and appropriate 
assessments occur in a timely manner.   
Relationships between AOD and mental health services provide the 
opportunity for a seamless service delivery in withdrawal and post-
withdrawal care.  Implementation of these strategies will minimise the risk of 
clients ‘falling through the gaps’ at critical care transition points (e.g., mental 
health condition not severe enough to be case managed by area mental 
health services). 
Mental and primary health care providers (e.g., area mental health case 
managers, GP and psychiatrists) who are engaged in client care will provide 
important support during pre- and post-withdrawal phases. As part of care 
planning, AOD services should seek to maintain these links when a client 
commences withdrawal, to ensure continuity of care.   
The Victorian Dual Diagnosis Initiative (VDDI) was established in 2001 to 
facilitate dual diagnosis capacity building across AOD and mental health 
services in Victoria.  Services provided by VDDI include primary and 
secondary consultations, and education and training to AOD and mental 
health services, to enhance service capacity at a local level. 
Localised dual diagnosis teams can produce effective relationships across 
agencies, to support the integrated management of clients.  These teams 
operate at a local level, between allied AOD and mental health services, and 
include representatives from the AOD service, the mental health service and 
dual diagnosis specialists. 
An integrated approach between mental health and AOD services is 
considered best practice.  
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Skills and training  
AOD clinicians have varying degrees of skill, knowledge and experience.  In 
accordance with dual diagnosis capability standards for AOD services, 
clinicians should demonstrate competence in screening, assessment and the 
development of IITPs based on the outcomes of the assessment.  Staff 
should also have the capacity to identify personal and organisational 
limitations in care and management of either disorder; referring for further 
treatment or assessment as required.  
VDDI has developed a diploma encompassing the five core competencies 
required of staff working in this area:   
• AOD staff must complete two mental health competencies:  
• Orientation to mental health work  
• Provide non-clinical services to people with mental health issues 
  
• Mental health staff must complete two AOD competencies: 
• Orientation to AOD work 
• Assess the needs of clients who have AOD issues   
 
• All staff must complete the dual diagnosis competency: 
• Provide interventions to meet the needs of consumers with mental 
health and alcohol or other drug issues 
Mental health first aid training is recommended for AOD clinicians, including 
suicide intervention.   It is an effective strategy for care of clients presenting 
with mental health crisis before specialised professional assistance is 
received or until the crisis resolves. 
All AOD clinical service staff will complete a dual diagnosis induction 
program. 
All AOD clinical service staff will be trained in mental health first aid. Clear 
emergency policies and procedures will be integrated into staff induction and 
orientation processes, with regular updates/reviews for all staff in clinical 
environments. 
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16.6 Withdrawal care planning 
The complexities of clients with a dual diagnosis require a flexible approach 
toward withdrawal care planning.  Substance misuse and mental health 
conditions should both be regarded as primary disorders. Both warrant 
independent assessment and the development of an ITP should integrate 
strategies for substance and mental health issues.  
Integrated treatment relationships between AOD and mental health clinicians 
enhance treatment outcomes for the client.  Multidisciplinary responses can 
be a useful approach in the development of an ITP. Service providers from 
both AOD and mental health teams discuss the elements of withdrawal care 
with the client; ensuring role clarity and consistency in working toward 
mutually agreeable treatment goals. 
An integrated approach involving the assessment of both disorders and their 
interactions will help to identify which symptoms are the most urgent/high 
risk and require clinical attention first.  
Information about mental health and substance use disorders obtained 
during assessment will inform the withdrawal care plan. 
16.7 Pre-admission planning 
Pre-admission planning provides an opportunity for clients to obtain 
information about the withdrawal care experience. For dual diagnosis clients, 
it is particularly important to reduce the level of anxiety associated with entry 
to an unfamiliar environment in the event of community residential or 
inpatient withdrawal. Therefore, clients should receive adequate orientation 
to the service, staff and layout as well as information regarding the 
withdrawal itself and what may be experienced, including common 
withdrawal symptoms and changes that may occur during the episode. 
In addition, the following should be ascertained: 
• If the client is currently linked with other health service providers 
• If the client is taking, or requires, any mental health medications during 
the withdrawal care period  
• Links with a primary health care provider, such as a GP, who is able to 
take on prescribing responsibilities  
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If the client is case managed by an area mental health service, there should 
be liaison between their case manager and/or treating doctor with the AOD 
service and client prior to admission to ensure treatment plans are 
complementary and, where possible, integrated.  The dual diagnosis team 
(AOD service, mental health and dual diagnosis specialist) can ensure the 
client is fully informed of their treatment options. 
Interactions associated with any psychotropic medications and the client’s 
primary drug of concern, as well as withdrawal medication, need to be 
ascertained prior to withdrawal. Alterations in medication dosing may be 
necessary to accommodate these potential interactions. Further, some illicit 
drugs will potentiate the effects of the prescribed drugs and some will inhibit 
their effects. 
Psychosocial issues, such as ensuring that a client’s accommodation and 
income will remain secure whilst undertaking withdrawal care, also need to 
be considered in pre-admission planning. 
16.8 Withdrawal care 
Clinicians will be familiar with the general principles of withdrawal care 
(refer section 3).  
Careful monitoring of physical and emotional health is essential throughout 
withdrawal care. As withdrawal symptoms can exacerbate underlying mental 
health conditions such as depression, it is important to differentiate between 
symptoms of withdrawal and mental health conditions for early identification 
of suicidality.  
Assessment should also continue throughout withdrawal care. The 
emergence of more significant mental health issues, such as mania or 
psychosis, may occur as the withdrawal progresses. When mental health 
symptoms arise in withdrawal, it is important to consider how well the client 
is medicated for their withdrawal, as inadequate medicating may exacerbate 
these symptoms.  
Withdrawal service staff will consider the potential for withdrawal to 
complicate clients’ existing medical conditions and provide specialist 
medical care and monitoring, as required. 
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16.8.1 Psychosocial and pharmacological interventions 
for withdrawal care 
Care of both AOD and mental health disorders can be loosely categorised 
into pharmacological and non-pharmacological/psychosocial strategies. 
Ideally, these interventions will be integrated into psychosocial and 
pharmacological treatments.  
Goodness-of-fit between client and treatment strategy can be determined 
through a thorough assessment of: 
• Individual circumstances (e.g. do they have sufficient support) 
• Level of need (e.g. does symptom severity require a pharmacological 
response) 
• Level of risk (e.g. are they a high risk for self harm)  
• Previous treatment success 
Mental health interventions will be tailored to individual needs and will 
complement the medical management of withdrawal symptoms.  
Psychosocial considerations 
Psychosocial issues that should be explored during assessment are detailed 
in Table 25 below.  Where relevant, strategies to address these issues will 
be incorporated in the treatment plan. 
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Table 25: Psychosocial issues to address during withdrawal 
care 
Psycho-social issues  Focus 
Perceived barriers to achieving goal of 
withdrawal care 
Relationship issues 
Geographic isolation 
Access to appropriate AOD  and mental health 
support and information 
Legal and financial issues 
Parenting and child protection issues 
Domestic violence 
Beliefs about withdrawal care Motivation for accessing withdrawal care 
Previous withdrawal experiences 
Previous experience with mental health episodes 
Fears and expectations  
Identified supports Appropriate accommodation 
Support network (family, friends, workers) 
Source: Key informant interviews 
Some AOD services may have clinical psychologists who are able to bulk bill 
for psychosocial services.  Under the GP Mental Health Care scheme 
(covered by Medicare), GPs may undertake early intervention (including 
providing focused psychological strategies), assessment and management 
of patients with mental health disorders, and refer clients to clinical 
psychologists for further care. Further information can be found at:  
http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pcd-gp-
mental-health-care-medicare. 
A range of psychosocial interventions may be available in AOD settings for 
people with a dual diagnosis, including: 
• Assessment and brief intervention 
• Motivational interviewing 
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• Contingency management 
• Cognitive behaviour therapy (CBT) 
• Psychodynamic therapy 
• Self-help approaches 
• Continuing care 
Motivational interviewing and CBT are often regarded as particularly 
successful when working with clients who have a dual diagnosis. 
The success of psychosocial strategies is dependent on the appropriateness 
of these strategies for the individual client and the development of an 
integrated treatment plan that includes medication management assistance 
where required.   
Pharmacological considerations 
Clinicians will consider the interactivity between prescription 
withdrawal medications and prescription mental health medication 
Clinicians will consider the ongoing pharmacological treatment needs 
of the client during withdrawal and prior to discharge. 
Prior to commencement of pharmacotherapy, prescription medications for 
mental health disorders should not be ceased without consultation with 
mental health services regarding any medication regimes. It is also important 
to ascertain whether the client is taking their mental health medications as 
prescribed and if there is any poly-substance use. 
To ensure a holistic approach to pharmacological interventions, clinicians 
must consider risk management strategies.  They must also complete a 
thorough assessment, refer to appropriate dual diagnosis specialists, and 
maintain linkages and supports with community mental health services. 
It is essential that care is taken not to over-sedate clients with withdrawal 
medications due to the possible interactions with mental health medications. 
Interactivity between commonly prescribed withdrawal medications and 
those prescribed for mental health disorders can impact dosing regimes. 
Ongoing pharmacological treatment needs of the client need consideration in 
discharge planning. The risk of relapse should be included as an area of 
concern when deciding on the most appropriate discharge medications.  
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Table 26 provides an overview of the interactivity of commonly prescribed 
withdrawal medications and medications commonly prescribed for mental 
health disorders. 
Table 26: Interactions between medication prescribed for 
substance misuse disorder and medication prescribed for 
mental health disorder 
 
Prescribed withdrawal medications 
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 M
ethadone 
 M
orphine/  
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orphine 
 D
isulfram
 
 B
enzo 
 Lofexidine 
Amitryptiline  1,7    
Antipsychotics 1 1  1  
Barbituates 1, 2* 1    
Benzo 1,3 1,3 3  3 
Buprenorphine 1,2**     
Chloral hydrate 1     
Chlorpromazine  7    
Clomipramine  1    
Fluoxetine 1   1  
SSRIs 1     
Tricyclics 1  3   
(Source: adapted from Trathen 2006) 
Table Key: 
1 Increased effect/toxicity of SM prescription 
2 Decreased effect of SM prescription  
3 Increased effect/toxicity of other MH prescription 
7  Myoclonus 
*reduced methadone levels but enhanced CNS depression  
** can cause either opiate withdrawal or enhanced CNS depression 
 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
157 
16.9 Planning for post-withdrawal 
Post-withdrawal support is an essential component of the treatment 
continuum for clients with a dual diagnosis.  
In addition to the principles documented in section 9.3, this section provides 
some specific considerations for clients with a dual diagnosis. Planning for 
post-withdrawal is an essential element of appropriately managing the needs 
of dual diagnosis clients and it needs to be in place prior to discharge. 
The following provides an overview of areas for consideration in post-
withdrawal planning, which will vary according to individual need: 
• Clients are linked with a primary health care provider such as a GP for 
medication management 
• An integrated care plan with primary health care providers and/or area 
mental health services is developed, including the provision of a mental 
health diagnosis post-withdrawal and monitoring of both disorders over 
time 
• Psychosocial issues are identified and appropriate linkages with support 
services and significant others are in place 
• Relapse prevention has been addressed in relation to a client’s AOD 
use as well as their mental health condition. Clients have an awareness 
of stressors and cues and how to avoid them, what to do if they do find 
themselves in a problematic situation, and where to find help (including 
psychiatric triage numbers and telephone counselling) 
• Educational material has been provided to clients regarding the effects 
of AOD on mental health and mental health medications 
• Links have been established with post-withdrawal and dual diagnosis 
support groups/agencies 
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16.10 Resources 
A range of resources are available to provide clinicians, clients and families 
of people with a dual diagnosis with further information and support.  They 
comprise journals, websites and support agencies.  Examples include: 
• Families where a Parent has a Mental Illness (FaPMI) 
Support and information for families where a parent may have a 
mental illness and/or substance abuse problems 
http://www.health.vic.gov.au/mentalhealth/families/index.htm  
• The Journal of Dual Diagnosis 
Providing the latest research in the co-occurrence of mental health 
and substance use disorders.  Available on a subscription basis, in 
print or online 
• InfoXchange 
Information and resources for Victorian community support services  
http://www.infoxchange.net.au/news 
• National Cannabis Prevention and Information Centre (NCPIC) 
Information and resources for Australian service providers, 
cannabis users and family members  
http://ncpic.org.au/  
• SANE 
Advocacy, education and research for people with a mental illness, 
their families, health professionals and the community  
http://www.sane.org/  
• Mental Illness Fellowship Australia (MIFA) 
Self-help, support and advocacy group for people with a mental 
illness, their families and friends 
http://esvc000144.wic027u.server-web.com/  
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• ARAFMI  
Peak support agency for carers of people with a mental illness. Also 
provides respite care, intensive home-based and outreach support, 
prevention and recovery care, and education for service providers 
http://www.arafemi.org.au/  
• Association of Participating Service Users (APSU)  
Advocacy group for AOD service users 
www.apsuonline.org.au 
• beyondblue 
Information, support, training, programs and research related to 
depression 
http://www.beyondblue.org.au 
• Victorian Dual Diagnosis Initiative (VDDI) support services 
o Dual Diagnosis Support Victoria  
A support network for students, clinicians and health 
professionals working with people with a dual diagnosis 
http://dualdiagnosis.ning.com   
o Dual Diagnosis Australia and New Zealand 
Community website providing information related to dual 
diagnosis. Maintained by Eastern Hume Dual Diagnosis 
Service 
http://www.dualdiagnosis.org.au/ 
o VDDI Education & Training Unit (State-wide) 
T: 03 9288 2383 
o Metropolitan Lead Agencies 
Eastern Dual Diagnosis Team (Blackburn) 
T: 03 9875 1600 
NEXUS (Fitzroy) 
T: 03 9288 3824 
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Southern Dual Diagnosis Service (Dandenong) 
T: 03 8792 2330 
SUMITT (Western) (Footscray) 
T: 03 8345 6682 
Further contact details for metropolitan and regional VDDI units can be found 
in Appendix 1. 
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18 APPENDICES 
Appendix 1: AOD support services 
DirectLine 
24-hour counselling and referral for anyone with a question or problem 
related to alcohol or drug use.  
DirectLine is part of Turning Point’s statewide telephone service network, 
providing 24-hour, seven-day counselling, information and referral to alcohol 
and drug treatment and support services throughout Victoria. Turning Point's 
professional counsellors are experienced in alcohol and drug-related 
concerns. 
DirectLine counsellors can provide: 
• Immediate counselling and support, including crisis intervention 
• Support in dealing with the impact of drug use on the family and 
relationships 
• Assistance to develop strategies to deal with an alcohol or drug problem 
• Harm minimisation strategies 
•  Information and referral to treatment and support services across  Victoria 
DirectLine is a free, anonymous and confidential service. 
DirectLine (Victoria)  T: 1800888 236 
ADIS (Tasmania)   T: 1800 811 994 
ADIS (Northern Territory)   T: 1800 131 350 
Drug and Alcohol Clinical Advisory Service (DACAS) 
24-hour specialist telephone consultancy service for alcohol and drug 
practitioners and health and welfare workers.  
DACAS takes calls from doctors, nurses and other health and welfare 
professionals seeking advice on the clinical management of alcohol and drug 
issues. DACAS consultants include counsellors, specialist doctors and 
pharmacists. 
DACAS (Victoria) T: 1800 812 804      
DACAS (Tasmania)  T: 1800 630 093 
DACAS (Northern Territory)  T: 1800 111 092 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
172 
Family Drug Help 
The ‘listening ear’ service responding to families experiencing alcohol and 
drug-related difficulties. 
T: 1300 660 068 (Victoria) 
Quit Victoria 
Quit offers a range of direct and indirect resources for people wanting to quit 
and resources for professionals helping others to quit.  
Professionals in the health, education and community service areas can 
encourage and support smoking cessation. Quit provides information and 
training to assist them in this role. 
T: 03 9663 7777 
F: 03 9635 5510 
Web queries: webquery@quit.org.au       
General queries: query@quit.org.au  
Quitline: Quitline@quit.org.au  
Syringe Helpline 
Information and referral service responding to the problem of discarded 
injecting equipment. 
T; 1800 552 355 (Victoria) 
Women’s Alcohol and Drug Service (WADS) 
WADS is located at the Royal Women's Hospital, Victoria 
T: 03 9344 3631                E: wads@thewomens.org.au 
YSASline 
Alcohol and drug assessment and referral service for young people. 
YSASline 24-hour telephone service provides information, counselling and 
referral to YSAS services and youth-specific alcohol and drug services 
throughout Victoria. 
YSASline is open to young people, their families, health and welfare 
workers, police and ambulance workers, and the wider community. 
T: 1800 014 446 (Victoria) 
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Victorian Dual Diagnosis Initiative (VDDI) Units 
Support network for professionals working in AOD or mental health services 
with the objective of facilitating building dual diagnosis capacity across 
Victoria.   
VDDI units operate in metropolitan and regional areas. 
VDDI Education & Training Unit (Statewide) 
St Vincent's Hospital 
Nicholson St, Fitzroy VIC 3065 
(PO Box 2900) 
T: 03 9288 2383 
Metropolitan Lead Agencies 
Eastern Dual Diagnosis Team 
Suite 6  60–64 Railway Rd, Blackburn  VIC 3130 
T: 03 9875 1600 
Metropolitan areas: Central East, Outer East  
Rural areas: Eastern Hume 
NEXUS 
St Vincent’s Hospital 
P.O. Box 2900, Fitzroy VIC 3065 
T: 03 9288 3824 
Metropolitan areas: Yarra, Boroondara, Banyule, Nillumbik 
Rural areas: Loddon and Northern Mallee 
Southern Dual Diagnosis Service 
c/- SEADS 
2/229 Thomas St, Dandenong VIC 3175 
T: 03 8792 2330 
Metropolitan areas: Port Phillip, Kingston, Bayside, Greater Dandenong, 
Casey, Cardinia, Mornington Peninsula, Frankston, parts of Monash, Glen 
Eira, Stonington 
Rural areas: Gippsland and La Trobe Valley 
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SUMITT (Western ) 
3–7 Eleanor St, Footscray VIC 3011 
T: 03 8345 6682 
Metropolitan areas: Maribyrnong, Wyndham, Brimbank, Hobsons Bay, 
Melton, Moonee Valley, Moreland, Hume, Darebin, Melbourne City and 
Whittlesea 
Rural areas: Grampians, Barwon, South West and Goulburn Valley 
VDDI Rural Services 
Barwon 
Barwon Health, Drug Treatment Service 
40 Little Malop St, Geelong VIC 3220 
T: 03 5273 4000 
Gippsland 
Gippsland Dual Diagnosis, Box 424, Traralgon VIC 3844 
T: 03 5128 0009 
Glenelg 
South West Health Care 
Lava St (PO Box 197), Warrnambool VIC 3280 
T: 03 5561 3813 
Goulburn 
Monash St, Shepparton VIC 3630 
T: 03 5832 2111 
PO Box 800, Seymour VIC 3660 
T: 03 5735 0333 
 
Grampians 
Grampians Psychiatric Services 
P.O Box 577, Ballarat VIC 3356 
T: 03 5320 4100 
Loddon 
Bendigo Health Care Group 
PO Box 126, Bendigo 3550 VIC 
T: 03 5454 7608 
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Eastern Hume 
Eastern Hume Dual Diagnosis Service 
Box 1225, Wangaratta VIC 3677 
T: 03 5722 2677 
www.dualdiagnosis.org.au 
Northern Mallee 
Ramsay Health, Mildura Base Hospital 
107 Pine Ave, Mildura 3500 VIC 
T: 03 5018 7917 
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Appendix 2: Client intoxication  
Patients who use drugs or alcohol often present intoxicated or having 
overdosed. The correct management of these conditions is an essential part 
of practice. Intoxication occurs when a person’s intake of a substance 
exceeds his or her tolerance and produces behavioural and/or physical 
abnormalities. It complicates the assessment and management of patients 
because: 
• psychoactive drugs affect mood, cognition, behaviour and physiological 
functioning 
• intoxication can have a major impact on informed consent to treatment 
and the validity of all further information reported by the patient 
•  intoxication can mimic or mask serious illness and injury 
• patients who are aggressive or disruptive because they are intoxicated 
can risk their own safety or the safety of others  
• severe intoxication can be life threatening by altering physical and 
mental functions leading to inappropriate actions or central nervous 
system depression and death 
Identifying intoxication and overdose 
In withdrawal settings, always assess the possibility that the patient is 
intoxicated. Some serious medical conditions can mimic intoxication. 
Objective observations should be given more weight than the patient’s 
report. 
Managing intoxication 
Assessment is urgent if intoxication is pronounced, and medical assessment 
is required if intoxication is worsening or affecting breathing, blood pressure 
or level of consciousness. Identify the most recent drug type, dose and time 
consumed.  
Consider the possibility that underlying illness (e.g. concussion, subdural 
haematoma, infections, diabetes or electrolyte disturbances) may be the 
cause of apparent intoxication.  
Check for possible head injury if the patient is incoherent, disoriented or 
drowsy.  
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Monitor the airway if breathing is affected or consciousness is impaired, as 
death may occur from respiratory depression or aspiration pneumonia.  
Keep intoxicated patients under observation until their intoxication 
diminishes and they are considered safe.  
If the intoxication does not diminish, assess the patient for other possible 
causes of the condition. 
Managing suspected overdose 
Monitor signs of intoxication to identify possible overdose (i.e., intoxication to 
the point of loss of consciousness) on the patient’s arrival and then as 
frequently as the patient’s state requires (usually 1–4 hourly). The Glasgow 
Coma Scale plus vital signs provide the best method of assessment. 
Indications of intoxication Indications of overdose 
Maladaptive behaviour 
Evidence of intoxication by history and physical 
examination 
Blood alcohol level by breath analysis. Saliva, 
urine or blood testing for alcohol and other drugs 
 
Behavioural and physical signs: 
Alcohol: loss of control of voluntary movements, 
slurred speech, disinhibition, low blood pressure, 
smells of alcohol 
Benzodiazepines: slurred speech, loss of control 
of voluntary movements, sedation, nystagmus 
(repetitive eye movement), low blood pressure, 
drooling, disinhibition 
Opioids: pinpoint pupils, sedation, low blood 
pressure, slowed pulse, itching and scratching 
GHB: rapid onset of drowsiness, disinhibition, 
dizziness, nausea, muscle spasms, movement 
and speech impairment 
In order of progressive impairment: 
• increasing agitation 
• cold and clammy skin 
• pinpoint pupils (opioids) 
• changing mental state 
(hallucinations, panic or 
deep depression) 
• changes to heart rate (e.g, 
irregular, below 60/min, or 
above 120/min) 
• lowered body temperature 
• slow and noisy respiration 
• muscle twitching 
• cyanosis 
• pulmonary oedema 
• stupor 
• convulsions 
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Indications of intoxication Indications of overdose 
 
Cannabis: increased pulse, confusion, 
restlessness, excitement, hallucinations, anxious 
or panicky, disconnected from reality, paranoia, 
violent or suicidal behaviour 
Psychostimulants (amphetamines, cocaine and 
ecstasy): Increased confidence, excitement, 
euphoria, anxiety, agitation, speech, 
hypervigilance, increased body temperature and 
blood pressure, dry mouth, paranoia, psychotic 
features 
LSD: anxiety, fear, frightening hallucinations, 
panic, feeling of loss of control, going mad, 
paranoia, violent or suicidal behaviour 
Magic mushrooms (psilocybin): Similar to LSD 
PCP: similar to LSD, with euphoria, numbness, 
psychosis, aggression 
Ketamine: thought disorder, hallucinations, 
perceptual distortion, anxiety, agitation, 
tachycardia, hypertension, analgesia and sensory 
dissociation 
• coma. 
People with decreased levels of 
consciousness require: 
• urgent medical assessment 
• management in a medical 
setting 
• monitoring of vital signs and 
neurological 
• function 
• examination and support of 
airway, breathing and 
circulation. 
Source: NSW Department of Health (2008a) NSW Drug and Alcohol Withdrawal 
Clinical Practice Guidelines. 
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Appendix 3: One week consumption calendar 
Drug 
type 
Sun Mon Tues Wed Thurs Fri  Sat 
A  L 100g L 20g L 200g L10g L150g L 150g L 150g 
T H 40 
cigs/day 
Nicotine 
=40x8 = 
320 mg 
H 
320 mg 
H 
240 mg 
H 
   
        
        
        
        
        
 
Drug type  
A = alcohol  
B = benzodiazepines  
O = opioids  
M = amphetamines 
T = tobacco 
Route 
 L = oral  
N = anal mg  
I = injecting  
H = inhalation 
S = subcutaneous 
Amount  
g = grams 
mg = milligrams 
$ = amount spent 
F = number of injections 
 
Source: Frank, L., & Pead, J. (1995). New Concepts in Drug Withdrawal: A Resource 
Handbook.  
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Appendix 4: Mental health screening tools 
PsyCheck  
Introduction, guides for use and training materials: 
http://www.psycheck.org.au/download.html  
Tool: 
http://www.turningpoint.org.au/library/psycheck/RESOURCES/SCREENING
_TOOL_FORM/Screening%20Tool_A4.pdf   
 
Kessler 10 (K10) 
Online scoring tool:  
http://www.beyondblue.org.au/index.aspx?link_id=1.237  
Tool: 
http://www.health.vic.gov.au/pcps/downloads/coordination/tool_profile_psych
osocial_may02.pdf or www.mhnocc.org/amhocn/Kessler_10_Manual.pdf 
 
Modified Mini Screen (MMS)  
Tool:  
http://www.oasas.state.ny.us/hps/research/documents/MMSTool.pdf  
 
Mental Health Screening Form MHSF3 
Tool: 
http://pathwayscourses.samhsa.gov/bully/pdfs_bully/bully_supps_pg40.pdf   
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Appendix 5: Coping and relaxation techniques  
Relaxation practice 1 – slow breathing 
This type of breathing uses your diaphragm rather than your chest. Your 
diaphragm is a membrane located across the abdomen, just underneath 
your ribcage. It serves as a kind of plunger to move air in and out of the 
lungs. When you are relaxed, your diaphragm is doing most of the work in 
breathing, while your chest should remain relatively still and shouldn’t move 
much at all. 
Step 1:  Sit comfortably in a chair with your head, back and arms supported. 
Uncross your legs and close your eyes if that feels comfortable. 
Step 2:  Put one hand flat on your chest and the other hand over your 
stomach between the ribs and the navel. Remember that you want your 
bottom hand – the one on your stomach – to move during this exercise, but 
not the hand on your chest. 
Step 3:  Take a breath in and hold it as you count to 10. Don’t make this a 
really deep breath. Just breathe in normally, using your diaphragm, and hold 
it in for a count of 10. 
Step 4:  When you get to 10, breathe out and mentally say the word ‘relax’ 
to yourself in a calm, soothing manner. 
Step 5:  Practise breathing in and out slowly in a 6-second cycle. Breathe in 
for 3 seconds and out for 3 seconds (in–2–3, out–2–3). As you breathe in, 
use your diaphragm as opposed to your chest. Your hand on your chest 
should remain relatively still. Every time you breathe out, mentally say the 
word ‘relax’ to yourself in a calm manner. 
Step 6:  After every 10 breaths in and out, hold your breath again for 10 
seconds and then continue breathing in the 6-second cycle (in–2–3, out–2–
3). 
Each time you breathe in imagine you are filling your stomach with air. 
Picture your stomach as a balloon that you are inflating with each in-breath 
and deflating with each out-breath. Observe your hands as you breathe. If 
you are relaxed, the hand over your abdomen should be moving more than 
the hand over your chest. There is no need to slow down the rate of your 
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breathing – this will happen naturally as you become relaxed. Try to breathe 
in through your nose and out through your mouth. Continue this process until 
any symptoms of anxiety, stress, tension or anger are gone. Monitor your 
slow breathing relaxation practice during the week using the relaxation 
practice log.   
 
Source: Lee, N., Johns, L., Jenkinson, R., Johnston, J., Connolly, K., Hall, K., et al. 
(2007). Clinical Treatment Guidelines for Alcohol and Drug Clinicians. No 14: 
Methamphetamine dependence and treatment. Fitzroy, Victoria: Turning Point Alcohol 
and Drug Centre Inc. 
Available at www.turningpoint.org.au/library/cg_14.pdf 
 
Relaxation practice 2 – progressive muscle relaxation 
Step 1, Learn to relax: Close your eyes. Remember to ‘relax’ as you move 
your body into a relaxed position. Make sure you are in a comfortable 
position with your eyes closed. 
Step 2, Hands and arms: Imagine that you are squeezing a lemon with your 
left hand. Squeeze it really hard so all the juice runs out. Hold it for five 
seconds really tight. Now, RELAX. Notice what it feels like as your hand 
relaxes. Do the same thing with your right hand. 
Step 3, Arms and shoulders: Imagine that you are like a cat stretching 
after lying in the sun. Stretch your arms high above your head. Reach as far 
as you can. Hold it for a few seconds. Now RELAX. Notice what your arms 
feel like when they are completely relaxed. 
Step 4, Shoulders and neck: Imagine you are a turtle and you see 
someone coming. Try to push your head back down into your shell so that 
you can hide. Push your head down. Hold it for five seconds. Now RELAX. 
Let the tightness in your neck go completely. 
Step 5, Jaw: Imagine you have a nut in your mouth and you are trying to 
crush it with your teeth. Bite down on it and try to break it. Hold it for five 
seconds. Now RELAX. Notice how good it feels to let your jaw relax 
completely. 
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Step 6: Face and nose: Imagine a fly has landed right on the tip of your 
nose but you can’t use your hand to shoo it away. Wrinkle your nose up to 
try and get rid of the fly. Now RELAX. Notice how good it feels to have a 
relaxed face. Now the fly has come back and it has landed on your forehead. 
Wrinkle your forehead up as much as you can to try and get the fly to go 
away. Now RELAX. Notice how good your forehead feels when it is not 
wrinkled and tense. 
Step 7, Stomach: Imagine someone is about to jump on your stomach. Try 
and make your stomach as hard as you can so that someone standing on it 
won’t hurt. Hold it for five seconds. Now RELAX. Notice how much better 
your stomach feels when it is completely relaxed and floppy. Now imagine 
that you have to squeeze through a narrow gap in the fence. Suck in your 
stomach and make it really skinny so that you can fit through. Now RELAX. 
Let your stomach go completely relaxed. 
Step 8, Legs and feet: Imagine that you are walking at the beach down 
where the sand is wet and squishy. Squish your toes down as far as you can 
in the sand. Keep squishing for five seconds. Now RELAX. Notice how 
different your legs and feet feel.  
Monitor your progressive muscle relaxation practice during the week using 
the Relaxation practice log. 
Source: Lee, N., Johns, L., Jenkinson, R., Johnston, J., Connolly, K., Hall, K., et al. 
(2007). Clinical Treatment Guidelines for Alcohol and Drug Clinicians. No 14: 
Methamphetamine dependence and treatment. Fitzroy, Victoria: Turning Point Alcohol 
and Drug Centre Inc.  
 
Also available at www.turningpoint.org.au/library/cg_14.pdf 
 
Relaxation practice 3 – mindful walking 
Mindful walking is a way of stepping out of ‘automatic pilot’ and can help you 
to practise paying attention to the present. 
Step 1:  Stand at one end of your walk, keeping your feet pointed forward 
and eyes straight ahead. 
Step 2:  Start slowly at first and, as best you can, pay attention to the way 
your feet and legs feel when you take each step forward. 
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Step 3:  Start with the left foot and follow with the right. 
Step 4:  Slowly move from one end of your walk to the other, aware of the 
particular sensations in the bottoms of your feet and heels as they make 
contact with the floor, and the muscles in your legs as they swing forward. 
Step 5:  Continue this process up and down the length of your walk for 
about 10 minutes. 
Step 6:  Your mind will wander away from this activity during your 10 
minutes of practice. This is normal. As best you can when you notice this 
has happened, gently re-focus your attention on your feet and legs and how 
they feel when they contact with the floor. 
Once you have mastered the basic steps of mindful walking, you may like to 
look for books or groups that can teach you more advanced techniques. 
Mindfulness has been developed by Buddhist practitioners and many groups 
conduct courses. 
Monitor your progressive muscle relaxation practice during the week using 
the Relaxation practice log.  
Source: Lee, N., Johns, L., Jenkinson, R., Johnston, J., Connolly, K., Hall, K., et al. 
(2007). Clinical Treatment Guidelines for Alcohol and Drug Clinicians. No 14: 
Methamphetamine dependence and treatment. Fitzroy, Victoria: Turning Point Alcohol 
and Drug Centre Inc. 
 
Available at www.turningpoint.org.au/library/cg_14.pdf 
 
Relaxation practice 4 – imagery 
Imagery/Visualisation 
Here is a copy of the imagery activity completed during your session. You 
may like to record this on a tape and listen to it during your relaxation 
practice. 
Step 1:  Sit comfortably in a chair with your head, arms and back supported. 
Close your eyes and take a few deep breaths. When you’re ready, clear your 
mind of thoughts and images as if it is a blank computer screen. 
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Step 2:  Think of a place where you feel relaxed and safe. It could be a 
place you’ve been in the past or a place you can imagine being relaxed. 
When you think of a place, imagine it in as much detail as you can. 
Step 3:  Ask yourself the following questions about your relaxed and safe 
place: 
• Is it night or day? 
• What can you see around you? 
• Are you alone or with someone else? 
• What can you hear? 
• Is there any characteristic smell of this place? 
• What can you feel with your fingertips and on the surface of your skin? 
Step 4:  Stay in your relaxing place and tune in to your body sensations. Ask 
yourself the following questions: 
• What do you notice about your muscles? 
• Are they tense or loose? 
• What about your heart rate? 
• And your breathing rate? 
• Do you feel relatively warm or cool? 
• Do you notice anything else about your body? 
Step 5:  Stay in this relaxed place for a few minutes, giving you time to just 
continue breathing and being in a state of relaxation. Remember this relaxed 
state so that you can enter it again later when you need to. 
Step 6:  Slowly clear your mind of images and thoughts again and bring 
your awareness back to the here and now. Turn your attention to the sounds 
in the room and perhaps outside the room. Stretch your arms and legs and 
yawn if you want to. When you are ready, slowly open your eyes. 
Source: Lee, N., Johns, L., Jenkinson, R., Johnston, J., Connolly, K., Hall, K., et al. 
(2007). Clinical Treatment Guidelines for Alcohol and Drug Clinicians. No 14: 
Methamphetamine dependence and treatment. Fitzroy, Victoria: Turning Point Alcohol 
and Drug Centre Inc. 
 
Available at www.turningpoint.org.au/library/cg_14.pdf 
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Relaxation practice log 
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Source: Lee, N., Johns, L., Jenkinson, R., Johnston, J., Connolly, K., Hall, K., et al. 
(2007). Clinical Treatment Guidelines for Alcohol and Drug Clinicians. No 14: 
Methamphetamine dependence and treatment. Fitzroy, Victoria: Turning Point Alcohol 
and Drug Centre Inc.   
 
Available at www.turningpoint.org.au/library/cg_14.pdf 
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Better sleep checklist  
 
Go to sleep as soon as you feel tired. Sleep cycles cause people to 
feel tired approximately every 90 minutes – if you ignore the cues, you 
may have to wait for another 90 minutes. 
 
Set an alarm to wake you at the same time each morning, even on 
weekends and holidays. This helps your body to get into a regular 
sleep-wake routine. 
 
Use the bed only for sleeping and for sex. Reading, thinking and eating 
in bed can lead people to associate bed with activity and stress. 
 
Get out of bed when you can’t sleep after trying for 30 minutes and go 
back to bed as soon as you feel tired. Do something enjoyable when 
you get up (e.g. watching television or reading a book). 
 
Make sure that it is a quiet and relaxing activity, not one that will 
stimulate your brain too much! 
 
Do not watch the clock if you’re lying awake. Worrying that you’re not 
sleeping keeps your mind active and prevents you from actually 
getting to sleep. 
 
Write your problems on a piece of paper before going to bed then 
throw the paper out or put it aside to tackle in the morning. Say to 
yourself: ‘There’s nothing I can do about this tonight’. 
 
Avoid consuming caffeine (tea, coffee, cola drinks, chocolate) after 
mid-afternoon. 
 
Avoid drinking alcohol at dinnertime or afterwards. Although alcohol 
can induce sleep, it causes you to become wakeful (rebound 
insomnia) several hours after drinking it. Alcohol also interferes with 
the energy-restoring benefits of good sleep. 
 
Practise relaxation before going to bed. This helps to calm your body 
and mind and promotes entry into sleep. 
 
Sleep with a minimum of covers so that you do not overheat. Turn off 
heaters and electric blankets, and keep a window open. Overheating 
causes restlessness and a lack of deep sleep. 
 
Source: Lee, N., Johns, L., Jenkinson, R., Johnston, J., Connolly, K., Hall, K., et al. 
(2007). Clinical Treatment Guidelines for Alcohol and Drug Clinicians. No 14: 
Methamphetamine dependence and treatment. Fitzroy, Victoria: Turning Point Alcohol 
and Drug Centre Inc. 
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Appendix 6: Alcohol Withdrawal Assessment 
Scoring Tool & Guidelines (CIWA-Ar) 
Assessment Protocol 
a. Vitals, Assessment Now.    
b. If initial score ≥ 8 repeat q1h x 8 hrs, then 
    if stable q2h x 8 hrs, then if stable q4h. 
c. If initial score < 8, assess q4h x 72 hrs.  
   If score < 8 for 72 hrs, d/c assessment. 
    If score ≥ 8 at any time, go to (b) above.  
d. If indicated, (see indications below)  
    administer prn medications as ordered and  
    record on MAR and below.  
 
Date 
 
           
Time             
Pulse 
            
RR 
            
O2 sat 
            
BP 
            
Assess and rate each of the following (CIWA-Ar Scale):                      Refer to reverse for detailed instructions in use of the CIWA-Ar scale. 
Nausea/vomiting  (0 - 7) 
0 - none; 1 - mild nausea ,no vomiting; 4 - intermittent nausea;   
7 - constant nausea , frequent dry heaves & vomiting. 
            
Tremors  (0 - 7) 
0 - no tremor; 1 - not visible but can be felt; 4 - moderate w/ arms 
extended; 7 - severe, even w/ arms not extended. 
            
Anxiety  (0 - 7) 
0 - none, at ease; 1 - mildly anxious; 4 - moderately anxious or 
guarded; 7 - equivalent to acute panic state 
            
Agitation (0 - 7) 
0 - normal activity; 1 - somewhat normal activity; 4 - moderately 
fidgety/restless; 7 - paces or constantly thrashes about 
            
Paroxysmal Sweats (0 - 7) 
0 - no sweats;    1 - barely  perceptible sweating,  palms moist;  
4 - beads of sweat obvious on forehead;     7 - drenching sweat 
            
Orientation  (0 - 4) 
0 - oriented; 1 - uncertain about date; 2 - disoriented to date by no 
more than 2 days; 3 - disoriented to date by  > 2 days; 
 4 - disoriented to place and / or  person 
            
Tactile Disturbances (0 - 7) 
0 - none; 1 - very mild itch, P&N, ,numbness; 2-mild itch, P&N, 
burning,  numbness; 3 - moderate itch,  P&N, burning ,numbness;  
4 - moderate  hallucinations; 5 - severe  hallucinations; 
 6 – extremely severe hallucinations; 7 - continuous hallucinations 
            
Auditory Disturbances (0 - 7) 
0 - not present; 1 - very mild harshness/ ability to startle; 2 - mild 
harshness, ability to startle; 3 - moderate harshness, ability to 
startle; 4 - moderate hallucinations; 5 severe hallucinations;  
6 - extremely severe hallucinations; 7 - continuous.hallucinations 
            
Visual Disturbances (0 - 7) 
0 - not present;    1 - very mild sensitivity;      2 - mild sensitivity;   
3 - moderate sensitivity;       4 - moderate hallucinations;   5 - severe 
hallucinations;        6 - extremely severe hallucinations;   7 - 
continuous hallucinations 
            
Headache  (0 - 7) 
0 - not present; 1 - very mild; 2 - mild; 3 - moderate; 4 - moderately 
severe; 5 - severe; 6 - very severe; 7 - extremely severe 
            
Total  CIWA-Ar score: 
 
            
PRN Med:   (circle one)        
Diazepam        Lorazepam    
Dose given (mg):              
Route:             
        Time of PRN medication administration: 
 
            
Assessment of response (CIWA-Ar score 30-60 
minutes after medication administered) 
            
RN Initials             
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Procedure: 
Assess and rate each of the 10 criteria of the CIWA scale. Each criterion is 
rated on a scale from 0 to 7, except for ‘orientation and clouding of 
sensorium’ which is rated on scale 0 to 4. Add up the scores for all ten 
criteria. This is the total CIWA-Ar score for the patient at that time.   
Prophylactic medication should be started for any patient with a total CIWA-
Ar score of 8 or greater (i.e.  start on withdrawal medication). If started on 
scheduled medication, additional PRN medication should be given for a total 
CIWA-Ar score of 15 or greater. 
Document vitals and CIWA-Ar assessment on the Withdrawal Assessment 
Sheet. Document administration of PRN medications on the assessment 
sheet as well.  
The CIWA-Ar scale is the most sensitive tool for assessment of the patient 
experiencing alcohol withdrawal.  Nursing assessment is vitally important. 
Early intervention for CIWA-Ar score of 8 or greater provides the best means 
to prevent the progression of withdrawal.  
 
Source:  www.chce.research.va.gov/apps/PAWS/pdfs/CIWA-Ar.pdf 
 
Guidelines 
Nausea/Vomiting - Rate on scale  
0 – 7 
 Tremors - have patient extend arms 
& spread fingers. Rate on scale 0 – 7 
0 - None  0 - No tremor 
1 - Mild nausea with no vomiting 
2 
3 
 1 - Not visible, but can be felt fingertip 
to fingertip 
2 
3 
4 - Intermittent nausea 
5 
6 
 4 - Moderate, with patient’s arms 
extended 
5 
6 
7 - Constant nausea and frequent 
dry heaves and vomiting 
 7 - severe, even w/ arms not 
extended 
Continued over page 
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Anxiety - Rate on scale 0 – 7  Agitation - Rate on scale 0 – 7 
0 - no anxiety, patient at ease  0 - normal activity 
1 - mildly anxious 
2 
3 
 1 - somewhat normal activity 
2 
3 
4 - moderately anxious or guarded, 
so anxiety is inferred 
5 
6 
 4 - moderately fidgety and restless 
5 
6 
7 - equivalent to acute panic states 
seen in severe delirium or acute 
schizophrenic reactions. 
 7 - paces back and forth, or 
constantly thrashes about 
 
Paroxysmal Sweats  
Rate on Scale 0 – 7 
 
 
 
0 - no sweats 
 Orientation and clouding of 
sensorium  
Ask, ‘What day is this? Where are 
you? Who am I?”   
Rate scale 0 – 4 
1-  barely perceptible sweating, 
palms moist 
 0 – Oriented 
2 
3 
 1 – cannot do serial additions or is 
uncertain about date 
4 - beads of sweat obvious on 
forehead 
5 
 2 - disoriented to date by no more 
than 2 calendar days 
6  3 - disoriented to date by more than 2 
calendar days 
7 - drenching sweats  4 - Disoriented to place and/or person 
Continued over page 
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 
Turning Point Alcohol and Drug Centre Inc. 
191 
 
Tactile disturbances  
Ask, ‘Have you experienced any 
itching, pins & needles sensation, 
burning or numbness, or a feeling of 
bugs crawling on or under your 
skin?’ 
 Auditory Disturbances  
Ask, ‘Are you more aware of sounds 
around you? Are they harsh? Do they 
startle you? Do you  
hear anything that disturbs you or 
that you know isn’t there? 
’ 
0 – none  0 - not present 
1 - very mild itching, pins & needles, 
burning, or numbness 
 1 - Very mild harshness or ability to 
startle 
2 - mild itching, pins & needles, 
burning, or numbness 
 2 - mild harshness or ability to startle 
3 - moderate itching, pins & 
needles, burning, or numbness 
 3 - moderate harshness or ability to 
startle 
4 - moderate hallucinations  4 - moderate hallucinations 
5 - severe hallucinations  5 - severe hallucinations 
6 - extremely severe hallucinations  6 - extremely severe hallucinations 
7 - continuous hallucinations  7 - continuous hallucinations 
Visual disturbances  
Ask, ‘Does the light appear to be 
too bright? Is its colour different 
than normal? Does it hurt your 
eyes? Are you seeing anything that 
disturbs you or that you know isn’t 
there?’ 
 
 Headache  
Ask, ‘Does your head feel different 
than usual?  
Does it feel like there is a band 
around your head?’  
Do not rate dizziness or light 
headedness. 
 
0 - not present  0 - not present 
 
1 - very mild sensitivity  1 - very mild 
 
2 - mild sensitivity  2 - mild 
 
3 - moderate sensitivity  3 - moderate 
 
4 - moderate hallucinations  4 - moderately severe 
 
5 - severe hallucinations  5 - severe 
 
6 - extremely severe hallucinations  6 - very severe 
 
7 - continuous hallucinations  7 - extremely severe 
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Appendix 7:  The Subjective Opiate Withdrawal  
Scale (SOWS)  
Date __________________________________ 
Time ________________________________dd 
 
Please score each of the 16 items below according 
to how you feel now   (Circle one number) 
 
Symptoms Not at 
all 
A little Moderately Quite 
a bit 
Extremely 
1 I feel anxious 0 1 2 3 4 
2 I feel like 
yawning 
0 1 2 3 4 
3 I am perspiring 0 1 2 3 4 
4 My eyes are 
teary 
0 1 2 3 4 
5 My nose is 
running 
0 1 2 3 4 
6 I have 
goosebumps 
0 1 2 3 4 
7 I am shaking 0 1 2 3 4 
8 I have hot 
flushes 
0 1 2 3 4 
9 I have cold 
flushes 
0 1 2 3 4 
10 My bones and 
muscles 
ache 
0 1 2 3 4 
11 I feel restless 0 1 2 3 4 
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Please score each of the 16 items below according 
to how you feel now   (Circle one number) 
 
Symptoms Not at 
all 
A little Moderately Quite 
a bit 
Extremely 
12 I feel nauseous 0 1 2 3 4 
13 I feel like 
vomiting 
0 1 2 3 4 
14 My muscles 
twitch 
0 1 2 3 4 
15 I have stomach 
cramps 
0 1 2 3 4 
16 I feel like using 
now 
0 1 2 3 4 
Range 0–64 
Source: Handelsman, L., Cochrane, K. J., Aronson, M. J. et al. (1987) Two New 
Rating Scales for Opiate Withdrawal, American Journal of Alcohol Abuse, 13, 293–
308. 
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Appendix 8:  Benzodiazepine Withdrawal 
Assessment Scale (BWAS) 
Vital signs to be taken daily—otherwise at the discretion of clinical 
staff.   
Note: Total score is indicative of increasing or decreasing severity of 
withdrawal. Scores are not directly linked to pharmacological management 
as occurs with alcohol scores based on the CIWA-Ar. 
Name: _____________________________  
UR: _____________________________ 
Date           
Time           
Blood pressure           
Temperature           
Pulse           
Respiration rate           
Benzodiazepine assessment score—Range 0, 1, 4 or 7 (see next page) 
Anxiety           
Restlessness/agitation           
Palpitations           
Headache           
Concentration           
Appetite           
TOTAL           
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Sleep (0700) Staff 
observation 
          
Sleep (0800) Client 
observation 
          
Other symptoms 
 
          
 
These questions refer to how the person is feeling right now, at the present 
moment. 
Anxiety Ask: ‘Do you feel nervous?’ 0   No anxiety—at ease 
1   Mild 
4   Moderately anxious or 
guarded so anxiety is inferred 
7  Equivalent to acute panic 
states as seen in severe delirium  
or acute schizophrenic reactions 
Restlessness/ 
Agitation 
Ask ‘Do you feel more restless 
or agitated than you are 
normally? 
0   Normal activity 
1   Somewhat more than normal 
activity 
4   Moderately fidgety or restless 
7   Unable to sit or stand still 
 Palpitations 
 
Ask ‘Are you aware of your 
heart racing in your chest?’ 
0   No palpitations 
1   Mild palpitations 
4   Moderate awareness of 
heartbeat 
7  Aware of heart racing 
constantly 
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Headache 
 
Ask ‘Do you have a headache 
or feeling of fullness in the 
head?’ 
0   No headache 
1   Mild 
4   Moderate 
7   Severe 
Concentration Ask ‘Do you have any difficulty 
concentrating?’ 
0   No difficulty concentrating 
1   Mild 
4   Moderate 
7   Severe 
 
Appetite 
 
Ask ‘Have you noticed any 
change in your appetite?’ 
0   No loss of appetite 
1   Slight loss 
4   Moderate loss 
7   Complete loss of appetite, 
unable to eat at all 
 
Sleep 
(0800 observations 
only—not to be 
included in total 
score) 
Ask ‘How did you sleep last 
night?’ 
0   Sufficient sleep 
1   Some sleep 
4   Moderately/restless sleep 
7   No sleep 
 
Source: DeCrespigny, C et al. (2003) Alcohol Tobacco and Other Drugs Guidelines for 
Nurses and Midwives: Clinical Guidelines. Flinders University and Drug and Alcohol 
Services Council Adelaide.  
 
Also available at www.dassa.sa.gov.au 
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Appendix 9: Clinical Institute Withdrawal 
Assessment Scale - Benzodiazepines 
Guide to the Use of the Clinical Withdrawal Assessment Scale for 
Benzodiazepines 
Person Report: 
For each of the following items, circle the number that best describes how 
you feel. 
Do you feel irritable? 0 
Not at all 
1 2 3 4 
Very much so 
Do you feel fatigued? 0 
Not at all 
1 2 3 4 
Unable to function 
Do you feel tense? 0 
Not at all 
1 2 3 4 
Very much so 
Do you have difficulties 
concentrating? 
0 
Not at all 
1 2 3 4 
Unable to 
concentrate 
Do you have any loss of 
appetite? 
0 
Not at all 
1 2 3 4 
No appetite, unable 
to eat 
Have you any numbness or 
burning on your face, hands 
or feet? 
0 
No 
numbness 
1 2 3 4 
Intense 
burning/numbness 
Do you feel your heart racing? 
(palpitations) 
0 
No 
disturbance 
1 2 3 4 
Constant racing 
Does your head feel full or 
achy? 
0 
Not at all 
1 2 3 4 
Severe headache 
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Do you feel muscle aches or 
stiffness? 
0 
Not at all 
1 2 3 4 
Severe stiffness or 
pain 
Do you feel anxious, nervous 
or jittery? 
0 
Not at all 
1 2 3 4 
Very much so 
Do you feel upset? 0 
Not at all 
1 2 3 4 
Very much so 
How restful was your sleep 
last night? 
0 
Very restful 
1 2 3 4 
Not at all 
Do you feel weak? 0 
Not at all 
1 2 3 4 
Very much so 
Do you think you didn't have 
enough sleep last night? 
0 
Very much 
so 
1 2 3 4 
Not at all 
Do you have any visual 
disturbances? (sensitivity to 
light, blurred vision) 
0 
Not at all 
1 2 3 4 
Very sensitive to 
light, blurred vision 
Are you fearful? 0 
Not at all 
1 2 3 4 
Very much so 
Have you been worrying 
about possible misfortunes 
lately? 
0 
Not at all 
1 2 3 4  
Very much so 
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Clinician Observations 
Observe behaviour 
for sweating, 
restlessness and 
agitation 
Observe tremor Observe feel palms 
0 
 
1 
 
 
2 
 
 
3 
 
4 
None, normal activity  
 
 
 
 
Restless 
 
 
 
 
Paces back and 
forth, unable to sit 
still 
0 
 
1 
 
 
2 
 
 
3 
 
4 
No tremor  
 
Not visible, can be felt in 
fingers 
 
Visible but mild 
 
 
Moderate with arms 
extended 
Severe, with arms not 
extended 
0 
 
1 
 
 
2 
 
 
3 
 
4 
No sweating visible 
 
Barely perceptible 
sweating, palms moist 
 
Palms and forehead 
moist, reports armpit 
sweating 
Beads of sweat on 
forehead 
Severe drenching 
sweats 
 
Total Score Items 1 – 20 
1–20 = mild withdrawal   
41–60 = severe withdrawal 
21–40 =moderate withdrawal          
61–80 = very severe withdrawal 
Source: Adapted from Busto, U.E., Sykora, K. & Sellers, E.M. (1989). A clinical scale 
to assess benzodiazepine withdrawal. Journal of Clinical Psychopharmacology, 9 (6), 
412–416. 
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Benzodiazepine withdrawal scale (CIWA-B) 
UR:  
Name:  
Address:  
DOB:  
 
 
Source:  Queensland Health (2002) Protocols for detoxification: General Practice and 
Community Settings. Queensland Government. 
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Appendix 10:  Amphetamine Withdrawal 
Questionnaire 
During the past 24 hours:  
(Circle one answer per question)  
1 Have you been craving amphetamine or 
methamphetamine? 
Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
2 Have you felt sad? Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
3 Have you lost interest in things or no 
longer take pleasure in them? 
Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
4 Have you felt anxious? Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
5 Have you felt as if your movements are 
slow? 
Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
6 Have you felt agitated? Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
7 Have you felt tired? Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
8 Has your appetite increased or are you 
eating too much? 
Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
9 Have you had any vivid or unpleasant 
dreams? 
Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
10 Have you been craving for sleep or 
sleeping too much? 
Not 
at all 
Very 
little 
A 
little 
Quite  
a lot 
Very 
much 
Scoring  
Not at all      = 0 Very little     = 1 A little = 2  
Quite a lot   = 3 Very much  = 4  
Possible range of scores is 0–40 with higher score indicating greater 
severity. 
 
Source: Srisurapanont M, Jarusuraisin N & Jittiwutikarn J (1999) Amphetamine 
withdrawal: Reliability, validity and factor structure of a measure. Australian and New 
Zealand Journal of Psychiatry 33:89–93. 
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Appendix 11: Cannabis Withdrawal 
Assessment Scale 
Note: Total score is indicative of increasing or decreasing severity of 
withdrawal. Scores are not directly linked to pharmacological management 
as occurs with alcohol scores based on the CIWA-Ar. 
 
Name: _____________________________________________________   
DOB:  ________________________ 
 
Date           
Time           
Temperature           
Pulse           
Respiration rate           
Blood pressure           
Pupil size            
Reaction           
Weight           
Continued over page 
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Score range = 0–7 
Restlessness/agitation           
Palpitations           
Racing thoughts           
Headache           
Feelings of unreality           
Fear           
Drowsiness           
Hunger           
Appetite           
TOTAL           
Sleep (0800 obs only)           
Other symptoms 
 
 
          
Continued over page 
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These questions refer to how the person is feeling right now, at the present 
moment. 
Restlessness/Agitation Ask ‘Do you feel more 
restless than you are 
normally?’ 
0   Normal activity 
1   Somewhat more than 
normal activity 
4   Moderately fidgety or 
restless 
7   Unable to sit or stand still 
Racing thoughts Ask ‘Are your thoughts 
racing?’ 
0   No racing thoughts 
1   Mild 
4   Moderate 
7   Severe 
Mood changes—
Observation 
 
Ask ‘Are your moods 
changing over a 
short period (hours)?’ 
0   No mood changes, feels 
stable 
1   Mild 
4   Moderate 
7   Severe 
Feelings of unreality 
 
Ask ‘Do you feel that 
things around you are not 
real or change in shape?’ 
0   No 
1   Mild 
4   Moderate 
7   Severe feelings of 
unreality, everything looks 
strange or different 
Fear 
 
Ask ‘Do you feel fearful?’ 0   No fear 
1   Mildly fearful 
4   Moderately fearful 
7   Extremely fearful 
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Drowsiness—
Observation 
Ask ‘Do you feel sleepy 
or drowsy?’ 
0   No drowsiness 
1   Mild 
4   Moderate 
7   Severe, unable to stay 
awake 
Hunger 
 
Ask ‘Do you feel hungry?’ 0   No hunger 
1   Mild 
4   Moderate 
7   Severe and constant 
feelings of hunger 
Appetite 
 
Ask ‘Have you noticed 
any change in 
your appetite?’ 
0   No loss of appetite 
1   Slight loss 
4   Moderate 
7   Complete loss of appetite, 
unable to eat at all 
Sleep 
 
Ask ‘How did you sleep 
last night?’ 
0   Sufficient sleep 
1   Some sleep 
4   Moderate/restless sleep 
7   No sleep 
 
Source: DeCrespigny, C et al. (2003) Alcohol Tobacco and Other Drugs Guidelines for 
Nurses and Midwives: Clinical Guidelines. Flinders University and Drug and Alcohol 
Services Council, Adelaide. 
 
Available at 
www.dassa.sa.gov.au/webdata/resources/files/ATOD_Clinical_Guidelines-book2.pdf 
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Appendix 12: Fagerström Nicotine Dependence 
Scale 
Question Answer  Score 
1. How soon after waking up do you smoke 
your first cigarette? 
Within 5 minutes 
6–30 minutes 
31–60 minutes 
3 
2 
1 
2. Do you find it difficult to abstain from 
smoking in places where it is forbidden? 
Yes 
No 
1 
0 
3. Which cigarette would you hate to give up? The first one in the morning 
Any other 
1 
0 
4. How many cigarettes a day do you smoke? 10 or less 
11–20 
21–30 
31 or more 
0 
1 
2 
3 
5. Do you smoke more frequently in the 
morning than in the rest of the day 
Yes 
No 
1 
0 
6. Do you smoke even though you are sick in 
bed for most of the day? 
Yes 
No 
1 
0 
 Total   
Score very low dependence 
low dependence 
medium dependence 
high dependence 
very high dependence 
0–2 
3–4 
5 
6–7 
8+ 
 
Source: Fagerstrom KO, Heatherton TF, Kozlowski LT. (1990) Nicotine addiction and 
its assessment. Ear, Nose and Throat Journal, 89(11), p.763–765. 
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